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ABSTRACT 
 
SHARON L. MYERS: Pesticide Use and Self-Reported Uterine Leiomyomata among Farm 
Women: An Analysis of the Agricultural Health Study with Assessment of Outcome 
Misclassification 
(Under the direction of Dr. Donna Baird and Dr. Andrew Olshan) 
 
 
 Uterine leiomoyomata (fibroids), benign tumors that develop in the majority of 
women, are the leading indication for hysterectomy in the United States.  Although it is well-
established that ovarian hormones are involved in fibroid pathogenesis, few studies have 
examined the role of endocrine disrupting chemicals.  This study investigated the relationship 
of pesticide use and self-reported fibroids among 16,526 women, aged 18-59, in the 
Agricultural Health Study (AHS).  The impact of outcome misclassification from use of self-
report was assessed by incorporating estimates of self-report validity. 
 Validity was estimated using self-report of clinical diagnosis and ultrasound findings 
from Right From The Start (RFTS) (n=2,046) and the Uterine Fibroid Study (UFS) (n=869).  
Log-binomial regression was used to estimate sensitivity and specificity and examine 
differences by various factors.  Overall sensitivity was ≤0.50 in both studies.  Sensitivity was 
higher in blacks than whites (RFTS: 0.34 vs. 0.23; UFS: 0.58 vs. 0.32) and increased with 
age.  Parous white women had higher sensitivity than nulliparae.  Specificity was 0.98 in 
RFTS and 0.86 in UFS.  Ethnic differences were modest in UFS (Specificity Ratio, black vs. 
white: 0.90; 95% confidence interval [CI]: 0.81, 0.99).  Parity was inversely associated with 
specificity among UFS black women (Specificity Ratio: 0.84; 95% CI: 0.73, 0.97).    
   
 iv
 The association between pesticide use and fibroid diagnosis in the AHS was 
estimated with odds ratios (OR) and 95% CI, adjusting for age and state (Iowa/North 
Carolina).  Ever use of agricultural pesticides was associated with fibroids, with users of ≥3 
pesticides having the highest odds compared to never users (OR: 1.31, 95% CI; 1.12, 1.53).  
Use of any of 10 possible hormonally active pesticides was associated with fibroids when 
compared with never use of any pesticide (OR: 1.28; 95% CI: 1.12, 1.45).  When pesticides 
were grouped by chemical class, organophosphate users had slightly higher odds than users 
of other agricultural pesticides (OR: 1.17, 95% CI: 1.05, 1.31).   
 These results suggest a possible association between agricultural pesticide exposure 
and uterine fibroids that warrants further investigation.  Allowing for the imperfect outcome 
measurement which was demonstrated in the self-report validity analysis resulted in 
estimates that were further away from the null. 
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CHAPTER 1: INTRODUCTION AND AIMS 
 
 Uterine leiomyomata (fibroids) are benign neoplasms of uterine smooth muscle tissue 
that develop in the majority of women (1).  Fibroids can cause menstrual abnormalities, 
pelvic pain, and pregnancy complications (2), and account for approximately 32% of all 
hysterectomies in the United States (3).  Established risk factors include African-American 
race, increased premenopausal age, and earlier age at menarche (4).   
 The development and progression of uterine fibroids are known to be highly hormone 
dependent, but there is an incomplete understanding of the precise mechanisms or etiology of 
the disease.  Earlier investigations of oral contraceptive use (as a source of exogenous 
hormones) have yielded equivocal results, primarily due to the possibility of reverse causality 
and detection bias (4).  Exposure to endocrine-disrupting chemicals (EDCs)—which can 
either mimic ovarian hormones or exert agonistic effects on hormone receptors—may play a 
part in the development and growth of these tumors.  Despite evidence from animal models 
and in vitro experiments to suggest that EDCs (including some pesticides) may affect fibroid 
pathogenesis (5-9), few epidemiologic studies have investigated these exposures as possible 
risk factors.  To my knowledge, only one study of 25 women has examined pesticides and 
found higher concentrations of DDT in leiomyomatous tissue compared to surrounding 
normal myometrium (10).   
     One of the methodological challenges in observational studies of uterine fibroids is in 
the correct identification of women with and without fibroids.  In particular, studies that use 
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self-reported fibroid diagnosis to identify cases and controls could result in identification of 
risk factors that are associated with disease symptoms or reproductive health care utilization 
rather than the disease itself.  Furthermore, since many women with fibroids remain 
asymptomatic, it is likely that a sizeable proportion who report no previous fibroid diagnosis 
actually have undetected fibroids (2, 11).     
 The purpose of this dissertation research was to examine whether pesticide use is 
associated with prevalence of uterine fibroids among farm women in the Agricultural Health 
Study (AHS), a cohort of licensed pesticide applicators and their spouses in North Carolina 
and Iowa.  Women who personally mix or apply pesticides for agricultural applications have 
the potential for higher exposures to more toxic restricted-use pesticides.  I hypothesized that 
women who have used pesticides will be more likely to report having uterine fibroids, and 
that associations will be stronger among women who have used possible endocrine-
disrupting pesticides in a farming application compared to those who have only used 
commercially-available pesticides in residential applications.   
 Because the Agricultural Health Study relies on self-reported diagnosis, I 
implemented methods to correct for outcome misclassification by incorporating measures of 
self-report accuracy in the logistic regression models (12).  In order to obtain reasonable 
assumptions regarding self-report sensitivity and specificity, I used data from Right from the 
Start (RFTS) and the Uterine Fibroid Study (UFS).  Both of these studies collected self-
reported fibroid diagnosis from participants and performed ultrasound screening to identify 
women with fibroids.  In addition to informing this research, I sought to provide data that 
could be useful to others in assessing the impact of misclassification when using self-report 
to classify fibroid status.     
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 Aim 1 was therefore to evaluate the validity of self-reported fibroid diagnosis and 
examine the possible determinants of reporting quality in women from RFTS and UFS.  
RFTS is an ongoing community-based prospective study of early pregnancy, conducted since 
2000, which performed early first trimester ultrasound examinations.  The UFS was a cross-
sectional study conducted in 1996-1999 to estimate uterine fibroid prevalence among 
randomly-selected members of an urban health plan.        
 Aim 2 was to examine the association between pesticide use and self-reported uterine 
fibroids among female farmers and farmers’ wives in the AHS.  I performed sensitivity 
analyses to assess the impact of outcome misclassification in addressing the following 
specific questions:     
• Do women who report using pesticides have increased odds of uterine 
fibroids, compared to never users? 
• Is there a difference in the magnitude of the effect depending on whether 
women report only residential pesticide use, or use pesticides in agricultural 
applications? 
• Is there an association between use of select pesticides that have been 
identified as possible endocrine disruptors and uterine fibroid prevalence? 
  
   
CHAPTER 2: REVIEW OF THE LITERATURE 
 
2.1 EPIDEMIOLOGY OF UTERINE FIBROIDS 
 Uterine leiomyomata (uterine fibroids) are benign, hormone-dependent tumors of 
uterine smooth muscle origin.  Although estimates vary somewhat, fibroids occur in 70 to 
80% of women in the United States by the time they reach menopause (1).  However, only 20 
to 50% of women with tumors become symptomatic (2, 11).  Despite their benign nature, 
uterine fibroids can cause significant co-morbidities such as heavy menstrual bleeding, 
anemia, pelvic or abdominal pain, and pregnancy complications (13-18).  These factors make 
uterine fibroids an important public health problem.  
 The etiology of fibroids is not well-understood, although it is well-accepted that 
steroid hormones play a part in tumor development.  Epidemiologic studies, therefore, have 
generally focused on risk factors that might influence a woman’s circulating hormone levels.  
These include age, race, smoking, alcohol use, oral contraceptive use, and various 
reproductive and menstrual cycle characteristics.  Of these, age, race, and certain 
reproductive/menstrual factors show the most consistent associations with uterine fibroids.  
The risk of fibroids increases with age during the reproductive years, with an estimated 
cumulative incidence of over 70% by age 50 (1, 19-22).  They typically regress after 
menopause (23), and it is estimated that postmenopausal women have a 70 to 90% reduced 
risk of fibroid diagnosis relative to premenopausal women (24-26).  
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 The incidence of uterine fibroids is 2 to 3 times higher in African-American women 
compared to white women (1, 20, 27).  A higher prevalence among black women is evident 
in all age groups (1, 20, 28), and does not seem to be explained by racial differences in health 
care access and utilization or other established risk factors (20, 29, 30).  Moreover, black 
women tend to have a younger age at diagnosis and larger and more numerous tumors than 
do white women (30, 31).  The biological basis for these racial differences remains unclear, 
however, and genetic susceptibility studies are limited and inconsistent (32). 
 Reproductive risk factors that have been well-investigated in relation to fibroids are 
age at menarche, parity, and timing of pregnancies.  Most studies have found an inverse 
association between age at menarche and uterine fibroids, leading some researchers to 
hypothesize that increased lifetime exposure to circulating sex hormones from earlier menses 
onset might play a role (33-37).  Studies have consistently reported that parous women are 20 
to 40% less likely to be diagnosed with fibroids compared to nulliparous women (25, 27, 34, 
35, 37, 38).  Some, but not all, have further shown an inverse relationship between uterine 
fibroids and number of births (25, 34, 38).  The association with parity persisted even after 
accounting for the possible confounding effects of infertility (35, 37) and breastfeeding 
history (37) in two large prospective cohorts.  Two other studies that have examined 
lactation, which suppresses ovarian hormones, have not supported an association between 
breastfeeding and fibroids (24, 34).   Evidence of a protective effect of pregnancy may be 
limited to viable pregnancies only, since there has been no association found between 
spontaneous or induced abortions and uterine fibroids; these results are difficult to interpret 
however, because of possibilities of selection bias in the study designs (37-39).   
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 There is some evidence to suggest that the timing of pregnancy may also be important 
to some degree in explaining its apparent protective effect.  A large prospective cohort study 
of nurses (the Nurses’ Health Study, NHS) which measured incident ultrasound- or 
hysterectomy-confirmed fibroid diagnosis, found a lower risk among women who first gave 
birth at ≥25 years of age compared to those whose first birth occurred at ≤24 years of age; in 
both groups, risk of diagnosis increased with increasing years since last birth (35).  A 
prospective study of black women (the Black Women’s Health Study, BWHS) also reported 
an inverse association between age at first birth and incident fibroids confirmed by 
ultrasound or hysterectomy, and a positive association with number of years since last birth 
(37).  The Uterine Fibroid Study (UFS), a cross-sectional ultrasound screening study of 
premenopausal women, found that childbearing in the mid-reproductive years (age 25-29) 
was the most protective for fibroid development, supporting the theory that smaller/early 
fibroid tumors might be eliminated with apoptosis during postpartum uterine remodeling 
(40).  More recently, a prospective study of pregnant women which compared early first 
trimester to postpartum ultrasound results found that 36% of tumors were no longer 
detectable at the postpartum ultrasound and 79% of the remainder had decreased in size (41). 
 The relationship between oral contraceptive (OC) use and fibroids is unresolved.  The 
prevalence/incidence of uterine fibroids among women who have ever used OCs has been 
reported to be reduced (25, 26, 33, 34), similar (24, 35, 37), or increased (42) compared to 
never users.  One case-control study found a steady decrease in the risk of surgically-
confirmed fibroids with increasing years of OC use (25).  In the NHS, no clear pattern 
emerged with years of use among current OC users or years since last use, and only women 
who reported first using OCs between 13-16 years of age had higher risk of fibroids 
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confirmed by ultrasound or hysterectomy compared to never users (35).  The BWHS reported 
similar results (37).  These inconsistencies could be due to differences in study design and 
population or to differences in the estrogen and progesterone content of oral contraceptive 
formulations.  Spurious associations could also arise if the use of oral contraceptives is 
related to the degree of fibroid symptoms. 
 Most investigations have found a positive association between the highest body mass 
index (BMI) category at enrollment and uterine fibroids, but no evidence for an increasing 
trend among successively higher BMI categories (25, 33, 34, 43-45).  BMI was not 
associated with fibroids in two case-control studies (24, 36) and among whites in the UFS 
(46).  Two studies have examined other weight measures among premenopausal women.  
The NHS, whose population was overwhelmingly white, found positive associations with 
weight gain since age 18 and current waist-to-hip ratio, but little evidence of an association 
with BMI at age 18 or childhood/adolescent body size (43, 44).   The BWHS reported 
increased incidence rates for ultrasound- or hysterectomy-confirmed fibroids at all BMI 
categories above the referent of <20.0 kg/m2, but stronger associations among parous women 
(who also had elevated risks with increasing weight gain since age 18); waist circumference 
and waist-to-hip ratio were not associated with leiomyoma risk (45).  Obesity may be 
involved in the progression of uterine fibroids through effects on endogenous hormone 
levels, although the exact mechanisms and their relative importance are unknown.  
Conversion of androgen to estrone by excess adipose tissue and decreases in sex-hormone 
binding globulin may induce a relatively hyper-estrogenic state not normally present in 
postmenopausal women, while decreased metabolism of estradiol into more inactive 
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metabolites could be a factor in increasing the bioavailability of estradiol in premenopausal 
women (47-50).   
 Other factors that are associated with obesity—such as hyperinsulinemia or 
hypertension—could also play a role, although few studies have examined these aspects.  In 
the BWHS, the incidence of ultrasound- or hysterectomy-confirmed fibroids was lower in 
black women reporting a diabetes diagnosis compared to those without diabetes (51).  The 
UFS found a similar association with ultrasound-detected prevalent fibroids among blacks, as 
well as a reduction in fibroid prevalence comparing the highest to lowest tertiles of insulin 
levels among black women with large fibroids (52).  A case-control study found no 
association with a history of diabetes, but a positive association among women taking 
diabetes medication; these findings were based on small numbers, however (53).  Fibroids 
(confirmed by ultrasound or surgery) were positively associated with a history of 
hypertension in two clinic-based case control studies (53, 54) as well as with blood pressure 
(treated as a continuous variable) in NHS participants (55).   
 Behavioral factors that have been investigated include smoking, alcohol use, and 
physical activity.  Of these, smoking has been studied most extensively, albeit with 
inconsistent results.  Current, but not past, smoking has been inversely associated with 
uterine fibroids in several studies, even after controlling for BMI in three of those studies 
(24, 25, 34, 56, 57).  No association was found, however, in the large prospective cohorts of 
the NHS (43) and the BWHS (58), and a small case-control study found no association with 
smoking duration (33).  Smoking has been hypothesized to reduce the risk of fibroids 
through anti-estrogenic effects, but studies of smokers and non-smokers have shown lower 
endogenous estrogen levels only in post-menopausal women (49, 59-61).  Alcohol 
   
  9
consumption has been shown to increase estradiol levels in some (62, 63), but not all (64-67), 
studies.  A positive association between current alcohol intake and uterine fibroids was 
reported in the BWHS (58) and the NHS (20).  Physical activity has been reported to be 
protective for breast and endometrial cancers (68), but its association with uterine fibroids 
has not been well-studied.  A comparison of athletes versus non-athletes found lower 
prevalence of fibroids in the former group, however, these results are difficult to interpret due 
to the possible confounding effects of diet and weight (56).  The UFS also noted an inverse 
association among both African-American and white women for the highest category of 
physical activity versus the lowest after adjusting for possible confounders  (46).     
2.1.1 Methodological Challenges 
 The principal methodological issue in uterine fibroid research is that these benign 
tumors arise in a large percentage of reproductive-age women without coming to clinical 
attention because they do not cause any symptoms.  It is estimated that only 20 to 50% of 
women with one or more fibroid tumors will experience symptoms (13).  This poses certain 
methodological challenges for epidemiologic investigations of the prevalence of this 
condition (reviewed by Schwartz and Baird (69-72)).  Obviously, any study design that uses 
imperfect disease measurement methods will suffer from some degree of misclassification 
bias.  With regard to uterine fibroids, the misclassification can be extensive because the 
“non-diseased” group will most likely include a large proportion of women with subclinical 
fibroids.  In the UFS for example, 51% of premenopausal black or white women who 
reported no previous diagnosis actually had fibroid tumors detected at study ultrasound, 
while 15% of women who claimed they had a previous fibroid diagnosis did not show 
evidence of fibroids on ultrasound.   
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 Histologic evidence is considered the gold standard for uterine fibroid ascertainment 
(72), but studies utilizing surgically-confirmed cases can suffer from selection bias to the 
extent that determinants of a woman’s decision to undergo surgery are related to risk factors 
of interest.  Historically, the standard treatment for fibroids has been hysterectomy, but  more 
conservative surgeries (such as myomectomy and uterine artery embolization) and medical 
treatments are increasingly available (73).  A woman’s chosen treatment mainly depends on 
the severity of symptoms, the size and location of tumors, and the desire to keep her uterus 
for reasons both related and unrelated to childbearing.  Consequently, previous studies 
among women undergoing hysterectomy could show spurious associations with factors (e.g., 
parity) that are instead related to the treatment choice (e.g., women who have their desired 
number of children are more likely to choose hysterectomy).  Similarly, findings from studies 
of other special populations—such as women recruited from family planning, gynecologic, 
or infertility clinics—are difficult to interpret, as the likelihood of incidental detection 
increases among women who seek medical care for symptoms from other gynecologic 
conditions.  This may result in mistakenly identifying factors as related to uterine fibroid 
prevalence when they are actually related to those other conditions.    
 These challenges have impacted the design and interpretation of previous studies.  As 
with other conditions with a long preclinical phase, little is known about the onset and 
progression of these tumors because the temporality of risk factors with regard to disease 
onset cannot be established.  A good example is the UFS, which minimized the 
misclassification and selection biases described above by systematically screening a 
randomly selected sample of women, but is limited in the ability to relate certain risk factors 
to fibroid onset due to its cross-sectional design.  On the other hand, two well-known 
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longitudinal designs—the NHS and BWHS—have been better able to correlate the 
assessment of risk factors with disease (i.e. first fibroid diagnosis) through regular follow-up 
of their cohorts.  However, detection bias cannot be ruled out in these studies because they 
relied on self-reported clinical diagnosis instead of systematic screening.  Although both 
studies found high positive predictive value of self-report in a sample of cases verified 
through medical records, it is likely that there is substantial case under-ascertainment and that 
factors related to the probability of a woman being diagnosed (e.g., access to and use of 
health care, other conditions, presence of symptoms) could account for some of the 
associations detected.  An illustrative example is the BWHS validation subsample, in which 
55% of cases reported being diagnosed because of fibroid-related symptoms; the remaining 
45% were diagnosed incidentally, either during a routine pelvic examination (32%) or while 
receiving care for another condition (13%) (21).  Nonetheless, these studies provide an 
important contribution to the relatively limited research in uterine fibroid epidemiology.  
Data that could be used to examine and possibly adjust for outcome misclassification—such 
as the sensitivity and specificity estimates from this dissertation research—would be 
extremely helpful, especially in the analysis of the large prospective cohort studies that are 
ongoing. 
2.2 ROLE OF HORMONES IN UTERINE FIBROID PATHOGENESIS 
 Although little is known about the etiology of uterine fibroids, it is widely accepted 
that ovarian hormones are involved in their pathogenesis.  The strongest evidence for this is 
the observation that fibroids occur in women in their reproductive years and typically regress 
after menopause (25, 74).  Clinical trials showing reduction in uterine volume and fibroid 
regression after treatment with GnRH agonists—which create a hypoestrogenic and 
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hypoprogestagenic state—also provide support for the role of estrogen and progesterone 
activity on fibroid growth (75-77).  The use of selective estrogen receptor modulators 
(SERMs) has had mixed results in humans, underscoring the complexity of the endocrine 
system and the disparate activity of endocrine-modulating compounds in different target 
tissues.  Tamoxifen for example, which is used as an antiestrogen in breast cancer treatment, 
has partial agonist effects in the uterine endometrium; some case reports of women being 
treated for breast cancer have suggested that it may result in growth of existing uterine 
fibroids (78-80).  Trials of the antiprogesterone mifepristone have shown promise in inducing 
fibroid regression (81, 82), and other selective progesterone receptor modulators are being 
explored.     
 In addition to the clinical evidence, in vitro and in vivo studies have clearly indicated 
the role of both estrogen and progesterone signaling in the growth of uterine fibroids 
(reviewed by Marsh et al. (83)).  Despite the similarity in serum estradiol and progesterone 
levels among women with and without uterine fibroids (84), important differences between 
leiomyomatous and myometrial tissue have been demonstrated.  Compared to normal 
myometrium, uterine leiomyoma (UL) cells have elevated levels of both estrogen receptors 
(ER-α and ER-β) (85-87) and increased proliferation and transcriptional response to estrogen 
stimulation (85, 88, 89).  In addition, elevated expression of the enzyme aromatase, which 
converts androgens to estrogen, was found in fibroid smooth muscle cells, signifying the 
potential de novo production of estrogen by leiomyoma tissue (90-92).   
 Uterine fibroids also have increased concentrations of progesterone receptors A and B 
compared with normal myometrium (93, 94), and have the highest mitotic count during the 
luteal phase of the menstrual cycle, when progesterone production is at its peak (95).  As 
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with estrogen, progesterone induces proliferation and up-regulates growth factors, proteins 
that can have inhibitory and/or stimulatory effects on cell replication (96, 97).  Certain 
growth factors, which may stimulate fibroid growth by increasing extracellular matrix, have 
also been found to be over-expressed in uterine fibroids (reviewed by Maruo et al. (98)).  The 
relative importance of and relationships between ovarian hormones, growth factors, and 
binding proteins in uterine fibroid development remain unclear.  The fact that different 
tumors in the same woman can have different growth rates argues against a simple model of 
hormonal regulation.  However, the increased sensitivity to estrogen raises the possibility that 
the growth of these tumors may be influenced by exposures to environmental estrogens (i.e., 
xenoestrogens).  
2.3 ENDOCRINE-DISRUPTING ACTIVITY OF PESTICIDES 
 The potential for pesticides to act as endocrine-disruptors was first suggested in the 
early 1950s, when DDT and some of its analogs were found to have estrogenic activity in 
animal models (99, 100).  Endocrine disruption refers to the ability of a chemical to either 
mimic or block the action of endogenous hormones by 1) binding directly with steroid 
receptors; 2) inhibiting steroid synthesis; or 3) modulating hypothalamic-pituitary feedback 
loops (101).  With regard to pesticides, the focus of most toxicologic research to date has 
been on their estrogenic potential (especially organochlorine insecticides), although some 
have been shown to have effects on progesterone, androgen, and other hormones (101).  This 
section will focus on the evidence for estrogenic activity and female reproductive effects. 
 The hallmark of estrogen action was presented by Hertz as its proliferative effect on 
the female genital tract (102).  This definition has long been considered the standard for 
testing the estrogenicity of compounds in vitro, and is the basis for the E-Screen assay which 
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measures proliferation in human breast cancer MCF7 cells (103).  The most widely used test 
of estrogenicity in vivo is the rodent uterotrophic assay, which measures changes in uterine 
weight after administration of the suspect compound (104).  Other assays and combinations 
of testing strategies have been developed, especially in response to the initiation of the U.S. 
Environmental Protection Agency’s (EPA) Endocrine Disruptor Screening Program 
(information available on-line at http://www.epa.gov/endo/pubs/assayvalidation/index.htm).   
 Examples of estrogenic pesticides are DDT and some of its analogues, kepone 
(chlordecone), and methoxychlor and its metabolite HPTE (101).  DDT, kepone, and 
methoxychlor have been ranked as “Category 1: Evidence for endocrine disruption in living 
organisms” by the European Union (105) and as “known” endocrine disruptors based on the 
weight of evidence by the Illinois Environmental Protection Agency (106).  These 
compounds have demonstrated estrogenic activity in vitro and have been linked to adverse 
effects on fertility, early pregnancy, and reproductive tract development in murine models.  
One of the most well-studied pesticides is DDT and its analogues, which can be estrogenic, 
anti-estrogenic, or anti-androgenic.  DDT and some of its breakdown products increase cell 
proliferation in estrogen-responsive cell lines (103, 107), show ERα and/or ERβ agonist 
activity (108, 109), induce human ER-mediated transcriptional activation in vitro (110), and 
increase estradiol secretion in porcine granulosa and theca cells (111-113).  DDT, o,p'-DDT, 
or p,p'-DDT also exhibited some degree of estrogenicity by causing an increase in uterine 
weight and early vaginal opening in murine models (114, 115).  Neonatal exposure to the 
organochlorine pesticide kepone in rats leads to persistent vaginal estrus and anovulation 
(116).  Precocious puberty, persistent vaginal estrus, and problems in initiating and 
maintaining pregnancy were observed in mice and rats administered methoxychlor neonatally 
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or during the peri-implantation period (117-120).  In addition to DDT and methoxychlor, the 
pesticides lindane, endosulfan, toxaphene, and dieldrin were shown to increase cell 
proliferation in the E-Screen assay (121).   
 A recent review by Mendola et al. (122) has described some of the existing 
epidemiologic findings (and limitations) with regard to environmental contaminants and 
female reproductive health.  With the exception of one study of about 700 female greenhouse 
workers in Italy (123), studies published in the last ten years have found some association 
between agricultural or horticultural pesticide exposure and impaired fertility and 
fecundability such as increased time-to-pregnancy and risk of spontaneous abortion 
(reviewed in Mendola et al. (122)).  Younger age at menarche has been associated with 
increased serum DDT levels in a cross-sectional analysis of 466 female Chinese textile 
workers (124), but not related to serum DDE and mirex in a cross sectional analysis of 138 
Native American girls living near a U.S. Superfund site (125).   Women who reported ever 
having mixed or applied pesticides had longer menstrual cycle lengths, increased risk of 
missed periods, and older age at menopause compared to never users in the relatively large 
Agricultural Health Study cohort (126, 127).  A small (n = 60) study of serum DDT levels 
among young Chinese women enrolled at the time of their premarital health examination 
found no effect on menstrual cycle length or duration (128); the cross-sectional analysis of 
Chinese textile workers (n = 466) reported an increased risk of short cycle length (124).  
Inconsistencies in results in this limited number of epidemiologic studies are probably due to 
several factors, not the least of which is the inability to construct an adequate exposure 
measurement that incorporates the magnitude, duration, and timing of these exposures 
relative to the outcome of interest.  Exposure measurement approaches varied and could 
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account for differences in study results.  Some used serum pesticide metabolite measures, 
which are generally more reliable than self-reports, but even these studies could be difficult 
to interpret if blood samples are taken after the outcome of interest occurs or if there is 
inadequate adjustment for factors that might affect body burden (e.g., BMI).  Recall bias may 
have also played a role when outcomes were assessed retrospectively.  Finally, studies of 
special populations (e.g. greenhouse workers) that are exposed to high concentrations are 
difficult to compare because these groups may be exposed to varying mixtures of chemicals 
(measured and unmeasured) that could either lead to a spurious association with a correlated 
exposure of interest or could dilute its association.    
2.4 ENDOCRINE-DISRUPTING CHEMICALS AND UTERINE FIBROIDS 
 The existing research on the relationship between EDCs and uterine fibroids is 
limited.  Results from in vivo/in vitro studies lend support to the hypothesis that exogenous 
estrogens might affect fibroid growth, but the epidemiologic findings are few and 
inconsistent.  It has been suggested that the increased prevalence of uterine fibroids in Baltic 
gray seals during the 1970s was related to highly elevated levels of DDT and PCBs in Baltic 
biota; a more recent study using a lifetime exposure index indicated that PCB concentrations, 
rather than DDT, better explained the variation in fibroid prevalence over time (129).  
Female mice exposed prenatally to diethylstilbestrol (DES) displayed reproductive tract 
abnormalities, including uterine fibroids, in adulthood (7, 130).  Administration of 
environmentally relevant doses of bisphenol A resulted in increased fibroid incidence in 
neonatally exposed mice compared to controls (8).   
 The most compelling animal evidence for a possible relation between xenoestrogens 
and fibroids comes from the Eker rat model.  The Eker rat spontaneously develops uterine 
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fibroids with high frequency that share many of the phenotypic characteristics of human 
fibroids.  The ELT-3 cell line developed from these animal models has been shown to be 
estrogen receptor-positive and responsive to estrogen in culture (131-133).  Using this model, 
Hodges et al. (5) confirmed that DES acts as a potent estrogen agonist in the uterine 
myometrium of intact animals, that ELT-3 cells proliferated in a dose-dependent manner in 
response to DES, and that DES was able to upregulate the expression of the progesterone 
receptor (an estrogen-responsive gene).  The same group also showed that the phytoestrogens 
coumestrol, genistein, and naringenin as well as five organochlorine pesticides—
methoxychlor (and its metabolite HPTE), kepone, endosulfan, toxaphene, and dieldrin—had 
estrogenic activity either by inducing a transcriptional response or cell proliferation in vitro 
(134).  More recently, researchers at the National Institute of Environmental Health Sciences 
(NIEHS) found that exposure to fenvalerate, a pyrethroid insecticide, increased the rate of 
growth in vitro of human uterine leiomyomata as well as Eker rat leiomyomatous and smooth 
muscle cells (9). 
 Very few human studies of EDCs and uterine fibroids have been conducted to date.  
Significantly higher concentrations of DDT and its metabolites were found in leiomyomatous 
tissue compared to surrounding normal myometrium in a sample of 25 women with fibroids 
(10).  The Uterine Fibroid Study (n = 1,323) reported an odds ratio of 2.4 (95% confidence 
interval: 1.1, 5.4) for uterine fibroids comparing white women who reported prenatal DES 
exposure to those who did not (135).  However, a collaborative follow-up study of almost 
2,700 DES-exposed and unexposed women did not find an association with self-reported 
fibroid surgery that was confirmed via medical records (age-adjusted Incidence Rate Ratio: 
0.9; 95% CI: 0.6, 1.5) (136).  The Seveso Women’s Health Study, a prospective study of 956 
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women living in the vicinity of a chemical plant explosion in 1976, found a statistically 
significant inverse association between serum levels of 2,3,7,8-tetrachlrodibenzo-p-dioxin 
(TCDD) at the time of the explosion and hazard of self-reported fibroids confirmed by 
medical records (137), in line with data that TCDD acts as an antiestrogen in the rat uterine 
myometrium (138).  Jackson et al. investigated possible endocrine-disrupting heavy metals in 
a cross-sectional analysis of uterine fibroids and endometriosis among 1,425 premenopausal 
women in the National Health and Nutrition Examination Survey, 1999-2002.  Although 
women with previous uterine fibroid diagnosis had significantly higher mean blood lead and 
mercury levels than those without fibroids, there were no differences in the adjusted odds of 
fibroids across tertiles of exposure (139).   
  
 
   
CHAPTER 3: METHODS 
 
 This dissertation research had two primary objectives: Aim 1 described the accuracy 
of self-reported uterine fibroid diagnoses and Aim 2 examined the relationship between 
pesticide use and uterine fibroid prevalence among farm women.   
 I used data from the Right from the Start and the Uterine Fibroid Study to examine 
the validity of self-reported fibroid status by comparing it to results from study ultrasound 
examinations.  Together, these two studies comprised 2,119 white and 796 black 
premenopausal women aged 18-49.  Sensitivity (the proportion of women reporting a 
diagnosis among those with ultrasound-detected fibroids) and specificity (the proportion of 
women reporting no diagnosis among those with no evidence of fibroids at ultrasound) were 
estimated using log-binomial regression.  Sensitivity ratios and specificity ratios, and their 
95% confidence intervals (CI) were examined to assess whether validity of self-report is 
associated with characteristics such as age, race, or parity.   
 I examined whether pesticide use is associated with self-reported fibroids among 
16,526 white female private pesticide applicators and wives of private pesticide applicators, 
aged 21-59, enrolled in the Agricultural Health Study.  My focus was on pesticides identified 
as hormonally active based on review of the toxicological literature.  I also examined 
pesticide use patterns to assess whether the strength of the association with fibroid diagnosis 
differed according to type and number of pesticides used.  In order to account for bias 
resulting from outcome misclassification, I used an outcome correction method (12) in the 
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logistic regression models, incorporating self-report sensitivity and specificity estimates 
obtained from Aim 1.   
3.1 DATA SOURCES 
3.1.1 Aim 1: Right from the Start and the Uterine Fibroid Study 
Right from the Start (RFTS) is an ongoing prospective study of early pregnancy (28, 
140).  The study has been conducted since 2000, and utilizes community-based recruitment 
procedures to identify women who are pregnant or planning a pregnancy.  A short telephone 
interview was used to screen women for eligibility and obtained informed consent.  Women 
who elected to participate in the study were required to review and sign an informed consent 
form and the HIPAA authorization for Use of Protected Health Information.  Starting in 
2004, an abbreviated enrollment questionnaire collected demographic data and information 
on pregnancy status and fibroid diagnosis; more detailed information on 
medical/reproductive history, health behaviors, and current pregnancy was collected in a 
telephone interview during the first trimester.  Ultrasound was also performed on study 
participants during the first trimester of pregnancy.   
The Uterine Fibroid Study (UFS) was a cross-sectional study of approximately 1,500 
randomly-selected female members of a Washington DC-area health plan (1).  Enrollment 
and initial ultrasound screening occurred in 1996-99.  Women were contacted by telephone 
to confirm eligibility and give informed consent to participate in the study.  Postmenopausal 
women were interviewed about prior diagnoses of fibroids, and those with surgically-induced 
menopause were asked for permission to review their medical records.  Premenopausal 
women were screened for fibroids with pelvic ultrasound.  Data on medical history, 
demographics, and lifestyle were collected by self-administered questionnaires.  Information 
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on reproductive and gynecologic history (including previous fibroid diagnoses) was obtained 
through a telephone interview. 
3.1.2 Aim 2: Agricultural Health Study 
 The Agricultural Health Study (AHS) is a longitudinal cohort of approximately 
60,000 licensed pesticide applicators and their spouses (~32,000) in North Carolina and 
Iowa.  Individuals applying for a restricted-use pesticide license in Iowa and North Carolina 
were recruited at state licensing agencies between 1993 and 1997 (Phase I) (141).  Those 
who agreed to participate in the study completed an Enrollment Questionnaire and were 
asked to identify their spouses for enrollment in the study.  Married male private applicators 
were given two questionnaires to be completed by their female spouse.  Women (applicators 
or spouses) who completed the Phase I questionnaires were eligible for follow-up telephone 
interviews between 1999 and 2003 (Phase II).  Data on fibroid diagnoses, farm-related 
exposures, ever use of up to 50 pesticides, demographic variables, reproductive history, and 
general health and medical history were obtained from self-administered questionnaires and 
telephone interviews.   
3.1.3 Required Approvals 
 The UFS was approved by the Institutional Review Boards (IRB) at the National 
Institute of Environmental Health Sciences (NIEHS) and George Washington University.  
Approval for RFTS was granted by the IRBs at the University of North Carolina, University 
of Tennessee, and the University of Texas.  The AHS was approved by the IRBs at NIEHS, 
the National Cancer Institute, and their contractors which carried out the study.  This 
dissertation research was reviewed by the University of North Carolina Public Health-
Nursing IRB, which determined that this study was exempt from the requirements of the US 
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Department of Health and Human Services regulations, and therefore does not require IRB 
approval (Study #08-1907).  
3.2 ANALYTIC APPROACH: STUDY AIM 1 
The objective of Aim 1 was to evaluate the validity of self-reported fibroid diagnosis 
and examine the possible determinants of accurate reporting in black and white women aged 
18 to 49 years.     
3.2.1 Study Population 
The study population included records from two study data sets: RFTS and the UFS.  
For this analysis, the population was restricted to non-Hispanic white and African-American 
women because the proportion of women of Hispanic ethnicity or other race was small.  
Further restrictions specific to each parent study data set are described below.       
Although RFTS began in 2000, my analysis population was restricted to African-
American and white (non-Hispanic) women who were recruited starting in 2004 (RFTS-2 
and RFTS-3), when a question about previous uterine fibroid diagnosis was added to the 
enrollment questionnaire.  RFTS-2/3 participants are women in very early pregnancy or those 
planning to become pregnant living near study sites in North Carolina and Tennessee (28, 
140).  Participants were recruited from prenatal care clinics and the general community using 
a variety of methods such as direct mail and promotional materials.  To be eligible for RFTS-
2/3, women had to be at least 18 years of age, speak English or Spanish, plan to remain in the 
study area for the next 18 months, not have used assisted reproductive technology, and 
enrolled prior to 9 completed weeks’ gestation (if already pregnant).  Women who were 
planning to become pregnant were followed for up to six months and enrolled if they became 
pregnant.  Beginning in 2007 (RFTS-3), the follow-up period for women trying to conceive 
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was shortened to three months.  Women were allowed to re-enroll in the study if they became 
pregnant again, but I only included data from the first enrollment.  Between 2004 and 2008, a 
total of 2,411 women were enrolled and 2,341 (97%) had both ultrasound and self-report 
information.  Women whose self-reported race/ethnicity was non-Hispanic white (n = 1,756) 
or non-Hispanic black (n = 290) were included in this analysis (Figure 3.1). 
 UFS participants were female members of a prepaid urban health plan with 
approximately 50% black membership and a broad socioeconomic base (1).  A random 
sample of 2,384 women was sent an advance letter describing the study and then contacted 
by telephone to confirm eligibility and obtain informed consent.  To be eligible for the study, 
women had to be 35-49 years old, members of the health plan’s Washington, DC site, and 
able to complete the data collection in English.  Approximately 88% of the original sample 
was contacted and screened for eligibility.  Sixteen percent of the 2,102 screened women 
were ineligible for the study, mainly because they were no longer receiving care at the study 
site.  A total of 1,430 out of 1,786 eligible women (80%) participated; study participation 
rates were similar among black and white women (1).  In addition to the race/ethnicity 
criterion defined above, the analysis population was further limited to women who were 
premenopausal at the time of their baseline interview, had an ultrasound performed, and 
whose ultrasound results were definitive (i.e. women who had classifications of “diffuse 
heterogeneity” or indeterminate results are excluded).  The UFS population for analysis 
consists of 363 Caucasian and 506 African-American women (Figure 3.2).             
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Figure 3.1 Right from the Start (RFTS) participants and final analysis population 
 
 
5,017 RFTS pregnancies, 
2000-2008 
70 women with no 
ultrasound results or 
fibroid screener response 
2,536 pregnancies to women 
enrolled 2004 to 2008 
2,481 pregnancies to 
women enrolled prior 
to 2004 
2,411 women first time 
enrollment 
125 subsequent 
pregnancies to women 
who re-enrolled in study 
Analysis Population (n = 2,046) 
 
1,756 non-Hispanic Caucasian 
290 non-Hispanic African-American 
157 Hispanic, 133 Native 
American/Asian/ Other, and 
5 missing race 
2,341 respondents with first 
trimester or early loss ultrasound 
Exclusions 
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Figure 3.2 Uterine Fibroid Study (UFS) participants and final analysis population 
 
 
3.2.2 Uterine Fibroid Measurements 
Self-report 
Women who screened as eligible in the RFTS-2/3 immediately completed an 
enrollment interview in which they were asked “Have you ever been told by a medical 
provider that you have uterine fibroids?”  Previous fibroid diagnosis in the UFS was 
ascertained in a telephone interview prior to the study ultrasound and clinic visit.  Women 
were asked “Have you ever been told by a doctor or other health professional that you have 
uterine fibroid tumors or a leiomyoma, a benign tumor of the uterus or womb?”  In addition, 
the UFS collected an extensive history including age at first diagnosis, diagnostic and follow-
1,430 UFS participants 
152 women without 
sonogram data and 122 
with diffuse/ 
indeterminate results 
504 white and 819 
black women 
107 not black or white 
race/ethnicity  
1,143 premenopausal 
women 
180 postmenopausal 
women
Analysis Population (n = 869) 
 
363 non-Hispanic Caucasian 
506 African-American 
Exclusions 
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up examinations, and treatment.  Women were categorized as having a previous diagnosis if 
they answered “yes” to the initial question and did not have any answers in the next few 
questions to indicate that it had been a misdiagnosis.     
Ultrasound 
In both the UFS and RFTS, fibroid identification at ultrasound examination was 
based on Muram criteria (142), modified to include masses of ≥0.5 cm in diameter.  RFTS-
2/3 participants underwent an endovaginal ultrasound as early as 6 and no later than 13 
weeks of gestation.  Previous analysis of RFTS data showed no difference in fibroid 
prevalence by gestational age at ultrasound (28), so detection is unlikely to be influenced by 
the timing of the ultrasound within this narrow window.  Examinations were performed by 
sonographers certified by the American Registry of Diagnostic Medical Sonographers 
(ARDMS).  Sonographers received additional study training for consistency in identifying 
and measuring uterine fibroids, and instructions not to discuss the results of the examination 
with study participants (28).  Measurements included fibroid number, location, and size; each 
tumor was examined three times during the ultrasound to reduce the chance of misidentifying 
focal contractions as fibroids (28).  Digital images of the ultrasound results were sent to study 
investigators for review. 
 Premenopausal participants in the UFS underwent both transabdominal and 
transvaginal ultrasound examinations at a clinic visit within three months of study entry.  
Ultrasound was performed by ARDMS-certified sonographers who recorded measurements 
of the size (length, width, anteroposterior diameter) of each tumor, the size and location of 
the two largest tumors > 2 cm in diameter, and the size of the three largest submucosal 
tumors (1).  Results were reviewed by a radiologist trained in ultrasonography.  Women who 
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had had a recent pelvic ultrasound at the clinic (n = 170) were not examined again, but were 
classified as positive or negative for fibroids based on the radiology records from the recent 
examination.  Recorded measurements included the number, location, and size of the fibroid 
tumors.      
Outcome Definition 
 Using the measurements described above, I created a dichotomous variable 
(SR_CORR) to indicate whether the self-reported diagnosis matched results from the 
ultrasound or information about prior fibroid surgeries (SR_CORR=1 if self-report and 
ultrasound results agreed; 0 if they did not agree).  Study ultrasound can be negative for 
women who report a previous fibroid diagnosis and who elected to have their fibroids 
removed.  Data on previous surgery to remove fibroids were available in both the UFS (from 
questionnaire and medical records) and RFTS (from the questionnaire).  For purposes of this 
analysis, women who had previous fibroid surgery were treated as having fibroids, even if 
the study ultrasound did not show evidence of fibroids. 
 The main “outcomes” of interest are sensitivity and specificity, which were estimated 
by restricting the analysis to different groups as follows:   
• Sensitivity (Se), defined as proportion of women correctly reporting a fibroid 
diagnosis and limiting analysis to women with fibroids on ultrasound or 
previous fibroid surgery (D+).  
 Se = Pr (SR_CORR=1 | D+) 
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• Specificity (Sp), defined as proportion of women correctly reporting no 
fibroid diagnosis and limiting analysis to women with no fibroids on 
ultrasound and no previous fibroid surgery (D-).  
 Sp = Pr (SR_CORR=1 | D-) 
Although I originally proposed to also estimate overall agreement, I found this measure to be 
somewhat uninformative and excluded it from the analysis.  For example, overall agreement 
was relatively good even if sensitivity was very poor (if specificity was very high), and 
tended to obscure the fact that many true fibroid cases were unreported.   
3.2.3 Possible Predictors of Reporting Accuracy 
 I explored the variables described below as possible predictors of sensitivity and 
specificity.  As there is no previous literature on this subject, I chose covariates that are either 
associated with uterine fibroids or may be associated with reproductive health care utilization 
or the likelihood that a woman might have been screened for fibroids prior to study entry.   
 Age:  Women were asked their current age and date of birth at the start of each study.  
Women in RFTS ranged from 18 to 45 years old, with a mean age of 30 for white and 27 for 
black women.  In order to have a reasonable number of women in each category, I 
categorized age as 18-29, 30-34, and 35-45 for RFTS.  UFS participants were between 35 
and 49 (by design), and both black and white women were about 41 years old on average.  
For the UFS, age was categorized into 5-year groups (35-39, 40-44, 45-49). 
 Race/Ethnicity:  Race and ethnicity were self-reported by respondents in both studies.  
In RFTS, race and ethnicity were asked separately while in the UFS, race and Hispanic 
ethnicity were combined into one question (e.g., white/not Hispanic, white/Hispanic).  Clinic 
records were used in the UFS to complete race information if missing.  In both studies, 
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women could select more that one race category (e.g., black and white).  For purposes of this 
analysis, race is defined as African-American if respondents selected “Black” either alone or 
in combination with another category, and as white if they identified themselves as “White.”  
Respondents who identified themselves as Hispanic are not included in this analysis. 
Education:  Among other factors, socioeconomic status is associated with access to 
and use of health care services (143).  I used education as a proxy measure of socioeconomic 
status in this analysis.  Self-reported years of completed schooling is a reliable measure and a 
meaningful indicator of SES for adults (144).  RFTS asked for years of schooling completed 
and was categorized as follows: <16, “High school/some college;” 16, “4 years of college;” 
and >16, “Post-baccalaureate.”  UFS participants reported their highest level of education in 
the self-administered mail questionnaire by selecting from among a list of eight choices, 
which were collapsed into the categories above.  The “high school/some college” category 
includes a small percentage of women with less than a high school education: 19 white and 
21 black RFTS women, and 11 black UFS women.   
BMI (kg/m2) was categorized following standard ranges found in the literature: 
≤24.99, 25.00-29.99, and ≥30.00 kg/m2.  In the RFTS, BMI was calculated from height and 
weight measurements recorded at the first trimester ultrasound visit.  I used self-reported 
height and weight “around the time you got pregnant” for six records that were missing this 
information.  In the UFS, height and weight were measured at the clinic visit. 
Parity:  The First Trimester RFTS interview asked participants “How many times in 
total have you been pregnant, counting this pregnancy?” and then collected a detailed history 
of past pregnancies, including pregnancy outcome.  Similarly, the UFS telephone interview 
included the question “Have you ever been pregnant?”  Women who responded “yes” were 
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then asked about the outcome of each pregnancy.  For each pregnancy, respondents selected 
from the following options (options differ slightly for RFTS and UFS): live birth, stillbirth, 
miscarriage, elective/induced abortion, ectopic/tubal, molar pregnancy, and other.  If the 
respondent reported a live birth or stillbirth, gestational age was estimated based on her 
response to whether the baby was “born early, late, or on time” and “how many weeks 
(early/late).”  Using these data, parity was defined as a dichotomous variable 
(nulliparous/parous) based on whether the woman reported any births ≥20 weeks completed 
gestation.  
 Previous miscarriage (yes/no) was classified as “yes” based on self-report of 
miscarriage, confirmed using the reported gestational age (if < 20 weeks completed 
gestation).  In RFTS, women were asked if any of their pregnancies ended in a miscarriage.  
Women reporting a miscarriage were then asked “How far along in the pregnancy were you 
when the pregnancy ended?”  The UFS pregnancy history section was similar, but women 
reporting a miscarriage were asked “How many weeks did this pregnancy last, counting from 
the last normal menstrual period before this pregnancy?”      
 Fibroid size:  Uterine fibroid size was examined with respect to sensitivity only.  Size 
of fibroid tumors may be related to the incidence and severity of symptoms such as abnormal 
bleeding, abdominal bloating, and pelvic discomfort (13, 145), and may therefore be related 
to the likelihood of a woman seeking care.  Fibroid size was categorized as <2.00, 2.00-3.99, 
and ≥4.00 cm based on the largest measured diameter for the fibroid tumor(s) detected.  A 
total of 16 (1%) RFTS and 23 (3%) UFS participants reported having previous surgery to 
remove fibroids.  I assumed that tumor size in these women would have to be clinically 
significant to require treatment and therefore coded their fibroid size as ≥4.00 cm. 
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Factors influencing presence/absence of fibroids at ultrasound 
For a subset of women who reported a previous fibroid diagnosis, I explored 
additional factors in relation to whether or not they had fibroids detected at the time of the 
study ultrasound.  Although there are very few investigations of fibroid growth over time, 
there is some evidence that each tumor might have its own intrinsic growth rate, and that 
some tumors can spontaneously shrink (31).  Pregnancy may also influence the regression of 
fibroids, possibly through postpartum uterine remodeling (40, 41).  I used self-reported age at 
first fibroid diagnosis, date of study ultrasound, and the pregnancy history described above to 
construct the following variables:  time interval between previous diagnosis and study 
ultrasound (categorized as ≤2, >2 to 6, >6 to 12, and >12 years); any pregnancy (yes/no); and 
any term birth (live or still, >37 weeks’ gestation) between previous diagnosis and study 
ultrasound (yes/no).   
3.2.4 Data Analysis 
 All analyses were limited to non-Hispanic white and African-American 
premenopausal women because of the small number of other race/ethnicities.  I analyzed 
RFTS and UFS data separately because of differences in the age distribution and other 
characteristics of the study populations.  Within each study, both overall and race-specific 
results were presented because most epidemiologic studies analyze these groups separately, 
and race-specific estimates would be of greatest utility for assessing outcome 
misclassification in other studies. 
 First, I examined the univariate distribution of all variables included in this analysis, 
including those used for constructing variables of interest.  The distribution of observations 
(including percent missing) was assessed for categorical variables using one-way frequency 
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tables and for continuous variables using descriptive statistics.  I assessed digit preference for 
self-reported age at diagnosis in the UFS by examining a histogram of the frequency 
distribution of the terminal digit in the reported age.  The overall distribution did not vary 
significantly from what would be expected under the assumption of equal proportions (χ2 test 
P value = 0.63).  RFTS asked women for the date of previous diagnosis rather than age.  
 Next, for each study data set, I examined the joint distributions between sensitivity 
and specificity (the outcomes) and each of the possible predictors, stratified by race.  
Differences in the race-specific distributions among some of the predictors deemed it 
necessary to collapse some categorical variables in order to have adequate numbers for the 
regression analysis.  In both RFTS and the UFS, for example, few black women had a 
graduate degree and few white women had only a high school diploma, making it necessary 
to collapse the categories at either end of the education variable.  Similarly, there was a small 
percentage of black women in the “underweight” category (BMI <20.00 kg/m2), so it was 
collapsed with the 20.00-24.99 kg/m2 category.     
 Log-binomial regression was used to estimate sensitivity and specificity and their 
95% confidence intervals.  Prevalence ratios from the log-binomial model are interpreted 
here as the sensitivity or specificity in one group compared to that in a referent group.  
Estimation of sensitivity and specificity ratios was accomplished by limiting the analysis 
population to certain subsets as defined below and regressing SR_CORR (correct self-report: 
Yes=1, No=0) on each of the potential predictors separately. 
   
         Outcome             Analysis subset                Estimate interpretation 
Sensitivity Fibroids on ultrasound 
or prior fibroid surgery 
Proportion of women who self-report 
a previous fibroid diagnosis among 
those with ultrasound-confirmed 
fibroids or prior surgery 
Specificity No fibroids at study 
ultrasound and no prior 
fibroid surgery 
Proportion of women who self-report 
no previous diagnosis among those 
with no evidence of fibroids at 
ultrasound and no previous fibroid 
surgery 
 
 Linearity of dose-response trends for categorical predictors (including age) was 
examined using common referent coding and by treating categorical variables as ordinal 
parameters in the models.  Age was categorized for purposes of displaying results of the 
association between age and sensitivity/specificity, but included as a continuous variable for 
purposes of adjustment.  The linearity of the associations of sensitivity/specificity and age as 
a continuous variable was assessed by adding a quadratic term to the model and retaining it if 
the Wald P value was <0.05.  
 Age and race were evaluated as potential effect measure modifiers.  These variables 
were selected because increasing age up to menopause and African-American race are well-
established risk factors for uterine fibroids, and because it seemed plausible that differences 
in other (measured and unmeasured) covariates across groups might influence the association 
with self-report validity.  Effect measure modification was assessed visually by examining 
stratum-specific prevalence ratios separately for race and age, and by computing a Mantel-
Haenszel χ2 test for homogeneity with a P <0.10 significance level.   
 Final multivariable models included covariates that were associated (P <0.10) in 
univariable models with sensitivity or specificity in either RFTS or the UFS.  Sensitivity 
ratios were adjusted for parity and age as a continuous variable (with a quadratic term in the 
   
  34
UFS analysis to accommodate non-linearity).  Specificity ratios were adjusted for parity in 
analysis of UFS data, but I did not adjust for any covariates in the RFTS specificity analysis 
due to the small number of women who reported a previous diagnosis but did not have 
ultrasound-detected fibroids.  There were some instances in which the log-binomial model 
did not converge, especially in the RFTS specificity analysis.  In these instances, prevalence 
ratios and 95% confidence intervals were estimated by Poisson regression using robust error 
variances (146).  
Analysis of factors influencing presence/absence of fibroids at ultrasound 
 Based upon the results of the specificity analysis, further investigation was made 
among the subset of UFS women reporting a previous diagnosis in order to explore possible 
reasons for the lower self-report specificity compared to RFTS women.  Only the UFS black 
women were examined (n = 221) because there were few UFS white women reporting a 
previous diagnosis who did not have ultrasound-detected fibroids.  Factors since diagnosis 
(described in Section 3.2.3) were examined to determine if they were associated with 
whether or not a woman who reported a diagnosis still had fibroids detected at ultrasound.  I 
excluded 14 records in which the self-reported age at diagnosis was deemed inaccurate based 
on review of other variables in the data set.  For the pregnancy analysis, 14 women were 
excluded because it could not be determined whether the pregnancy occurred before or after 
the diagnosis.   
 Two-way crosstabulations by each of the factors of interest provided information on 
the percentage of women who had fibroids at ultrasound among those reporting a previous 
diagnosis.  Logistic regression was used to test for statistically significant effects, controlling 
for age at interview.    
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3.3 ANALYTIC APPROACH: STUDY AIM 2 
 The objective of Aim 2 was to examine the association between pesticide exposure 
and self-reported uterine fibroid prevalence among women in the Agricultural Health Study 
(AHS), with a focus on pesticide use patterns and use of possible hormonally active 
pesticides.  Results from the validity analysis of self-reported fibroid diagnosis (Aim 1) was 
used to assess and correct for outcome misclassification in these analyses.   
3.3.1 Study Population 
 The majority of female participants in the AHS were wives of private pesticide 
applicators; about 4% of female participants were themselves private pesticide applicators.  
Approximately 82% of eligible pesticide applicators enrolled in Phase I of the study between 
1993 and 1997 (147).  Once enrolled, male private pesticide applicators (mostly farmers) 
were given a Spouse Questionnaire and Female and Family Health Questionnaire to take 
home to their wives.  A telephone interview was conducted to collect data from non-
respondents to the take-home questionnaires.  Altogether, 75% of wives completed the self-
administered Spouse Questionnaire (19% of whom completed by telephone).  Follow-up 
telephone interviews (Phase II) were conducted approximately five years later, between 1999 
and 2003.  Approximately 69% of female private applicators (n = 921) and 74% of wives (n 
= 23,682) completed the follow-up interview.  Compared to Phase II respondents, 
nonrespondents were slightly younger, had less education, resided in North Carolina, and 
more likely to report their ethnicity as non-white.  The nonresponse rate for female 
applicators was lower than for spouses.  Nonrespondents were also more likely to have 
reported never personally mixing or applying pesticides in the Enrollment Questionnaire 
(Table 3.1). 
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 The study population for Aim 2 consists of 16,526 white women who completed the 
Enrollment or Spouse Questionnaires in Phase I and the Phase II Health Module and were 21 
to 59 years old in the Phase II follow-up (Figure 3.3).    
Table 3.1 Differences in demographic and other characteristics for female applicators and 
wives of pesticide applicators, by Phase II respondent status 
Phase II respondent 
(n = 24,603) 
 Phase II nonrespondent 
(n = 8,883) Characteristic 
No. %  No. % 
Type      
  Applicator  921  3.7   436  4.9 
  Spouse  23,682  96.3   8,447  95.1 
State      
  Iowa  17,242  70.1   4,902  55.2 
  North Carolina  7,361  29.9   3,981  44.8 
Education      
  Less than high school  1,053  4.9   603  7.9 
  High school grad/GED  8,519  39.5   3,214  41.9 
  Vocational school/ some college  6,569  30.5   2,260  29.5 
  College degree or higher  5,377  24.9   1,583  20.6 
  Other  41  0.2   13  0.2 
  Missing  3,044    1,210  
Race      
  White  23,602  98.5   8,240  97.4 
  Black  247  1.0   143  1.7 
  Native American / Asian / Other  125  0.5   78  0.9 
  Missing  629    422  
Hispanic ethnicity      
  No  23,337  99.1   8,192  99.1 
  Yes  206  0.9   75  0.9 
  Missing  1,060    616  
Age at enrollment      
  < 30  1,275  5.2   762  8.6 
  30 – 39  5,907  24.0   2,375  26.7 
  40 – 49  7,178  29.2   2,337  26.3 
  50 – 59  6,103  24.8   1,850  20.8 
  60 – 69  3,434  14.0   1,112  12.5 
  70 and over  705  2.9   445  5.0 
  Missing  1    2  
  Mean (SD) 47.2 (11.7)  46.2 (13.0) 
Lifetime use of pesticides      
  Never  9,674  40.3   4,150  48.9 
  Ever  14,336  59.7   4,333  51.1 
  Missing  593    400  
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Figure 3.3 Agricultural Health Study participants and final analysis population 
 
 
3.3.2 Outcome Definition 
 The outcome of interest is self-reported physician diagnosis of uterine fibroids, 
defined as a dichotomous variable.  The Phase II questionnaires were completed via 
computer-assisted telephone interview (CATI), and included a Female Health Module which 
collected information about current reproductive health as well as past diagnoses of various 
Non-Hispanic white private pesticide 
applicators n = 1,175 
Exclusions 
n = 100 missing/don’t 
know/refused information 
on uterine fibroid diagnosis 
n = 16 missing/conflicting 
pesticide information 
Non-Hispanic white spouses of private 
pesticide applicators n = 29,820 
16,642 women less than 60 years old at Phase II (72% of Phase II respondents) 
Phase II Respondents 
Females enrolled in the Agricultural Health Study 
(1,357 applicators and 32,129 spouses) 
Missing race/ethnicity: 
135 applicators and 
1,561 spouses 
Final analysis population 
15,985 spouses 
376 private applicators 
165 spouses who were also applicators 
n = 813 n = 22,184
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medical conditions.  Women were asked “Has a doctor or other health professional ever told 
you that you had uterine fibroids?”  If the woman responded yes, she was then asked “How 
old were you when the doctor first told you that you had (this /uterine fibroids)?”   
3.3.3 Exposure Assessment 
 Exposure metrics used in this analysis are from the Phase I questionnaires.  Women 
were asked about ever use of 50 specific pesticides: 18 herbicides, 22 insecticides, 4 
fumigants, and 6 fungicides.  (A list of these pesticides appears in Appendix A, Table A.1.)  
 Use of hormonally active pesticides:  One of the specific questions to be addressed in 
this dissertation research was whether use of possible hormonally active pesticides was 
associated with self-report of fibroid diagnosis.  Farr (148) conducted a review of the 
toxicological literature related to AHS pesticides and their endocrine disrupting potential in 
2003.  Based on these results and updated evidence from more recent publications 
(summarized in Appendix A), 17 of the pesticides had some evidence of endocrine 
disruption, ovotoxicity, or estrus cycle effects.  For the purposes of this dissertation, I 
focused only on those pesticides that showed evidence of effects that may be relevant to 
uterine fibroid pathogenesis, such as estrogenic or progesteronic activity.  Because the ovary 
is the primary source of these hormones in the uterus, chemicals that disrupt the estrus cycle 
or exert ovarian or uterine effects were also possible candidates.  This narrowed the list to 10 
pesticides, for which evidence is summarized in Table A.3: the organochlorines DDT, 
chlordane, lindane, dieldrin, and toxaphene; mancozeb; atrazine; alachlor; carbon 
tetrachloride; and permethrin/pyrethroids.  A dichotomous variable (ever use of hormonally 
active pesticides) was set to 1 if the woman reported ever use of any of these pesticides and 0 
if she did not use any pesticide at all. 
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 Pesticide use patterns:  An additional question was whether women who used any 
pesticides were more likely to report uterine fibroids than those who did not, and whether 
there was an increasing trend of fibroid diagnosis with type and number of pesticides used.  
In the Spouse Questionnaire, women were asked if they personally treated their home, lawn, 
or pets for pests.  A categorical variable was created to capture wives’ pesticide use patterns; 
residential use questions were not included in the Applicator Questionnaire.  The referent 
category consists of women who never used or applied pesticides in their lifetime. 
“Residential only” refers to women who did not indicate use of any specific pesticide on the 
list of 50, but reported that they personally treat their own home for “flies, fleas, 
cockroaches, ants, or insects other than termites,” their “lawn for pests (e.g., weeds, insects, 
or fungus),” or use home fumigants/flea bombs to control fleas.  “Common agricultural 
pesticides” includes women who specified that they used one or more of the most frequently 
reported pesticides (149): glyphosate, carbaryl, malathion, 2,4-D, and diazinon.  Women who 
specified use of pesticides other than the five most common were further differentiated by 
number used:  “1-2 other agricultural” or “≥3 other agricultural.”  An “Other” category was 
added to capture women who reported mixing/applying pesticides but selected “something 
else” (i.e., other specify) when asked about specific pesticides used.  Responses to additional 
questions about frequency and duration of pesticide application were varied, and one-third of 
these women also reported residential use.  There were no consistent patterns in responses to 
these questions to indicate whether these women used pesticides in residential or agricultural 
applications. 
 In addition to the main exposures of interest, more general exposure variables were 
also examined.  These included ever/never use variables for pesticide groupings by chemical 
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class (organochlorines, organophosphates, carbamates, and triazines) as well as for individual 
pesticides.  Years lived or worked on a farm and whether the respondent grew up on a farm 
were also assessed in relation to fibroid diagnosis.   
3.3.4 Covariates  
 Potential confounders were identified using a Directed Acyclic Graph and based on 
established and possible risk factors for uterine fibroids (Figure 3.4).  Among these possible 
confounders, only age, age at menarche, and parity are established risk factors and were 
considered in this analysis.  Data were collected via self-administered questionnaires or 
telephone interviews in Phases I and II.   
 Age at interview in years was created using the date of birth reported by the 
respondent and the date of the Phase II interview.  Birth date was first asked at enrollment 
and verified/corrected during the Phase II interview.  
 Timing of births was created using the pregnancy history reported in the Phase I 
Female and Family Health Questionnaire and updated in the Phase II Female Health Module.  
Maternal age (in years) at the birth of each child was calculated using the woman’s date of 
birth and the date of birth of each child.  A categorical variable (none, all births <24, one or 
more births ≥24 years of age) was created based on previous reports that births to women 
after their mid-twenties might partially account for the apparent protective effect of 
pregnancy (40).      
 Age at menarche was reported in the Phase I Female and Family Health 
Questionnaire.  Respondents could select from five age categories: less than 12, 12, 13, 14, 
and 15 or older.   
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 State of residence is an assigned variable based on the respondent’s state (Iowa/North 
Carolina) at enrollment.  Other analyses of Agricultural Health Study data have found a 
difference in personal and farm characteristics and pesticide use profiles among applicators 
and spouses in these two states (149, 150).  Differences in the distributions of these 
characteristics may confound the association between pesticide exposures and fibroid risk. 
Figure 3.4 Hypothetical causal diagram 
 
 
 In addition to these variables, data from the Female and Family Health Questionnaire 
and Phase II Female Health Module were used to identify women who reported having had a 
hysterectomy for purposes of assigning sensitivity and specificity estimates in the outcome 
correction model, as described below.  Women were first asked “Have you gone through 
Pesticide Use 
Uterine 
Fibroids ?
Age at menarche 
Parity 
Physical Activity? 
Oral contra-
ceptive use? Age 
Obesity? 
Alcohol? 
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menopause (the change of life) or had surgery that caused you to completely stop having 
menstrual periods?”  Women who answered yes were then asked what type of menopause 
they had, and selected from a list of options.  Those who indicated that they had a full or 
partial hysterectomy were flagged for the outcome correction method. 
3.3.5 Data Analysis 
  Exploratory analyses were first conducted by examining the frequency distributions 
and descriptive statistics for each of the variables included in this analysis.  Although these 
data have gone through extensive data editing and consistency checks, I inspected all 
variables for implausible or out-of-range values and where possible, used other data collected 
in the questionnaires to check for logic and consistency with the key variables of interest.  
Bivariate distributions of fibroid status with the exposures of interest and each of the 
covariates were also examined, as was the percentage of records with missing responses on 
the covariates.  To get a clearer picture of the relationship between age and fibroid status, I 
categorized age as 21-29 (due to small numbers) and then by successive 2-year categories 
(e.g., 30-31, 32-33, …, 58-59), and plotted the log-odds of fibroids by age.  The log-odds of 
fibroids tended to increase in a linear fashion for the most part, but seemed to level off (or 
even form a slightly inverse “U” shape) after about age 50.   
“Uncorrected” regression model 
 Logistic regression was used to estimate the association between pesticide use and 
uterine fibroid prevalence.  The first step was to use the uncorrected outcome, self-reported 
uterine fibroid diagnosis.  Although effect measure modification was not a primary focus, a 
number of the possible endocrine disrupting pesticides were removed from the market in the 
late 1970s and ’80s.  Because the likelihood of use of discontinued pesticides is age-
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dependent (e.g., younger women would not have used DDT), odds ratios and 95% 
confidence intervals were estimated for each age stratum (21-34, 35-39, 40-44, 45-49, 50-54, 
55-59) and visually inspected for differences.  I tested for statistical interaction by age of the 
associations between fibroids and pesticide use patterns, ever use of hormonally active 
pesticides, and chemical class pesticide groupings by including interaction terms for each 
exposure and age with a P < 0.10 significance level.   
 I evaluated the linearity assumption for categorical predictors by including disjoint 
indicator terms and inspecting graphs of the log-odds of fibroids plotted against the 
variable’s categories (151).  When a linear trend was seen, I modeled the variable as a single 
ordinal (e.g., 0, 1, 2) variable and computed a Wald P value for its coefficient.  Based on the 
non-linear relationship between log odds of fibroids and age, I added a quadratic term for age 
in the models.  The quadratic term for age was statistically significant, but resulted in very 
small changes in the exposure effect estimates.  However, excluding the quadratic term 
resulted in a poorly-fit model as assessed by the Hosmer-Lemeshow goodness-of-fit test (P 
<0.0001) (152), so it was retained.     
 A backward elimination approach was used to build the final multivariable logistic 
regression model.  Age (continuous), age squared, and state of residence were forced into the 
models.  Each of the other two covariates was dropped one at a time sequentially from the 
full model (starting with the covariate with the highest P-value in the full model and working 
down), and retained if it resulted in a 10% or greater change in the exposure odds ratio 
relative to the full model.   
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Outcome correction 
   The next step in the analysis was to run logistic regression models utilizing a method 
proposed by Magder and Hughes to correct for outcome misclassification (12).  This method 
incorporates values of sensitivity and specificity into the estimation of logistic regression 
parameters and corresponding variances using the Expectation-Maximization (EM) algorithm 
to obtain maximum likelihood estimates (153).  The procedure can be described as 
essentially performing a “…standard logistic regression considering each study subject as 
both diseased and not diseased with weights determined by the probability that the study 
subject is truly diseased given the data” (12).  To paraphrase their illustrative example, 
suppose a woman reports that she has had a fibroid diagnosis.  Given the sensitivity and 
specificity of the self-report and the values of that woman’s covariates, the probability that 
she truly has fibroids is estimated as 90%.  Then a standard logistic regression is performed 
with that woman entered twice: once as diseased with weight = 0.90 and again as non-
diseased with weight = 0.10.  These probabilities need to be recalculated after the logistic 
regression parameters are estimated because of the fact that the probabilities are partially 
based on the value of the parameters.  This leads to new probabilities, which lead to new 
regression parameters.  This process—estimating the probabilities and the regression 
parameters—is repeated until the parameter estimates converge. 
 The benefit of the Magder and Hughes method is that it accommodates varying 
sensitivity and specificity values for different subgroups of the analysis population.  Based on 
results from the validity analysis in Aim 1, sensitivity for white women increased with age 
(except for the oldest age group) but specificity decreased slightly with age.  The descriptive 
analysis of presence/absence of fibroids at ultrasound among women reporting a previous 
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diagnosis suggests, however, that these women may not have been wrong.  Rather, tumor 
regression could have occurred with intervening factors such as time since diagnosis or 
pregnancies. 
 I used a SAS macro available from the authors at 
http://medschool.umaryland.edu/epidemiology/software.asp to perform the outcome 
correction.  I used results from the Aim 1 analysis to inform the estimates for sensitivity and 
specificity of self-reported fibroids diagnosis.  For the main correction model, specificity was 
set to 0.95 but sensitivity varied by age: 18-29, 0.15; 30-34, 0.20; 35-39, 0.35; 40-44, 0.40; 
45-59, 0.30.  Sensitivity was set to 0.85 for women who reported having had a hysterectomy 
(n = 3,022) based on the assumption that they would be better reporters of fibroid diagnosis.  
As above, all corrected odds ratios were adjusted for age, age squared, and state.      
Additional analyses 
 Several secondary analyses were conducted.  First, I examined associations between 
specific pesticides and uterine fibroid diagnosis and compared effect estimates obtained 
using different referent groups: 1) including never users of any pesticides as well as users of 
pesticides other than that of interest and 2) only users of pesticides other than that of interest 
(Appendix B).   
 Next, I evaluated the degree to which assumptions about self-report validity influence 
the corrected odds ratios and 95% confidence intervals (Appendix C).  I used age-specific 
sensitivity (regardless of hysterectomy status) and specificity = 0.95 as the initial set of 
assumptions, and then varied sensitivity, specificity, and both.  Assumptions about self-report 
validity among women with hysterectomy were evaluated by varying sensitivity and 
specificity for this subset of women only.  Because the AHS population includes women up 
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to 59 years old, whereas the validity analysis population only includes women up to age 49, it 
was difficult to predict the shape of the sensitivity and specificity curves for women in older 
age ranges.  The final sensitivity analysis was conducted to examine the influence of 
different assumptions regarding sensitivity in the 50-59 year age group.   
   
CHAPTER 4: VALIDITY OF SELF-REPORTED UTERINE FIBROID STATUS 
 
4.1 ABSTRACT 
 Studies using self-reported uterine fibroid status to classify cases and non-cases are 
subject to misclassification because many women with fibroids are undiagnosed.  To assess 
the validity of this measure, the authors analyzed self-report of clinical diagnosis and 
ultrasound findings from 2,046 women, mostly <35 years of age, in Right From The Start 
(RFTS) and 869 women aged 35-49 in the Uterine Fibroid Study (UFS).  Log-binomial 
regression was used to estimate sensitivity (Se) and specificity (Sp) and examine differences 
by ethnicity, age, education, body mass index (BMI), parity, and miscarriage history.  
Overall sensitivity was ≤0.50 in both studies.  Sensitivity was higher in blacks than whites 
(RFTS: 0.34 vs. 0.23; UFS: 0.58 vs. 0.32) and increased with age.  Parous white women had 
higher sensitivity than nulliparous whites.  Specificity was 0.98 in RFTS and 0.86 in UFS.  
Ethnic differences were modest in the UFS (Sp Ratio, black vs. white = 0.90; 95% CI: 0.81, 
0.99).  Parity was inversely associated with specificity among UFS black women (Sp Ratio = 
0.84; 95% CI: 0.73, 0.97).  Misclassification of fibroid status can differ by factors of 
etiologic interest.  These findings will be useful to assess bias in studies using self-reported 
clinical diagnosis as the outcome measure. 
4.2 BACKGROUND 
 Uterine leiomyomata (fibroids) are benign neoplasms of uterine smooth muscle tissue 
that develop in the majority of reproductive-age women (1).  For some, fibroids can cause 
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menstrual abnormalities, pelvic pain, and pregnancy complications (2) severe enough to 
require surgical treatment.  However, many women with fibroids remain asymptomatic 
throughout their reproductive years.  An estimated 20 to 50% of women with fibroids will 
experience related symptoms (11, 13), and these women will be more likely to be diagnosed.   
 The large proportion of women with subclinical fibroids leads to an important 
methodological challenge for epidemiologic studies.  As with any condition with a long 
preclinical phase, any ascertainment method that does not attempt to identify asymptomatic 
women will misclassify a substantial percentage of true cases as non-cases.  This 
misclassification can be extensive when outcome ascertainment is obtained by self-report.  In 
one cross-sectional study with ultrasound screening, 51% of premenopausal women who 
reported no previous diagnosis had fibroids upon ultrasound examination (1).   
 Incidental detection also affects which women will be clinically diagnosed.  Women 
who are not experiencing fibroid-related symptoms could be diagnosed during a routine 
pelvic exam, obstetric ultrasound, or if seeking care for other gynecologic conditions.  The 
use of self-report could therefore result in spurious associations with factors not related to 
uterine fibroids, reflecting instead an underlying difference in the opportunity for diagnosis.  
In a large prospective cohort study that validated positive self-report among a subsample of 
women, 55% of cases reported being diagnosed because of fibroid-related symptoms; the 
remaining 45% were diagnosed incidentally, either during a routine pelvic examination 
(32%) or while receiving care for another condition (13%) (21).          
 The purpose of this analysis is to evaluate the validity of self-reported fibroid status 
and examine possible predictors of reporting quality.  It is well-established that fibroid 
prevalence increases with age and that black women are at higher risk than white women at 
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all ages (4, 72).  We therefore used data from two studies with a relatively high proportion of 
black participants and which, together, included women from 18-49 years old. 
4.3 METHODS 
4.3.1 Study Population 
 Data for this analysis come from two studies in which participants were 
systematically screened for uterine fibroids using ultrasound.  Right From The Start (RFTS) 
is an ongoing community-based prospective study of early pregnancy conducted since 2000.  
Women very early in pregnancy or those planning to become pregnant were recruited from 
the community and clinical care sites via outreach materials and advertisements.  Details of 
methods and study design are described elsewhere (28, 140).  Eligibility criteria included: at 
least 18 years of age, English or Spanish speaker, and no use of assisted reproductive 
technology in the index pregnancy.  Women who were planning a pregnancy were followed 
and enrolled if they became pregnant.  Questionnaire data were gathered through computer-
assisted telephone interview; information on basic demographics was obtained at enrollment, 
and questions about medical and reproductive history were asked in a first trimester 
interview.  Weight and height were collected in the enrollment interview and at the time of 
early first trimester ultrasound.    
 In 2004, the RFTS enrollment interview was amended to include a question on 
previous fibroid diagnoses.  Our analysis is therefore limited to women joining the study 
from this point onward.  Although women were allowed to re-enroll in the study, we only 
included records from the first time they were asked about previous fibroid diagnoses.  Study 
enrollment was required before 9 completed weeks of gestation.  Between 2004 and 2008, a 
total of 2,411 women were enrolled, and 2,341 (97%) had both ultrasound and self-report 
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information.  We included only women whose self-reported race/ethnicity was non-Hispanic 
white (n = 1,756) or non-Hispanic black (n = 290) in this analysis.  
 The Uterine Fibroid Study (UFS) was a cross-sectional study conducted to estimate 
uterine fibroid prevalence.  Details have been described previously (1).  To be eligible, 
women had to be 35-49 years old, members of the George Washington University health 
plan, and able to complete data collection in English.  Enrollment occurred between 1996 and 
1999.  Approximately 88% of the original random sample was contacted by telephone and 
screened for eligibility.  A total of 1,430 out of 1,786 eligible women (80%) participated.  
Information on demographic characteristics and reproductive and medical history were 
collected from telephone interviews and self-administered questionnaires.  Height and weight 
were measured at the clinic visit.  We excluded women whose reported ethnicity was other 
than non-Hispanic black or white (n = 107), postmenopausal women (n = 180), and those 
missing ultrasound (n = 152) or whose ultrasound results were not definitive (n = 122) to 
obtain our final analysis population of 363 white and 506 black women.  
4.3.2 Self-Report of Uterine Leiomyomata 
 Both RFTS and the UFS collected information on fibroid diagnosis by telephone 
interview prior to conducting the study ultrasound.  Women were asked if a doctor or 
medical care provider had ever told them that they had uterine fibroids, and responses were 
used to classify women’s self-reported fibroid status (yes/no).  The UFS interview also 
included a series of follow-up questions (e.g., diagnostic and follow-up examinations, 
treatment).  Fewer than 10 women who responded “yes” to the initial question subsequently 
indicated that the diagnosis had been incorrect; these women were classified as having no 
previous fibroid diagnosis. 
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4.3.3 Ultrasound Detection of Uterine Leiomyomata 
 RFTS participants underwent an endovaginal ultrasound as early as 6 and no later 
than 13 weeks of gestation.  Examinations were performed by sonographers certified by the 
American Registry of Diagnostic Medical Sonographers (ARDMS).  They received 
additional study training for consistency in identifying, measuring, and recording uterine 
fibroids.  Sonographers were instructed not to discuss prior knowledge of fibroid status with 
study participants.  Measurements included fibroid number, type, and size.  As described 
elsewhere (28), each tumor was examined three times during the ultrasound to reduce the 
chance of misidentifying focal contractions as fibroids, and the mean of these diameter 
measurements was calculated for each fibroid.   
 Premenopausal participants in the UFS underwent transvaginal (and, when necessary, 
transabdominal) ultrasound examinations within three months of study entry.  Details of the 
ultrasound protocol are described elsewhere (1).  ARDMS-certified sonographers performed 
the ultrasound, and findings were reviewed by a radiologist trained in ultrasonography.  
Recorded measurements included the number, location, and size of each tumor.  Women who 
had had a recent pelvic ultrasound (n = 170) were not examined again, but were classified as 
positive or negative for fibroids based on the radiology records.   
 In both studies, fibroid identification was based on Muram criteria (142), modified to 
include masses of ≥0.5 cm in diameter.  Women were classified as having uterine fibroids if 
the results of the ultrasound examination indicated presence of one or more fibroids.  Fibroid 
size was categorized as <2.00, 2.00-3.99, and ≥4.00 cm based on the largest measured 
diameter for the tumor(s) detected.  A total of 23 (3%) UFS and 16 (1%) RFTS participants 
reported having previous surgery to remove fibroids.  For purposes of comparing self-reports 
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with ultrasound results, these women were classified as having fibroids, even if the study 
ultrasound did not show evidence of tumors.  We assigned fibroid size as ≥4.00 cm for 
women who had fibroid surgery.    
4.3.4 Statistical Analysis 
 The validity of self-reported uterine fibroid status as compared to the “gold standard” 
ultrasound examination was measured by sensitivity and specificity.  Sensitivity was defined 
as the proportion of women who self-reported a previous fibroid diagnosis among those with 
ultrasound-confirmed fibroids or prior fibroid surgery.  Specificity was defined as the 
proportion of women who self-reported no previous diagnosis among those with no evidence 
of fibroids at ultrasound and no previous fibroid surgery.  Data for RFTS and UFS were 
analyzed separately due to differences in the study populations. 
 Log-binomial regression was used to estimate sensitivity and specificity with 95% 
confidence intervals (CI).  Prevalence ratios obtained from the regression models are 
interpreted in this analysis as the sensitivity (or specificity) of self-report in one subgroup 
compared to that in a reference group.  Sensitivity ratios and specificity ratios were used to 
examine differences in self-report validity according to age at interview, education, body 
mass index (BMI), parity, miscarriage history, and (for sensitivity only) size of the largest 
fibroid detected at ultrasound.   
 We first conducted univariate analyses to assess the association of each individual 
predictor with sensitivity and specificity, respectively.  We tested for statistical interaction by 
ethnicity and age using the Mantel-Haenszel χ2 test for homogeneity with a P <0.10 
significance level.  Based on this a priori criterion, ethnicity was an effect measure modifier 
for the association between sensitivity and parity in RFTS (P =0.06), and sensitivity and 
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fibroid size in UFS (P <0.05).  We present both overall and ethnicity-stratified estimates 
below.  To build the final models, we included covariates that were associated (P <0.10) with 
sensitivity (or specificity) in the univariate analyses.  We adjusted sensitivity ratios for parity 
(any previous birth vs. none) and age as a continuous variable (with a quadratic term for age 
in the UFS analysis to accommodate non-linearity).  We adjusted specificity ratios for parity 
in analysis of UFS data, but did not adjust for any covariates in the RFTS specificity analysis 
due to the small number of women who did not have ultrasound-detected fibroids but 
reported a previous diagnosis.  Linearity of trends for categorical predictors was examined 
using common referent coding and by treating categorical variables as ordinal parameters in 
the models.  Poisson regression with robust error variance was used to estimate prevalence 
ratios and 95% confidence intervals when log-binomial models did not converge (146).  All 
P values are two-sided.   
 All analyses were carried out with the statistical software package SAS 9.1 (SAS 
Institute, Inc., Cary, North Carolina).  
4.4 RESULTS 
4.4.1 Characteristics of Analysis Population 
 The majority (86%) of RFTS participants was white, compared to the slightly higher 
percentage of black women in the UFS (Table 4.1).  Overall, RFTS participants were about 
10 years younger than UFS participants.  On average, black women were 2.8 years younger 
than white women in RFTS, but there was no difference in average age between black and 
white women in the UFS.  Black and white women differed with respect to education, BMI, 
and parity in both study populations.  Among women with a previous pregnancy, there was 
no difference in miscarriage history between white and black women.  The prevalence of 
   
  54
both self-reported and ultrasound-detected fibroids was higher among black women 
compared to white women in both study populations but lower in both groups in RFTS 
compared to UFS participants.  Furthermore, a higher percentage of black than white women 
had fibroids ≥ 4 cm in diameter.  Among those who had a previous diagnosis in the UFS, the 
reported age at first diagnosis was 3 years younger in black women compared to white 
women.   
4.4.2 Validity of Self-Reported Uterine Leiomyomata 
 Sensitivity (Se) was low among participants of both studies (Table 4.2).  Half of the 
UFS participants who had fibroids at study ultrasound reported a previous diagnosis (Se: 
0.50; 95% CI: 0.45, 0.54).  Sensitivity was even lower (Se: 0.27; 95% CI: 0.22, 0.32) in 
RFTS.  As shown in Figures 4.1 and 4.2, black women had higher sensitivity of self-report 
than did white women; this was more pronounced in the UFS participants (Sensitivity Ratio 
[SeR] for black vs. white: 1.73; 95% CI: 1.33, 2.25).  Sensitivity was associated with age at 
interview in both studies (Figures 4.1 and 4.2).  In RFTS, overall sensitivity increased from 
0.12 (95% CI: 0.07, 0.21) in 18-29 year-old women to 0.41 (95% CI: 0.31, 0.53) in 35-45 
year-olds (P for trend < 0.005).  Among UFS participants, there was increased sensitivity for 
black women in their 40s compared to 35-39 year-olds, but no significant differences by age 
for white women.   
 Figure 4.2 provides sensitivity ratios for additional demographic and reproductive 
factors.  Parity was associated with higher sensitivity of self-report among white women, 
with the strongest association seen in white RFTS participants (SeR for parous vs. 
nulliparous: 2.90; 95% CI: 1.51, 5.60).  Women with higher education tended to have higher 
sensitivity of self report, although this association was statistically significant only when 
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comparing UFS black women with the highest education to those with the lowest (SeR of 
post-baccalaureate vs. high school/some college: 1.27; 95% CI: 1.05, 1.55).  Sensitivity in 
RFTS blacks with some graduate-level education was also elevated compared to those with 
less than four years of college (SeR: 1.87; 95% CI: 0.78, 4.51).  Neither BMI nor miscarriage 
history was a predictor of self-report sensitivity in either study population. 
 In both studies, women with larger fibroids at the ultrasound examination had 
significantly higher sensitivity of self-report (Table 4.3).  After adjusting for age and parity, 
sensitivity was three to four times as high in women with tumors ≥ 4 cm compared to those 
whose largest tumor was < 2 cm in diameter.  This was seen among both black and white 
women in RFTS and white UFS participants.  Among UFS black women, however, the 
association with fibroid size was not as strong (SeR for ≥ 4 vs. < 2 cm: 1.88; 95% CI: 1.42, 
2.49). 
 Specificity (Sp)—the proportion of women reporting “no fibroid diagnosis” among 
those with no ultrasound-detected fibroids—was high in both study populations.  In RFTS, 
overall specificity was 0.98 (95% CI: 0.97, 0.99) compared to 0.86 (95% CI: 0.82, 0.90) in 
the UFS (Table 4.4).  Unlike the sensitivity results, there were few differences in specificity 
of self-report among the factors considered (Figure 4.3).  In the RFTS population, specificity 
was almost equal between blacks and whites (0.98 and 0.97, respectively).  However, 
specificity for black women in the UFS was lower compared to whites (Specificity Ratio 
[SpR]: 0.90; 95% CI: 0.81, 0.99).  As shown in Figure 4.1, age at interview was inversely 
associated with specificity in RFTS (P for trend < 0.01) but not the UFS (P for trend = 0.15).  
In both study populations, parous women had lower specificity compared to nulliparae, and 
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this was seen among both blacks and whites (Figure 4.3).  Specificity was unrelated to 
education, BMI, or miscarriage history. 
 Agreement between self-report and ultrasound fibroid status can be calculated from 
data included in Tables 4.2 and 4.4.  Overall agreement was 88% in RFTS and 65% in the 
UFS (data not shown).  The combination of differences in sensitivity, specificity, 
and prevalence of ultrasound-detected fibroids by race and age yielded the highest agreement 
(93%) in the youngest (ages 18-29) white women, and the lowest agreement (47%) in the 
oldest white women (ages 45-49).  Among black women, agreement between self-report and 
ultrasound fibroid status was also highest in the youngest age group, and varied from 83 to 
60%.  
 We examined factors since diagnosis—time interval, age at ultrasound, intervening 
pregnancy—among UFS women to investigate what might account for their lower specificity 
(that is, proportionally more women reporting a fibroid diagnosis when the study ultrasound 
was negative).  Only the UFS black women were examined (n = 221) because there were few 
UFS white women reporting a previous diagnosis who did not have ultrasound-detected 
fibroids.  A short time interval between prior diagnosis and study ultrasound was associated 
with increased concordance between self-report and ultrasound.  Concordance was highest 
(90.4%) among women who reported a diagnosis within two years of the study ultrasound.  
Age at ultrasound was also important, even after controlling for years since diagnosis.  
Concordance was 23% higher for women 40 or older relative to that for women 35-39 years 
old at the time of the ultrasound examination.   
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4.5 DISCUSSION 
 To our knowledge, this is the most detailed assessment of the validity of self-reported 
information on fibroid status.  We evaluated the sensitivity and specificity of self-report in 
two different study populations: Right From The Start, consisting of pregnant women, most 
of whom were under 35, and the Uterine Fibroid Study, which included 35-49 year-old 
women randomly selected from members of an urban health plan.  Using study ultrasound 
screening results as the indicator of “true” fibroid status, sensitivity of self-report was low 
among both study populations: 0.27 in RFTS and 0.50 in UFS.  In contrast, specificity of 
self-report was high (0.98) in RFTS to moderate (0.86) in UFS.   
4.5.1 Factors Associated with Validity of Self-Report 
 Race/ethnicity.  Self-report among black women was more sensitive but less specific 
than respective values in whites.  The higher sensitivity of self-report in black women 
compared to white women may be related to their younger age at onset resulting in larger and 
more numerous tumors compared to similarly-aged whites (20, 28, 30).  Better reporting 
among black women with fibroids could occur if these differences lead to more severe 
symptoms or easier detection during routine pelvic examination.  In addition, increased 
awareness of black women as a “high-risk” group could lead to increased surveillance and a 
higher likelihood of detection.   
 Age.  Age at interview was positively associated with sensitivity of self-report up to 
age 44, but appeared to drop in the 45-49 year age group, especially in white women.  The 
reason for this non-monotonic relationship is unclear, but may be related to fibroid size, 
which our results showed to be strongly predictive of self-report sensitivity.  Among UFS 
white women with fibroids, the proportion with tumors ≥ 4 cm in diameter was lower in the 
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45-49 year-olds compared to the 35-44 year-olds (0.22 vs. 0.28, respectively).  In 
comparison, the proportion of black women with large tumors increased with age.  This may 
reflect a real difference in the natural progression of these tumors, such that fibroids that first 
develop in white women in their 40’s remain small enough to go undetected.  In a study 
which tracked fibroid growth in tumors from 72 premenopausal women, older white women 
had a lower fibroid growth rate than their younger counterparts, while this age difference was 
not seen in black women (31).   
 In contrast with sensitivity, age was associated with a decrease in specificity in RFTS.  
Although not statistically significant, this inverse association was also seen in the UFS.  This 
could reflect respondent reporting error, or resolution of previously existing tumors.  In the 
few studies that have measured changes in fibroid size over time, tumor regression occurred 
in a small percentage of cases (22, 31, 154).  Our finding that the proportion of apparent 
false-positives increased with duration between first diagnosis and ultrasound suggests that 
specificity may be affected by time since diagnosis as well as age at interview.  Among UFS 
black women who reported having had a previous diagnosis within two years before the 
study, 90% had fibroids detected at the ultrasound examination.  This was consistent with 
findings from two prospective cohorts with biennial follow-up, in which over 90% of 
positive self-reports were confirmed in a validation subsample (20, 21).   
 Parity.  Parity was associated with higher sensitivity and lower specificity of self-
report.  Women who had been pregnant may have had an increased opportunity for diagnosis 
because of pregnancy-related ultrasound examinations.  However, we did not find a further 
association with miscarriage history, which could have increased gynecologic surveillance 
and thus increased self-report.  The decrease in specificity with parity might be due to a 
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protective effect of pregnancy in eliminating or reducing the size of fibroids.  Postpartum 
uterine remodeling was originally put forth by Baird and Dunson (40) as a possible 
mechanism for the reduced risk of fibroids seen among parous women.  More recently, a 
prospective study of pregnant women which compared early first trimester to postpartum 
ultrasound results found that 36% of tumors had resolved and 79% of the remainder had 
decreased in size (41).   
4.5.2 Strengths and Limitations 
 The relatively large sample size in both RFTS and the UFS was an asset for this 
analysis.  These data enabled us to examine black women (who are at higher risk for fibroids) 
as well as white women over a large age range.  However, we were limited in our ability to 
assess certain factors in finer detail (e.g. education level) or to conduct some subgroup 
analyses due to smaller numbers.  Generalizability of our findings to other groups must also 
be considered.  Women in RFTS volunteered for the study, and most had planned 
pregnancies.  Compared to the general population, they were more highly educated, less 
likely to smoke, and more likely to be married (28).  They had achieved the index pregnancy 
without fertility treatment, so women with fertility problems (possibly due to uterine 
fibroids) are under-represented.  UFS participants were members of a health plan and 
therefore had access to health care services.  Self-report from women with limited access to 
or use of health care might show lower sensitivity than our results.  The fact that we observed 
similar results in these two different study populations lends support to our overall findings. 
An additional strength of this analysis is use of transvaginal and transabdominal 
ultrasound to define “true” fibroid status.  Ultrasound has been shown to have high 
sensitivity (99%) and specificity (91%) when compared to histological results, which are 
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considered the gold standard (155).  A potential limitation in measuring true fibroid status is 
that the RFTS population consisted of pregnant women whose fibroids may have grown 
during early pregnancy (156).  Although ultrasound was performed early in the first 
trimester, it is possible that fibroids which were undetectable prior to pregnancy grew to a 
detectable size at the time of screening.  Identification of any such newly-detectable cases 
would result in lower sensitivity for this population.  Previous analyses of RFTS data showed 
no difference in fibroid prevalence by gestational age ultrasound (28), so detection is unlikely 
to be influenced by the timing of the ultrasound in the narrow time period in which 
examinations were conducted.  Pregnancy may also have affected the validity of the 
ultrasound results.  However, all ultrasounds were performed early in pregnancy and study 
sonographers were specially trained to measure each tumor three separate times to ensure 
that focal contractions were not mistaken for fibroid tumors. 
4.5.3 Impact of Findings 
 Our results suggest that using self-report would result in misclassification of a large 
proportion of true cases, and this misclassification might differ by ethnicity, age, and parity.  
Previous investigations (37, 157) using self-reported fibroid diagnosis have limited analyses 
to women under 35 in an attempt to reduce misclassification.  Our findings demonstrate that 
the high specificity and lower prevalence of fibroids among younger women would result in 
relatively fewer true cases being misclassified.  However, differences in reporting quality 
with respect to other factors may still lead to biased estimates, and could explain some of the 
inconsistencies in previous findings.  For example, higher sensitivity among parous women 
results in a higher likelihood of reporting a fibroid diagnosis.  In the simplest case (i.e., 
assuming no confounding, other measurement errors, or selection bias), this would lead to 
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parity being an apparent risk factor for uterine fibroids.  On the other hand, if women who 
report a fibroid diagnosis prior to the baseline of a prospective analysis are excluded, then 
cases would be differentially excluded among parous compared to nulliparous women, and 
parity would seem to be protective.   
 Sensitivity analyses performed in previous publications (44, 158) have used methods 
which apply the same validity estimates to the entire analysis population, not accounting for 
the differences in self-report validity by ethnicity, age, and parity that we detected.  Our 
results provide more detailed estimates that could be used for a more accurate assessment of 
misclassification bias in existing studies.  The availability of methods (12, 159, 160) that 
allow for varying sensitivity and specificity according to designated covariate patterns also 
provide an opportunity to calculate point and interval estimates that account for the 
differential validity of self-reported fibroid diagnosis.    
 In this analysis, between 35 to 90% of women with ultrasound-detected fibroids 
reported that they had never been diagnosed with fibroids. This finding highlights one of the 
critical needs in uterine fibroid epidemiology: the ability to correctly define cases and non-
cases and to clarify the relationships between risk factors that may be important in the onset 
of fibroids and those that play a role in their growth and detection.  Accurate outcome 
measurement, through ultrasound screening, is therefore critical to better understanding the 
etiology and natural history of uterine fibroids. 
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Table 4.1 Characteristics of Right From The Start (n = 2,046) and Uterine Fibroid Study (n = 
869) analysis populations, by race/ethnicity 
 Right From The Start   Uterine Fibroid Study 
 
White  
(n = 1,756) 
Black  
(n = 290)  
White  
(n = 363) 
Black  
(n = 506) 
  No. % No. %  No. % No. % 
Age at interview          
  <20 18 1.0 22 7.6  0  0
  20–24 134 7.6 80 27.6  0  0
  25–29 658 37.5 76 26.2  0  0
  30–34 629 35.8 85 29.3  0  0
  35–39 279 15.9 22 7.6  124 34.2 191 37.7
  40–44 38 2.2 5 1.7  122 33.6 178 35.2
  45–49 0 0  117 32.2 137 27.1
     Mean (SD) 30.2 (4.5) 27.4 (5.6)  41.9 (4.3) 41.4 (4.2) 
Highest educationa          
  High school 124 7.1 74 25.5  12 3.4 104 20.9
  Some college 229 13.0 95 32.8  33 9.3 228 45.8
  4 years of college 665 37.9 71 24.5  54 15.3 66 13.3
  Post-baccalaureate 737 42.0 50 17.2  254 72.0 100 20.1
  Missing 1   0    10   8   
BMI (kg/m2) at enrollmentb          
  <20.00 186 10.6 18 6.2  27 7.4 16 3.2
  20.00–24.99 945 53.8 75 25.9  183 50.4 117 23.2
  25.00–29.99 374 21.3 78 26.9  91 25.1 155 30.7
  ≥30.00 251 14.3 119 41.0  62 17.1 217 43.0
  Missing 0  0   0   1   
Parity          
  0 803 48.3 118 45.2  219 60.3 115 22.7
  1 608 36.6 93 35.6  52 14.3 120 23.7
  2 198 11.9 35 13.4  75 20.7 159 31.4
  3 or more 54 3.2 15 5.7  17 4.7 112 22.1
  Missing 93   29    0  0
Number of miscarriagesc          
  0 669 65.4 120 62.2  147 69.7 317 69.7
  1 277 27.1 57 29.5  47 22.3 112 24.6
  2 or more 77 7.5 16 8.3  17 8.1 26 5.7
  Missing 64 20  0  0
Previous fibroid diagnosis 
(self-report) 
 
  
  No 1680 95.7 255 87.9  294 81.0 271 53.6
  Yes 76 4.3 35 12.1  69 19.0 235 46.4
     Mean (SD) age  29.3 (5.2) 28.4 (4.0)  36.2 (5.6) 33.0 (7.2) 
     Missing age at diagnosis 15 7  4  14
table continues 
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Table 4.1 Characteristics of Right From The Start (n = 2,046) and Uterine Fibroid Study (n = 
869) analysis populations, by race/ethnicity (cont.) 
 Right From The Start   Uterine Fibroid Study 
 
White  
(n = 1,756) 
Black  
(n = 290)  
White  
(n = 363) 
Black  
(n = 506) 
  No. % No. %  No. % No. % 
Ultrasound-detected 
fibroids     
     
  No 1560 88.8 207 71.4  201 55.4 161 31.8
  Yes, size of largest tumor: 196 11.2 83 28.6  162 44.6 345 68.2
     <2.00 cm 96 49.0 38 45.8  62 38.3 78 22.6
     2.00–3.99 cm 62 31.6 19 22.9  60 37.0 140 40.6
     ≥4.00 cm 38 19.4 26 31.3  40 24.7 127 36.8
Mean (SD) age of first 
diagnosisd 31.1 (5.1) 29.1 (4.7) 
 
40.9 (5.9) 36.3 (7.5) 
  Missing 15 7  4  14
 Abbreviations: SD, standard deviation. 
 a  RFTS asked for years of schooling completed and was categorized as follows: ≤12, “High 
school;” 13-15, “Some college;” 16, “4 years of college;” and >16, “Post-baccalaureate.” The “high 
school” category includes some women with less than a high school education: 11 black UFS 
women, and 19 white and 21 black RFTS women.  The “postbaccalaureate” category includes 197 
white and 11 black women in the UFS who reported having a graduate/professional degree. 
 b  For RFTS, BMI was based on self-reported pre-pregnancy height and weight or first trimester 
clinic measures when missing.  
 c  Among 1,087 white and 213 black RFTS women with a previous pregnancy (prior to study 
enrollment); 211 white and 455 black UFS women with a previous pregnancy.  
 d  Among all women with fibroids previously diagnosed or newly-detected at ultrasound. 
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Table 4.2 Unadjusted sensitivity of self-reported uterine fibroid status among 279 Right From The Start and 507 Uterine Fibroid 
Study participants with fibroids detected at study ultrasound 
 All Women  White Women  Black Women 
  
No. 
Correct
 
 Totala 
 
 Se   95% CI  
 No. 
Correct
 
 Totala 
 
 Se   95% CI  
 No. 
Correct
 
 Totala 
 
 Se   95% CI 
Right From The Start 
Overall  74  279 0.27 0.22, 0.32   46  196 0.23 0.18, 0.30   28  83 0.34 0.25, 0.46 
Age at interview               
  18–29  11  89 0.12 0.07, 0.21   8  57 0.14 0.07, 0.27   3  32 0.09 0.03, 0.28 
  30–34  30  109 0.28 0.20, 0.37   15  74 0.20 0.13, 0.32   15  35 0.43 0.29, 0.63 
  35–45  33  81 0.41 0.31, 0.53   23  65 0.35 0.25, 0.49   10  16 0.63 0.43, 0.91 
Highest education                
  High school/Some college  13  65 0.20 0.12, 0.33   7  34 0.21 0.11, 0.40   6  31 0.19 0.09, 0.40 
  4 years of college  29  101 0.29 0.21, 0.39   19  76 0.25 0.17, 0.37   10  25 0.40 0.25, 0.65 
  Postbaccalaureate  32  113 0.28 0.21, 0.38   20  86 0.23 0.16, 0.34   12  27 0.44 0.29, 0.69 
BMI (kg/m2) at enrollment               
  ≤24.99  33  133 0.25 0.18, 0.33   24  114 0.21 0.15, 0.30   9  19 0.47 0.29, 0.76 
  25.00–29.99  16  70 0.23 0.15, 0.35   10  48 0.21 0.12, 0.36   6  22 0.27 0.14, 0.54 
  ≥30.00  25  76 0.33 0.24, 0.45   12  34 0.35 0.22, 0.56   13  42 0.31 0.20, 0.49 
Parity               
  Nulliparous  20  131 0.15 0.10, 0.23   10  94 0.11 0.06, 0.19   10  37 0.27 0.16, 0.46 
  Parous  51  139 0.37 0.29, 0.46   35  97 0.36 0.28, 0.47   16  42 0.38 0.26, 0.56 
Ever miscarryb               
  No  35  113 0.31 0.24, 0.41   22  75 0.29 0.21, 0.42   13  38 0.34 0.22, 0.53 
  Yes  25  69 0.36 0.26, 0.50   19  52 0.37 0.26, 0.52   6  17 0.35 0.19, 0.67 
table continues 
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 Table 4.2 Unadjusted sensitivity of self-reported uterine fibroid status among 279 Right From The Start and 507 Uterine Fibroid 
Study participants with fibroids detected at study ultrasound (cont.) 
 All Women  White Women  Black Women 
  
No. 
Correct
 
 Totala 
 
 Se   95% CI  
 No. 
Correct
 
 Totala 
 
 Se   95% CI  
 No. 
Correct
 
 Totala 
 
 Se   95% CI 
Uterine Fibroid Study 
Overall  253  507 0.50 0.45, 0.54   52  162 0.32 0.25, 0.40   201  345 0.58 0.53, 0.64 
Age at interview               
  35–39  66  149 0.44 0.37, 0.53   12  36 0.33 0.21, 0.53   54  113 0.48 0.39, 0.58 
  40–44  99  171 0.58 0.51, 0.66   19  48 0.40 0.28, 0.56   80  123 0.65 0.57, 0.74 
  45–49  88  187 0.47 0.40, 0.55   21  78 0.27 0.19, 0.39   67  109 0.61 0.53, 0.71 
Highest education                
  High school/Some college  136  256 0.53 0.47, 0.60   7  20 0.35 0.19, 0.64   129  236 0.55 0.49, 0.61 
  4 years of college  32  64 0.50 0.39, 0.64   7  22 0.32 0.17, 0.59   25  42 0.60 0.46, 0.76 
  Postbaccalaureate  78  175 0.45 0.38, 0.53   34  113 0.30 0.23, 0.40   44  62 0.71 0.61, 0.83 
BMI (kg/m2) at enrollment               
  ≤24.99  71  169 0.42 0.35, 0.50   25  89 0.28 0.20, 0.39   46  80 0.58 0.48, 0.69 
  25.00–29.99  83  150 0.55 0.48, 0.64   19  42 0.45 0.32, 0.63   64  108 0.59 0.51, 0.69 
  ≥30.00  99  187 0.53 0.46, 0.61   8  31 0.26 0.14, 0.47   91  156 0.58 0.51, 0.67 
Parity               
  Nulliparous  73  187 0.39 0.33, 0.47   33  111 0.30 0.22, 0.40   40  76 0.53 0.43, 0.65 
  Parous  18  320 0.56 0.51, 0.62   19  51 0.37 0.26, 0.53   161  269 0.60 0.54, 0.66 
Ever miscarryb               
  No  154  284 0.54 0.49, 0.60   27  64 0.42 0.32, 0.56   127  220 0.58 0.52, 0.65 
  Yes  61  121 0.50 0.42, 0.60   6  27 0.22 0.11, 0.45   55  94 0.59 0.49, 0.69 
 Abbreviations: Se, sensitivity; CI: confidence interval. 
 a  Subcategory numbers may not sum to total due to missing data. 
 b  Among women with a previous pregnancy. 
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Table 4.3 Relationship between size of largest fibroid detected at study ultrasound and sensitivity of self-report in 279 Right From 
The Start and 507 Uterine Fibroid Study participants with fibroids detected at study ultrasound 
White Women  Black Women 
Mean diameter of 
largest fibroid 
No. 
Correct Total Se  95% CI 
 
SeRa 95% CI  
No. 
Correct Total Se 95% CI SeRa 95% CI 
RFTS              
  <2.00 cm 14 96 0.15 0.09, 0.24 1.00 Referent  5  38 0.13 0.06, 0.30 1.00 Referent 
  2.00–3.99 cm 12 62 0.19 0.12, 0.32 1.42 0.73, 2.79  8  19 0.42 0.25, 0.71 4.09 1.47, 11.35 
  ≥4.00 cm 20 38 0.53 0.39, 0.71 3.08 1.76, 5.36  15  26 0.58 0.42, 0.80 4.15 1.56, 11.02 
UFS              
  <2.00 cm 8 62 0.13 0.07, 0.25 1.00 Referent  32  78 0.41 0.31, 0.54 1.00 Referent 
  2.00–3.99 cm 22 60 0.37 0.26, 0.51 2.93 1.42, 6.02  69  140 0.49 0.42, 0.58 1.19 0.87, 1.62 
  ≥4.00 cm 22 40 0.55 0.42, 0.73 4.26 2.11, 8.60  100  127 0.79 0.72, 0.86 1.88 1.42, 2.49 
 Abbreviations: RFTS, Right From The Start; UFS, Uterine Fibroid Study; Se, sensitivity of self-report; SeR, sensitivity ratio; CI, confidence 
interval. 
 a  Adjusted for age and parity. 
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Table 4.4 Unadjusted specificity of self-reported uterine fibroid status among 1,767 Right From The Start and 362 Uterine Fibroid 
Study participants with no fibroids detected at study ultrasound  
 All Women  White Women  Black Women 
  
No. 
Correct
 
 Totala 
 
 Sp   95% CI  
 No. 
Correct
 
 Totala 
 
 Sp   95% CI  
 No. 
Correct
 
 Totala 
 
 Sp   95% CI 
Right From The Start 
Overall  1,730  1,767 0.98 0.97, 0.99   1,530  1,560 0.98 0.97, 0.99   200  207 0.97 0.94,0.99 
Age at interview               
  18–29  889  899 0.99 0.98, 1.00   745  753 0.99 0.98, 1.00   144  146 0.99 0.97, 1.01 
  30–34  590  605 0.98 0.96, 0.99   543  555 0.98 0.97, 0.99   47  50 0.94 0.88, 1.01 
  35–45  251  263 0.95 0.93, 0.98   242  252 0.96 0.94, 0.98   9  11 0.82 0.62, 1.08 
Highest education                
  High school/Some college  445  457 0.97 0.96, 0.99   312  319 0.98 0.96, 0.99   133  138 0.96 0.93, 0.99 
  4 years of college  620  635 0.98 0.96, 0.99   575  589 0.98 0.96, 0.99   45  46 0.98 0.94, 1.02 
  Postbaccalaureate  664  674 0.99 0.98, 0.99   642  651 0.99 0.98, 0.99   22  23 0.96 0.88, 1.04 
BMI (kg/m2) at enrollment               
  ≤24.99  1,071  1,091 0.98 0.97, 0.99   998  1,017 0.98 0.97, 0.99   73  74 0.99 0.96, 1.01 
  25.00–29.99  374  382 0.98 0.96, 0.99   319  326 0.98 0.96, 0.99   55  56 0.98 0.95, 1.02 
  ≥30.00  285  294 0.97 0.95, 0.99   213  217 0.98 0.96, 1.00   72  77 0.94 0.88, 0.99 
Parity               
  Nulliparous  786  790 0.99 0.99, 1.00   706  709 1.00 0.99, 1.00   80  81 0.99 0.96, 1.01 
  Parous  833  864 0.96 0.95, 0.98   738  763 0.98 0.95, 0.98   95  101 0.94 0.90, 0.99 
Ever miscarryb               
  No  654  676 0.97 0.95, 0.98   577  594 0.97 0.96, 0.98   77  82 0.94 0.89, 0.99 
  Yes  346  358 0.97 0.95, 0.99   291  302 0.96 0.94, 0.98   55  56 0.98 0.95, 1.02 
table continues 
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Table 4.4 Unadjusted specificity of self-reported uterine fibroid status among 1,767 Right From The Start and 362 Uterine Fibroid 
Study participants with no fibroids detected at study ultrasound (cont.)  
 All Women  White Women  Black Women 
  
No. 
Correct
 
 Totala 
 
 Sp   95% CI  
 No. 
Correct
 
 Totala 
 
 Sp   95% CI  
 No. 
Correct
 
 Totala 
 
 Sp   95% CI 
Uterine Fibroid Study 
Overall  311  362 0.86 0.82, 0.90   184  201 0.92 0.87, 0.95   127  161 0.79 0.72, 0.85 
Age at interview               
  35–39  144  166 0.87 0.82, 0.92   84  88 0.95 0.91, 1.00   60  78 0.77 0.68, 0.87 
  40–44  112  129 0.87 0.81, 0.93   66  74 0.89 0.82, 0.97   46  55 0.84 0.74, 0.94 
  45–49  55  67 0.82 0.73, 0.92   34  39 0.87 0.77, 0.98   21  28 0.75 0.61, 0.93 
Highest education                
  High school/Some college  97  121 0.80 0.73, 0.88   23  25 0.92 0.82, 1.03   74  96 0.77 0.69, 0.86 
  4 years of college  47  56 0.84 0.75, 0.94   26  32 0.81 0.69, 0.96   21  24 0.88 0.75, 1.02 
  Postbaccalaureate  162  179 0.91 0.86, 0.95   132  141 0.94 0.90, 0.98   30  38 0.79 0.67, 0.93 
BMI (kg/m2) at enrollment               
  ≤24.99  151  174 0.87 0.82, 0.92   110  121 0.91 0.86, 0.96   41  53 0.77 0.67, 0.89 
  25.00–29.99  81  96 0.84 0.77, 0.92   45  49 0.92 0.84, 1.00   36  47 0.77 0.65, 0.90 
  ≥30.00  79  92 0.86 0.79, 0.93   29  31 0.94 0.85, 1.03   50  61 0.82 0.73, 0.92 
Parity               
  Nulliparous  137  147 0.93 0.89, 0.97   102  108 0.94 0.90, 0.99   35  39 0.90 0.81, 1.00 
  Parous  174  215 0.81 0.76, 0.86   82  93 0.88 0.82, 0.95   92  122 0.75 0.68, 0.83 
Ever miscarryb               
  No  149  180 0.83 0.77, 0.88   75  83 0.90 0.84, 0.97   74  97 0.76 0.68, 0.85 
  Yes  69  81 0.85 0.78, 0.93   33  37 0.89 0.80, 1.00   36  44 0.82 0.71, 0.94 
 Abbreviations: Sp, specificity; CI: confidence interval. 
 a  Subcategory numbers may not sum to total due to missing data. 
 b  Among women with a previous pregnancy. 
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Figure 4.1 Self-report sensitivity (upper panel) and specificity (lower panel) by 
race/ethnicity and age at interview for Right From The Start (n = 2,046) and Uterine Fibroid 
Study (n = 869) participants  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations: CI, confidence interval; RFTS, Right From The Start; UFS, Uterine Fibroid Study. 
Error bars indicate 95% confidence intervals. Estimates for the following RFTS age groups are 
excluded because there were fewer than 10 women in each race/age category: sensitivity for women 
aged 18-24 and black women over 40; specificity for black women aged 40-44. 
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Figure 4.2 Association of demographic and reproductive factors with sensitivity of self-
reported uterine fibroid status among 279 Right From The Start and 507 Uterine Fibroid 
Study participants with fibroids detected at study ultrasounda 
 
 
 
 a  Sensitivity ratios (sensitivity in a subgroup of interest compared to sensitivity in the reference 
group) are adjusted for age (continuous), parity, and (for unstratified estimates) race/ethnicity.  A 
quadratic term was entered for age in the UFS multivariate analysis due to non-linearity. 
 b  Among women with a previous pregnancy. 
 c  Estimates obtained using Poisson regression. 
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Figure 4.3 Association of demographic and reproductive factors with specificity of self-
reported uterine fibroid status among 1,767 Right From The Start and 362 Uterine Fibroid 
Study participants with no fibroids detected at study ultrasounda  
 
 
 
 a  Specificity ratios are specificity of self-report in subgroup of interest compared to specificity in 
the reference group.  UFS specificity ratios are adjusted for parity, and (for unstratified estimates) 
race/ethnicity.  RFTS estimates are unadjusted. 
 b  Among women with a previous pregnancy. 
 c  Estimates obtained using Poisson regression. 
 
   
CHAPTER 5: PESTICIDE USE AND UTERINE FIBROIDS AMONG WOMEN IN 
THE AGRICULTURAL HEALTH STUDY 
 
5.1 ABSTRACT 
 Uterine fibroids are the leading indication for hysterectomy in the US.  Although it is 
well-accepted that ovarian hormones play a role in fibroid growth, few studies have 
examined endocrine-disrupting chemicals as potential risk factors.  Using cross-sectional 
data from the Agricultural Health Study, the authors investigated the association between 
pesticide use and fibroids among 16,526 women aged 18-59.  Self-reporting of fibroids is 
known to be inaccurate because many women with fibroids are never diagnosed.  Therefore, 
sensitivity and specificity estimates obtained from a separate analysis of fibroid reporting 
accuracy were incorporated in logistic regression models to correct for outcome 
misclassification.  Both uncorrected (aOR) and corrected (cOR) estimates were adjusted for 
age and state (Iowa/North Carolina).  Ever use of agricultural pesticides was associated with 
fibroids, with users of ≥ 3 pesticides having the highest odds compared to never users of any 
pesticide (aOR: 1.31, 95% CI: 1.12, 1.53; cOR: 1.44, 95% CI: 1.11, 1.87).  Use of any of 10 
pesticides classified a priori as potentially hormonally active was associated with fibroids 
when compared with never use of any pesticide (aOR: 1.28, 95% CI: 1.12, 1.45; cOR: 1.48, 
95% CI: 1.20, 1.82), but odds were not increased when compared to users of other pesticides.  
When pesticides were grouped by chemical class, organophosphate users had slightly higher 
odds than women reporting use of other agricultural pesticides (aOR: 1.17, 95% CI: 1.05, 
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1.31; cOR: 1.21, 95% CI: 1.00, 1.45).  These results suggest a possible association between 
agricultural pesticide exposure and uterine fibroids that warrants further investigation.   
5.2 BACKGROUND 
 Uterine leiomyomata (fibroids) are benign neoplasms of uterine smooth muscle tissue 
that develop in the majority of women (1).  Fibroids can cause menstrual abnormalities, 
pelvic pain, and pregnancy complications (2), and are the leading indication for 
hysterectomies in the United States (161), accounting for over one-third of these surgeries 
(3).  Although a highly prevalent condition, fibroids remain clinically silent in a significant 
proportion of women with the tumors.  There is an incomplete understanding of the etiology 
of uterine fibroids, but it is well-established that their growth and development is dependent 
on estrogen and progesterone (83, 162).   
 Given the relationship between hormones and fibroid pathogenesis, the possible role 
of exogenous hormonally active agents deserves attention.  Exposure to chemicals that either 
mimic ovarian hormones or exert agonistic effects on hormone receptors may play a part in 
the growth of these tumors.  Animal models and in vitro experiments support the role of 
some pesticides and persistent organic pollutants in uterine leiomyoma cell proliferation (5, 
6, 9).  Prenatal diethylstilbestrol and bisphenol A exposure in mice has been shown to 
increase reproductive tract abnormalities, including uterine fibroids (7, 8).  Exposure to 
agricultural pesticides has been associated with menstrual cycle irregularities (127), age at 
menopause (126), and increased time-to-pregnancy (163) in humans, indicating that these 
compounds may have an effect on the female hormonal milieu.  However, the possible role 
of pesticides in the etiology of uterine fibroids has not been explored in epidemiologic 
studies.   
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 Women living on farms have increased opportunity for both direct and indirect 
pesticide exposure compared to the non-farming population.  We therefore examined the 
association between pesticide use and self-reported uterine fibroid status among women 
enrolled in the Agricultural Health Study, focusing on hormonally active pesticides and 
pesticide use patterns.  Because many women with fibroids remain asymptomatic and 
undiagnosed, the use of self-report to identify cases and non-cases is subject to 
misclassification.  In order to account for this misclassification bias, we employed an 
outcome correction method (12) using self-report sensitivity and specificity estimates 
obtained from a separate analysis of two study populations that were screened for fibroids 
using ultrasound.   
5.3 MATERIALS AND METHODS 
5.3.1 Study Population 
 The Agricultural Health Study (AHS) is a longitudinal cohort of approximately 
60,000 licensed commercial and private pesticide applicators and 32,000 spouses of private 
applicators in North Carolina and Iowa.  Study details have been described previously (141), 
and questionnaires are available on-line (www.aghealth.org/questionnaires.html).  
Individuals applying for a restricted-use pesticide license were recruited at state licensing 
agencies between 1993 and 1997.  Those who agreed to participate in the study completed an 
Enrollment Questionnaire and were asked to identify their spouses for enrollment in the 
study.  Married male private applicators (mostly farmers) were given two questionnaires to 
be completed by their female spouse.  A telephone interview was conducted to collect data 
from spouses that did not complete the take-home questionnaires.  Seventy-five percent of 
identified spouses enrolled in the study by completing the Spouse Questionnaire (19% of 
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whom completed by telephone).  The Spouse and Applicator Enrollment Questionnaires 
collected data on pesticide use, farming activities, general health and lifestyle factors, and 
demographics.  All women (applicators and spouses) also received the Female and Family 
Health Questionnaire which gathered information about reproductive history.  Institutional 
review boards of the National Institutes of Health and their contractors approved the study. 
 Women (applicators or spouses) who completed the enrollment questionnaire were 
re-contacted for follow-up telephone interviews approximately five years later, between 1999 
and 2003.  Data collected in the follow-up included a more extensive health history 
(including fibroid diagnosis) and updated reproductive history and pesticide use information.  
Approximately 69% of female private applicators (n = 921) and 74% of applicators’ wives (n 
= 23,682) completed the follow-up interview.  In this analysis, women who did not 
participate were about one year younger on average, had less education, and were more likely 
to reside in North Carolina, to report their ethnicity as non-white, and to report never 
personally mixing or applying pesticides in the Enrollment Questionnaire.   
 This analysis focused on female pesticide applicators and spouses of pesticide 
applicators who completed the follow-up interview.  We excluded women if they did not 
identify themselves as non-Hispanic white (n = 1,606) or were 60 or older at the time of 
follow-up (n = 6,355).  We further excluded 100 women missing uterine fibroid data and 16 
women with missing or conflicting information on pesticide use.  The final analysis subset of 
16,526 women included 15,985 wives of pesticide applicators and 541 women who were 
licensed private pesticide applicators. 
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5.3.2 Exposure Assessment 
 Lifetime pesticide use was reported at baseline (Spouse or Applicator Enrollment 
questionnaires).  Women were asked if they had ever personally mixed or applied pesticides 
in their lifetime, whether for agricultural or residential use.  Those who answered yes were 
then asked about ever use of 50 specific pesticides.  We constructed variables for ever/never 
use of individual pesticides, as well as pesticide groupings according to chemical structure 
(organochlorines, organophosphates, carbamates, and triazines).  Women also reported 
whether they grew up on a farm (“Before age 18, did you live at least half your life on a 
farm?”) and the number of years they had lived or worked on a farm.   
 Additional questions on residential pesticide use—whether or not they personally 
treated their own home or lawn for pests—were only asked in the Spouse Questionnaire.  We 
constructed a variable to capture wives’ pesticide use patterns based on answers to these 
questions and the individual pesticide questions.  The referent category included women who 
reported never mixing or applying any pesticides.  Women who reported residential use but 
did not report mixing or applying any of the 50 specific pesticides were categorized as 
“Residential only.”  Wives who reported use of any of the five most frequently reported 
agricultural pesticides—glyphosate, carbaryl, malathion, 2,4-D, and diazinon—were 
categorized as using “common agricultural pesticides.”  With the exception of diazinon, these 
pesticides are classified as general use pesticides by the US Environmental Protection 
Agency (EPA), and are generally considered to have low toxicity (149).  Women who used 
any of the specific pesticides other than the top five were categorized based on the number 
used: “1-2 other agricultural” or “≥3 other agricultural.”  Women who reported that they 
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mixed or applied pesticides but did not report using any of the 50 specific pesticides that 
were queried were classified as using “Other pesticides.” 
   Using the National Library of Medicine’s PubMed database, we updated an earlier 
literature review (127) on the endocrine-disrupting potential of pesticides listed in the AHS 
questionnaires.  This identified 10 possible hormonally active pesticides that showed effects 
possibly relevant to fibroid pathogenesis: the organochlorines DDT, chlordane, lindane, 
dieldrin, and toxaphene; mancozeb; atrazine; alachlor; carbon tetrachloride; and pyrethroids.  
Pesticides were selected based on in vivo or in vitro evidence either for 
estrogenic/progestagenic activity or follicle-stimulating hormone disruption.  Because the 
ovary is the primary source of steroid hormones in the uterus, we also included pesticides 
with evidence of estrus cycle disruption or effects on the ovary or uterus in animal models.  
For the analysis, we created a dichotomous variable to indicate ever/never use of any of these 
10 pesticides. 
5.3.3 Study Outcome and Covariates 
 The outcome of interest was uterine fibroid diagnosis as reported by participants in 
the follow-up interview.  Women who answered “yes” to the question “Has a doctor or other 
health professional ever told you that you had uterine fibroids?” were counted as cases.  
Possible confounders were identified based on previous literature on uterine fibroid risk 
factors and included age at follow-up, age at menarche, and parity (4).  Age at menarche 
(<12, 12, 13, 14, ≥15) was reported in the baseline Female and Family Health (FFH) 
Questionnaire.  Parity has been inversely associated with fibroids (reviewed by Laughlin et 
al. (4)), and there is some suggestion that births to women after their early-twenties might 
partially account for the apparent protective effect of pregnancy (40).  A categorical variable 
   
 78
was created to capture timing of births (none, all births before age 24, one or more births ≥24 
years of age) based on the reproductive history obtained in the FFH and updated in the 
follow-up interview.  State of residence (Iowa/North Carolina) was classified at the time of 
enrollment.  We also identified women who reported having had a hysterectomy (baseline 
FFH questionnaire or the follow-up interview) for purposes of assigning sensitivity and 
specificity estimates in the outcome correction model, as described below.  
5.3.4 Statistical Analysis 
 Logistic regression was used to estimate the cross-sectional association of pesticide 
use at enrollment in relation to uterine fibroid diagnosis.  Analyses were carried out with the 
statistical software package SAS 9.1 (SAS Institute, Inc., Cary, North Carolina).  To get a 
better picture of the shape of the relationship between age and fibroid status, we examined 
the log odds of fibroids by age, categorized as 21-29 and then by successive 2-year categories 
(e.g., 30-31, 32-33).  Based on this assessment, a quadratic term for age was added to the 
model and retained if the Wald P value was <0.05 (all P values are two-sided).   We 
evaluated the linearity assumption for categorical predictors on the log scale using indicator 
variables with common referent coding (151).  When a linear relationship was observed, we 
modeled the categorical predictor as a single ordinal variable and calculated a Wald P value 
for its coefficient.   
 The main exposures of interest in this analysis were pesticide use patterns and use of 
hormonally active pesticides.  We also examined ever use of individual pesticides (limited to 
those with at least 10 exposed cases) and chemical class groupings as main exposures in 
separate analyses.  All prevalence odds ratios (OR) and 95% confidence intervals (CI) were 
adjusted for age at follow-up (continuous), age squared, and state of residence.  We assessed 
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for confounding and effect measure modification for the main exposures and the chemical 
class groupings, because assessment for the individual pesticides would be unwieldy.  
Timing of births and age at menarche were not confounders of the association between 
fibroid diagnosis and pesticide use as assessed by at least a 10% change relative to the age- 
and state-adjusted odds ratios.  We tested for statistical interaction by age at follow-up by 
including an interaction term for each exposure and age and a P <0.10 significance level.  
Age at follow-up did not modify associations with any of the exposures tested.   
 Because fibroid status was ascertained via self-report, we used an outcome correction 
method in the logistic regression models to produce point estimates and confidence intervals 
that accounted for outcome misclassification bias.  Details of this method are described 
elsewhere (12) and the SAS macro is available on-line 
(http://medschool.umaryland.edu/epidemiology/software.asp).  Briefly, given known or 
assumed values for sensitivity and specificity of the outcome, an expectation-maximization 
(EM) algorithm (153) is used to obtain odds ratios and their variances.  We applied 
sensitivity and specificity estimates from a separate analysis of self-report validity that was 
conducted in two study populations which had self-reported fibroid status and “gold 
standard” ultrasound examination results (data not published).  Together, these studies 
included over 2,000 white premenopausal women aged 18-49.  Results demonstrated that 
sensitivity of self-report was generally low, but increased with age with a slight decline in 
women aged 45-49.  In contrast, specificity was generally high but had a small negative 
association with age.  Additional investigation suggested that women who reported having 
had fibroids previously but did not have them at ultrasound may not have been wrong.  
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Tumor regression could have occurred in association with intervening factors such as time 
between diagnosis and study ultrasound or pregnancies.   
 Therefore, for our main correction model (referred to as Corrected-1), we varied 
sensitivity by age but set specificity to 0.95.  We used the following values for sensitivity by 
age in the main outcome correction model: age 18-29, 0.15; 30-34, 0.20; 35-39, 0.35; 40-44, 
0.40; 45-59, 0.30.  We assumed that women who reported having had a hysterectomy (n = 
3,022) would be better reporters of fibroid diagnosis than those who had not, and set 
sensitivity to 0.85 and specificity to 0.95 for this subgroup.   
 Because of our specific interest in hormonally active pesticides and pesticide use 
patterns, we performed additional sensitivity analyses to evaluate the influence of our 
assumptions in these models.  We examined the assumption of high self-report specificity by 
running models in which specificity decreased with age, as observed in the earlier validity 
analysis (Corrected-2).  We also ran models in which sensitivity and specificity varied with 
age as in the Corrected-1 and -2 models, but treating all women as if they had not had a 
hysterectomy (Corrected-3 and Corrected-4).  Details of these additional analyses are 
provided in Tables 5.4 and 5.5. 
5.4 RESULTS 
5.4.1 Characteristics of Analysis Population 
 The majority of the study population was enrolled in Iowa, but women who resided in 
North Carolina at the time of enrollment had higher odds of reporting fibroids (Table 5.1).  
The odds of fibroids increased with age at follow-up (P for trend <0.0001) and decreased 
with age at menarche (P for trend <0.0001).  Women who gave birth before age 24 were 
more likely to report being diagnosed with uterine fibroids than those who had at least one 
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birth at 24 or older.  Slightly more than 18% of women had a hysterectomy by the time of 
follow-up and of these, 39% reported having had a fibroid compared to 9% of women who 
had not had a hysterectomy.  Number of years living or working on a farm was positively 
associated with fibroids (P for trend <0.0001), but the association was no longer statistically 
significant after adjustment for age and state (data not shown).  
5.4.2 Pesticide Use Patterns 
 The analysis of pesticide use patterns was limited to 15,985 wives of pesticide 
applicators who completed the Spouse Questionnaire that asked about residential pesticide 
use (Figure 5.1).  After controlling for age and state, the odds of fibroid diagnosis were not 
significantly different when comparing women who reported only residential use to those 
who never mixed or applied any pesticides (adjusted odds ratio [aOR] = 0.92; 95% CI: 0.76, 
1.10).  There was a trend for slightly increased odds of fibroids across categories of 
agricultural pesticide use, with women who used three or more agricultural pesticides having 
the highest odds compared to never users of any pesticides (aOR = 1.31; 95% CI: 1.12, 1.53).  
Odds were somewhat elevated for women who reported personally mixing or applying 
pesticides, but did not use any of the 50 specific pesticides (aOR = 1.15; 95% CI: 0.86, 1.53).  
Estimates from corrected models were further away from the null than uncorrected estimates 
(Figure 5.1), but after correction, there was little difference in the odds of fibroid diagnosis 
among agricultural pesticide use categories, with a corrected odds ratio (cOR) of 1.42 (95% 
CI: 1.16, 1.72) for common agricultural pesticide use and 1.44 (95% CI: 1.11, 1.87) for ≥ 3 
other agricultural pesticides.  Sensitivity analyses that varied assumptions used to correct for 
outcome misclassification generally resulted in odds ratios further away from the null.  The 
greatest difference between uncorrected and corrected estimates appeared in the Corrected-4 
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model, which varied both sensitivity and specificity by age and did not distinguish between 
women who did or did not have a hysterectomy (Table 5.4).   
5.4.3 Hormonally Active Pesticides 
 Approximately 16% of women in this analysis reported using one or more of the 10 
pesticides identified as possible hormonally active agents, estrus cycle disruptors, or utero- or 
ovotoxic (Table 5.2).  The odds of fibroid diagnosis in these women were 1.28 times as high 
as women who never mixed or applied any pesticides (95% CI: 1.12, 1.45).  Correcting for 
outcome misclassification further strengthened this association (cOR = 1.48; 95% CI: 1.20, 
1.82) (Table 5.2).  Results of sensitivity analyses (Table 5.5) followed similar patterns as 
above, with the strongest association seen in the Corrected-4 model (cOR = 4.23; 95% CI: 
1.86, 9.61).  However, there was no difference in the odds of fibroid diagnosis when women 
who used hormonally active pesticides were compared to those who used other pesticides 
(aOR = 1.02; 95% CI: 0.90, 1.15), either in uncorrected or corrected models.   
5.4.4 Use of Specific Pesticides 
 Table 5.3 provides results for the association of specific pesticides and chemical class 
groupings within the subset of women who used agricultural pesticides.  Of the four chemical 
classes investigated, ever use of organophosphates was weakly associated with fibroid 
diagnosis (aOR = 1.17; 95% CI: 1.05, 1.31).  The association was only slightly higher (cOR 
= 1.21; 95% CI: 1.00, 1.45) after correcting for outcome misclassification (data not shown).  
Among the specific organophosphate pesticides, use of coumaphos (aOR = 1.41; 95% CI: 
1.01, 1.96), malathion (aOR = 1.17; 95% CI: 1.05, 1.31), or parathion (aOR = 1.42; 95% CI: 
1.00, 2.00) was significantly (P < 0.05) associated with elevated odds of fibroid diagnosis.  
Carbon tetrachloride showed the strongest association with fibroid diagnosis among the 
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pesticides examined (aOR = 1.70; 95% CI: 1.02, 2.85).  Of the 10 pesticides identified a 
priori as possibly hormonally active, this was the only one significantly associated with 
fibroids.  There was a suggestive inverse association with fibroid diagnosis among users of 
the carbamate aldicarb (aOR = 0.57; 0.32, 1.00).  Spearman correlation coefficients among 
these five pesticides—coumaphos, malathion, parathion, carbon tetrachloride, and aldicarb—
were all ≤ 0.1, indicating that observed associations were not confounded by other pesticide 
use (data not shown).     
5.5 DISCUSSION 
 To our knowledge, this analysis is the first to explore the relationship between 
pesticide use and self-reported physician diagnosis of uterine fibroids.  The Agricultural 
Health Study provided a unique opportunity to examine detailed information about specific 
pesticides among a large cohort of women who have higher exposures than the general 
population.     
 Although women who reported using pesticides to treat pests around their home or 
lawn/garden did not have increased odds of fibroids compared to women who did not use any 
pesticides, we observed a positive association among agricultural pesticide users.  Evidence 
for an association with fibroids was found among ever users of the 10 pesticides we 
identified based on the toxicological evidence as possibly relevant to fibroid pathogenesis, 
when compared to women who did not use any pesticides.  When compared to women who 
used other agricultural pesticides, however, the odds of fibroid diagnosis were similar.  We 
therefore examined associations between fibroid diagnosis and specific pesticides among the 
subset of women who reported agricultural pesticide use.  We found significantly elevated 
odds among organophosphate pesticide users and, specifically, among women who used 
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coumaphos, malathion, or parathion.  None of these pesticides were identified as hormonally 
active as a result of our literature review, mainly because few studies have evaluated them for 
endocrine disrupting effects.  The fumigant carbon tetrachloride, which was identified as 
hormonally active, had the strongest association with fibroid diagnosis among all individual 
pesticides examined.  Early animal studies suggest that carbon tetrachloride acts indirectly, 
through hepatotoxic effects, to increase serum estradiol and progesterone levels, decrease 
estrone metabolism, and increase levels of these hormones in the uterus (164-166).  There are 
no studies investigating whether carbon tetrachloride acts directly as an estrogen or 
progesterone mimic or agonist.  
   Although there are no epidemiologic data to compare to our results, there is a 
plausible biological mechanism for the role of hormonally active agents in fibroid 
pathogenesis.  Results of clinical trials and experimental models, along with the observation 
that fibroids occur in women in their reproductive years and typically diminish after 
menopause, clearly indicate the role of both estrogen and progesterone in fibroid growth 
(reviewed by Marsh et al. (83)).  In vivo and in vitro experiments have suggested that 
hormonally active agents can exert effects similar to ovarian hormones on fibroids.  The most 
compelling evidence comes from the Eker rat, which spontaneously develops uterine fibroids 
with high frequency and many of the phenotypic characteristics of human fibroids.  
Diethylstilbesterol (DES), phytoestrogens, and some organochlorine pesticides 
(methoxychlor, kepone, endosulfan, toxaphene, and dieldrin) have been shown to have 
estrogenic activity in the Eker rat uterine leiomyoma (UL) cell line either by inducing a 
transcriptional response or cell proliferation in vitro (134).  More recently, fenvalerate, a 
pyrethroid insecticide, was observed to increase the rate of growth in vitro of human UL as 
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well as Eker rat UL and uterine smooth muscle cells (9).  None of the pesticides identified as 
being associated with fibroids in our analysis has been tested in the Eker rat.   
 Epidemiologic studies of the association between endocrine disruptors and uterine 
fibroids have been few.  One study that examined DDT found significantly higher 
concentrations in leiomyomatous tissue compared to surrounding normal myometrium in a 
sample of 25 women (10).  A prospective study of women living in the vicinity of a chemical 
plant explosion in Seveso, Italy found a statistically significant inverse association between 
serum levels of 2,3,7,8-tetrachlrodibenzo-p-dioxin (TCDD) and hazard of fibroid onset (137), 
in line with data that TCDD acts as an antiestrogen in the rat uterine myometrium (138).  A 
cross-sectional analysis of women in the National Health and Nutrition Examination Survey 
found no association with self-reported fibroid diagnosis and blood levels of the endocrine 
disrupting heavy metals lead, cadmium, and mercury (139).   
 Because we used self-reported fibroid diagnosis to classify cases and non-cases, we 
likely misclassified a substantial proportion of true cases that had not come to clinical 
attention.  In order to address this bias, we used a correction method in the logistic regression 
models to adjust for imperfect outcome measurement (12).  Our assumptions regarding self-
report accuracy were informed by an earlier analysis of data from the Uterine Fibroid Study 
(UFS) and Right from the Start (RFTS) which showed that, in particular, sensitivity of self-
report was quite poor and differed with age (data not published).  Because we assumed that 
misclassification was not dependent on exposure, results from models corrected for 
misclassification moved the odds ratio further away from the null than the (uncorrected) 
model which assumed perfect outcome measurement.     
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 Although the AHS collected information on many different pesticides, our exposure 
information is limited in terms of actual levels, duration, frequency, and timing.  The 
exposure measures were based on women’s report of ever/never pesticide use, and may not 
reflect exposures that preceded fibroid diagnosis.  Previous analyses of repeat interviews 
among a subset of farmers in the AHS indicated that agreement was relatively high (79-87%) 
for ever/never use of specific pesticides, but generally decreased with the amount of detail 
(e.g., duration , frequency) sought (167).   It is not unreasonable to assume that farm women 
may have similarly high accuracy with respect to ever/never use of pesticides.  It is unlikely 
that recall of pesticide use is different among women with and without fibroids because 
outcome data were gathered after information on pesticide use was collected.  Information on 
other sources or modifying factors of pesticide exposure was not collected, and women who 
were exposed to pesticides through field work, spray drift, or carry-home contamination 
could have been erroneously classified as unexposed.   
 The focus of this analysis was on pesticide use patterns and hormonally active 
pesticides.  The decision to label a pesticide hormonally active was based on a literature 
review that was limited to the published research.  For example, a total of 156 citations were 
found related to endocrine-disrupting effects of organochlorine pesticides, compared to 59 
for organophosphates.  We found no toxicological publications that examined coumaphos as 
an endocrine disruptor.  For this reason and because of the uniqueness of the AHS data set, 
we felt it important to present estimates for all pesticides with the caveat that some 
associations could have appeared by chance due to the number of exposures investigated.   
 Although retention rates were relatively good at the five-year follow-up, there were 
some differences between participants and nonparticipants which could have led to selection 
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bias.  Women who did not participate in follow-up were slightly younger, less educated, 
more likely to be from North Carolina, and more likely to have reported never personally 
mixing or applying pesticides in the Enrollment Questionnaire.  Follow-up participation rates 
were also lower among women who enrolled as applicators (and may have higher exposures) 
compared to applicators’ wives.  It is unclear whether these exclusions might have affected 
our results.       
 In conclusion, results of this analysis suggest that use of agricultural pesticides may 
be related to uterine fibroids in this population of farm women.  Odds of fibroids were 
significantly elevated in women who used the five most common, less toxic pesticides and 
further elevated among users of additional pesticides.  We illustrated the use of a relatively 
straightforward algorithm to assess the influence of bias arising from use of self-report to 
classify fibroid status.  Unlike simpler approaches used previously (44, 158), this method 
accommodates the differential reporting accuracy according to age that was indicated in a 
separate analysis of self-report validity (data not published).  Despite known problems with 
self-reported data, existing large cohorts such as the Agricultural Health Study provide 
important contributions to our understanding of fibroid risk factors and possible avenues for 
further investigation.  In vivo or in vitro testing of the pesticides which we observed to be 
associated with fibroid diagnosis would be a good first step to confirm these associations and 
explore possible mechanisms of action.    
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Table 5.1 Selected characteristics of 16,526 women aged 21-59 in the Agricultural Health 
Study, by self-reported uterine fibroid status, 1993-2003 
 
Characteristic 
Fibroids 
n = 2,360 
No fibroids 
n = 14,166 
Crude  
odds ratio 
95% confidence 
interval 
State     
  Iowa  1,687  10,825 1.00 Referent 
  North Carolina  673  3,341 1.29 1.17, 1.42 
Age (years) at follow-up      
  21 – 34  40  1,251 0.16 0.12, 0.23 
  35 – 39  154  2,195 0.36 0.30, 0.43 
  40 – 44  394  2,898 0.69 0.60, 0.79 
  45 – 49  572  2,899 1.00 Referent 
  50 – 54  607  2,596 1.19 1.05, 1.34 
  55 – 59   593  2,327 1.29 1.14, 1.47 
Age (years) at menarche     
  Less than 12  490  2,149 1.00 Referent 
  12  689  4,099 0.74 0.65, 0.84 
  13  666  4,245 0.69 0.61, 0.78 
  14  336  2,118 0.70 0.60, 0.81 
  15 or older  160  1,411 0.50 0.41, 0.60 
  Missing  19  144   
Timing of births     
  No births  108  650 1.07 0.87, 1.32 
  All births <24 years maternal age  553  2,499 1.42 1.28, 1.58 
  Any birth ≥24 years maternal age  1,646  10,589 1.00 Referent 
  Missing  53  428   
Self-reported hysterectomy     
  No  1,152  12,261 1.00 Referent 
  Yes  1,191  1,831 6.92 6.30, 7.61 
  Missing  17  74   
Grew up on farm     
  No  995  6,029 1.00 Referent 
  Yes  1,316  7,859 1.02 0.93, 1.11 
  Missing  49  278   
Years lived/worked on farm     
  Less than 5  61  561 1.00 Referent 
  5 – 10  149  1,339 1.02 0.75, 1.40 
  11 – 20  412  2,838 1.34 1.01, 1.77 
  21 – 30  527  3,031 1.60 1.21, 2.12 
  Over 30  1,085  5,589 1.79 1.36, 2.34 
  Missing  126  808   
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Table 5.2 Association between use of hormonally active pesticides and self-reported uterine fibroids among 16,526 women aged 21-
59 in the Agricultural Health Study, 1993-2003 
Fibroids  No Fibroids  Adjustedc  Corrected-1d Any possible hormonally- active 
pesticidea Total  
No. 
Exposed 
%b 
 Total  
No. 
Exposed 
%b 
 
OR 95% CI OR 95% CI 
Comparison group: never users 
of any agricultural pesticide 1,242 37 
 
7,912 28 1.28 1.12, 1.45 
 
1.48 1.20, 1.82 
        
Comparison group: users of any 
agricultural pesticides other 
than hormonally active 
pesticides 
 
1,533 30 
 
8,197 27 1.02 0.90, 1.15 0.98 0.81, 1.20 
Abbreviations: OR, odds ratio; CI: confidence interval. 
 a Pesticides identified a priori as hormonally active, estrus cycle disruptors, or utero- or ovotoxic: DDT, chlordane, lindane, dieldrin, toxaphene, 
maneb, atrazine, alachlor, carbon tetrachloride, and permethrin. 
 b A total of 462 women with fibroids and 2,210 women without fibroids were exposed to possible hormonally active pesticides. 
 c Adjusted for age (continuous), age squared, and state (IA/NC). 
 d Adjusted for age, age squared, and state and the following assumptions for outcome misclassification correction. Women reporting 
hysterectomy: sensitivity=0.85. Sensitivity for women who did not have a hysterectomy, by age at follow-up 18-29: 0.15; 30-34: 0.20; 35-39: 0.35; 
40-44: 0.40; 45-59: 0.30.  Specificity set at 0.95 for all women. 
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Table 5.3 Association between specific pesticide use and self-reported uterine fibroid 
diagnosis among 10,044 women aged 21-59 who mixed or applied agricultural pesticides in 
the Agricultural Health Study, 1993-2003 
 
Ever use in 
women with 
fibroids  
(n = 1,580)a 
 Ever use in 
women without 
fibroids 
(n = 8,464)a 
Pesticide name No. %  No. % 
Adjusted 
ORb 95% CI 
Organochlorines 221 14.5  918 11.3 1.05 0.90, 1.24 
 Aldrin 18 1.2  82 1.0 0.95 0.57, 1.60 
 Chlordane 133 9.0  520 6.5 1.11 0.91, 1.36 
 DDT 81 5.5  285 3.6 1.14 0.88, 1.48 
 Dieldrinc 8 0.5  34 0.4   
 Heptachlor 22 1.5  86 1.1 1.11 0.69, 1.78 
 Lindane 53 3.5  269 3.3 0.90 0.67, 1.22 
 Toxaphene 18 1.2  82 1.0 0.96 0.57, 1.61 
      
Organophosphates 827 52.7  3,871 46.0 1.17 1.05, 1.31 
 Chlorpyrifos 141 9.3  681 8.4 1.07 0.88, 1.30 
 Coumaphos 48 3.2  180 2.2 1.41 1.01, 1.96 
 Diazinon 353 23.2  1,613 19.9 1.11 0.97, 1.27 
 Dichlorvos 70 4.6  350 4.3 1.00 0.77, 1.31 
 Fonofos 62 4.1  270 3.3 1.13 0.85, 1.50 
 Malathion 639 41.2  2,844 34.4 1.17 1.05, 1.31 
 Parathion 44 2.9  153 1.9 1.42 1.00, 2.00 
 Phorate 58 3.8  310 3.8 0.92 0.69, 1.23 
 Terbufos 86 5.7  463 5.7 0.96 0.75, 1.22 
 Trichlorfonc 8 0.5  37 0.5   
      
Carbamates 913 58.3  4,564 54.2 1.00 0.90, 1.12 
 Aldicarb 14 0.9  116 1.4 0.57 0.32, 1.00 
 Carbofuran 66 4.4  273 3.4 1.14 0.87, 1.51 
 Carbaryl 891 57.5  4,454 53.8 0.99 0.88, 1.11 
 Benomyl 30 2.0  180 2.2 0.75 0.50, 1.11 
      
Triazines 183 12.0  898 11.0 1.01 0.85, 1.20 
 Atrazine 151 9.9  706 8.7 1.05 0.87, 1.26 
 Cyanazine 95 6.3  457 5.6 1.06 0.84, 1.33 
 Metribuzin 56 3.7  291 3.6 0.90 0.67, 1.21 
      
Other insecticides      
 Permethrin 166 10.7  844 10.1 1.04 0.87, 1.25 
       
                  table continues 
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Table 5.3 Association between specific pesticide use and self-reported uterine fibroid 
diagnosis among 10,044 women aged 21-59 who mixed or applied agricultural pesticides in 
the Agricultural Health Study, 1993-2003 (cont.) 
 
Ever use in 
women with 
fibroids  
(n = 1,580)a 
 Ever use in 
women without 
fibroids 
(n = 8,464)a 
Pesticide name No. %  No. % 
Adjusted 
ORb 95% CI 
Other herbicides       
 2,4-D 428 28.0  2,242 27.4 0.98 0.87, 1.11 
 2,4,5 TPc 7 0.5  38 0.5   
 2,4,5 T 26 1.7  92 1.1 1.29 0.83, 2.01 
 Alachlor 139 9.2  660 8.2 1.06 0.87, 1.29 
 Butylate 55 3.7  222 2.7 1.18 0.87, 1.60 
 Chlorimuron Ethyl 70 4.6  303 3.7 1.21 0.92, 1.58 
 Dicamba 129 8.5  660 8.1 1.00 0.82, 1.23 
 EPTC 42 2.8  230 2.9 0.90 0.64, 1.27 
 Glyphosate 1,019 65.4  5,333 63.9 1.07 0.96, 1.21 
 Imazethapyr 96 6.4  517 6.4 1.00 0.79, 1.26 
 Metolachlor 115 7.6  559 6.9 1.08 0.87, 1.34 
 Paraquat 45 3.0  192 2.4 1.13 0.81, 1.59 
 Pendimethalin 79 5.2  443 5.5 0.90 0.70, 1.15 
 Petroleum oil 131 8.7  598 7.4 1.15 0.94, 1.40 
 Trifluralin 176 11.7  835 10.3 1.07 0.90, 1.28 
       
Other fungicides       
 Captan 77 5.1  352 4.3 1.05 0.82, 1.36 
 Chlorothalonil 42 2.8  170 2.1 1.20 0.85, 1.71 
 Maneb 52 3.4  228 2.8 1.00 0.73, 1.37 
 Metalaxyl 51 3.3  305 3.7 0.77 0.56, 1.06 
 Ziramc 2 0.1  18 0.2   
       
Other fumigants       
 Aluminum phosphidec 5 0.3  28 0.3   
 Carbon tetrachloride 21 1.4  53 0.7 1.70 1.02, 2.85 
 Ethylene dibromidec 4 0.3  40 0.5   
 Methyl bromide 39 2.5  210 2.6 0.87 0.61, 1.25 
Abbreviations: DDT, dichlorodiphenyltrichloroethane; 2,4-D, 2,4-Dichlorophenoxyacetic acid; 2,4,5 
TP, (2,4,5-trichlorophenoxy)propionic acid; 2,4,5 T, (2,4,5-trichlorophenoxy)acetic acid; OR, odds 
ratio; CI, confidence interval. 
 a The total number of women with and without fibroids differs for each pesticide because of missing 
exposure data. 
 b Adjusted for age (continuous), age squared, and state (IA/NC).  Comparison group consists of 
women who used other agricultural pesticides.   
 c Odds ratios not reported if fewer than 10 exposed cases.   
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Table 5.4 Sensitivity analysis of pesticide use patterns and self-reported uterine fibroids among 15,985 wives of private pesticide 
applicators in the Agricultural Health Study, 1993-2003 
Adjustedb  Corrected-1c  Corrected-2d  Corrected-3e Corrected-4f 
Pesticide use patternsa  
OR 95% CI OR 95% CI OR 95% CI OR 95% CI OR 95% CI 
Never used 1.00 referent 1.00 referent 1.00 referent 1.00 referent 1.00 referent 
Residential use only 0.92 0.76, 1.10  0.78 0.57, 1.07  0.76 0.53, 1.09  0.79 0.50, 1.25  0.28 0.04, 2.22 
Commonly used 1.21 1.07, 1.35  1.42 1.16, 1.72  1.41 1.13, 1.76  1.60 1.20, 2.13  3.05 1.58, 5.91 
1-2 agricultural pesticides 1.26 1.09, 1.45  1.43 1.13, 1.82  1.39 1.06, 1.81  1.70 1.20, 2.41  3.48 1.70, 7.15 
≥ 3 agricultural pesticides 1.31 1.12, 1.53  1.44 1.11, 1.87  1.46 1.09, 1.94  1.80 1.22, 2.67  3.97 1.88, 8.38 
Other pesticides 1.15 0.86, 1.53  1.30 0.79, 2.14  1.19 0.66, 2.15  1.43 0.71, 2.86  2.03 0.40, 10.31 
Abbreviations: OR, odds ratio; CI: confidence interval. 
 a Never used: women who reported never mixing/applying any pesticide.  Residential use only: did not use any of the 50 named pesticides, but 
reported personally treating home/lawn/garden for pests.  Commonly used: used at least one of the five most frequently reported pesticides 
(glyphosate, carbaryl, malathion, 2,4-D, diazinon).  1-2 and ≥3 agricultural pesticides: used pesticides other than or in addition to the top five.  
Other pesticides: women who reported personally mixing/applying pesticides but used something other than 50 named.  A total of 27 fibroid cases 
and 158 non-cases were missing data on pesticide use patterns. 
 b Adjusted for age (continuous), age squared, and state (IA/NC). 
 c Adjusted for age, age squared, and state and the following assumptions for outcome misclassification correction. Women reporting 
hysterectomy: sensitivity=0.85. Sensitivity for women who did not have a hysterectomy, age at follow-up 18-29: 0.15; 30-34: 0.20; 35-39: 0.35; 40-
44: 0.40; 45-59: 0.30.  Specificity set at 0.95 for all women. 
 d Adjusted for age, age squared, and state and the following assumptions for outcome misclassification correction.  Women reporting 
hysterectomy: sensitivity=0.85 and specificity by age at follow-up: 18-29: 0.99; 30-34: 0.98; 35-39: 0.95; 40-44: 0.95; 45-59: 0.95.  Sensitivity for 
women who did not have a hysterectomy by age at follow-up 18-29: 0.15; 30-34: 0.20; 35-39: 0.35; 40-44: 0.40; 45-59: 0.30.  Specificity by age at 
follow-up, 18-29: 0.99; 30-34: 0.98; 35-39: 0.95; 40-44: 0.89; 45-59: 0.87. 
 e Adjusted for age, age squared, and state and the following assumptions for outcome misclassification correction.  Sensitivity by age at follow-
up, 18-29: 0.15; 30-34: 0.20; 35-39: 0.35; 40-44: 0.40; 45-59: 0.30.  Specificity set at 0.95 for all women.  
 f Adjusted for age, age squared, and state and the following assumptions for outcome misclassification correction.  Sensitivity by age at follow-
up, 18-29: 0.15; 30-34: 0.20; 35-39: 0.35; 40-44: 0.40; 45-59: 0.30.  Specificity by age at follow-up, 18-29: 0.99; 30-34: 0.98; 35-39: 0.95; 40-44: 
0.89; 45-59: 0.87.  
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Table 5.5 Sensitivity analysis of the association between use of hormonally active pesticides and self-reported uterine fibroids among 
16,526 women aged 21-59 in the Agricultural Health Study, 1993-2003 
Adjustedb Corrected-1c Corrected-2d Corrected-3e Corrected-4f Any possible hormonally- 
active pesticidea  
OR 95% CI OR 95% CI OR 95% CI OR 95% CI OR 95% CI 
Comparison group: never 
users of any pesticide 1.28 1.12, 1.45 
 
1.48 1.20, 1.82 
 
1.51 1.20, 1.90 
 
1.71 1.26, 2.32 4.23 1.86, 9.61 
              
Comparison group: users 
of other pesticides 1.02 0.90, 1.15 
 
0.98 0.81, 1.20 
 
1.02 0.81, 1.27 
 
0.98 0.72, 1.35 1.07 0.65, 1.77 
Abbreviations: OR, odds ratio; CI: confidence interval 
 a Pesticides identified a priori as hormonally active, estrus cycle disruptors, or utero- or ovotoxic: DDT, chlordane, lindane, dieldrin, toxaphene, 
maneb, atrazine, alachlor, carbon tetrachloride, and permethrin. 
 b Adjusted for age (continuous), age squared, and state (IA/NC). 
 c Adjusted for age, age squared, and state and the following assumptions for outcome misclassification correction. Women reporting 
hysterectomy: sensitivity=0.85. Sensitivity for women who did not have a hysterectomy, age at follow-up 18-29: 0.15; 30-34: 0.20; 35-39: 0.35; 40-
44: 0.40; 45-59: 0.30.  Specificity set at 0.95 for all women. 
 d Adjusted for age, age squared, and state and the following assumptions for outcome misclassification correction.  Women reporting 
hysterectomy: sensitivity=0.85 and specificity by age at follow-up: 18-29: 0.99; 30-34: 0.98; 35-39: 0.95; 40-44: 0.95; 45-59: 0.95.  Sensitivity for 
women who did not have a hysterectomy by age at follow-up 18-29: 0.15; 30-34: 0.20; 35-39: 0.35; 40-44: 0.40; 45-59: 0.30.  Specificity by age at 
follow-up, 18-29: 0.99; 30-34: 0.98; 35-39: 0.95; 40-44: 0.89; 45-59: 0.87.  
 e Adjusted for age, age squared, and state and the following assumptions for outcome misclassification correction.  Sensitivity by age at follow-
up, 18-29: 0.15; 30-34: 0.20; 35-39: 0.35; 40-44: 0.40; 45-59: 0.30.  Specificity set at 0.95 for all women. 
 f Adjusted for age, age squared, and state and the following assumptions for outcome misclassification correction.  Sensitivity by age at follow-
up, 18-29: 0.15; 30-34: 0.20; 35-39: 0.35; 40-44: 0.40; 45-59: 0.30.  Specificity by age at follow-up, 18-29: 0.99; 30-34: 0.98; 35-39: 0.95; 40-44: 
0.89; 45-59: 0.87. 
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Figure 5.1 Association between pesticide use patternsa and self-reported uterine fibroids 
among 15,985 wives of private pesticide applicators in the Agricultural Health Study, 1993-
2003   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations: OR, odds ratio; CI, confidence interval. 
 a  Never used (referent): never mixed/applied any pesticide.  Residential only: did not use any of the 
50 named pesticides, but personally treated home/lawn/garden for pests.  Common: used any of the 
five most frequently reported agricultural pesticides (glyphosate, carbaryl, malathion, 2,4-D, diazinon).  
1-2 and ≥ 3 other agricultural pesticides: used pesticides other than or in addition to the top five.  
Other pesticides: mixed/applied pesticides but used something other than 50 named. 
 b  Adjusted for age (continuous), age squared, and state (IA/NC). 
 c  Adjusted for age, age squared, and state and the following assumptions for outcome 
misclassification correction. Women reporting hysterectomy: sensitivity=0.85. Sensitivity for women 
who did not have a hysterectomy, age at follow-up 18-29: 0.15; 30-34: 0.20; 35-39: 0.35; 40-44: 0.40; 
45-59: 0.30.  Specificity set at 0.95 for all women. 
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CHAPTER 6: DISCUSSION 
 
6.1 SUMMARY OF FINDINGS 
 This dissertation research accomplished the following aims: 1) to conduct a detailed 
assessment of self-reported uterine fibroid status and factors that might influence self-report 
validity and 2) to examine the association between pesticide use and uterine fibroid 
prevalence, using information obtained in Aim 1 to assess the degree to which parameter 
estimates are biased as a result of using self-reported fibroid diagnosis. 
 For Aim 1, the validity of self-reported uterine fibroid status was assessed in two 
different study populations: Right from the Start, which included pregnant women, most of 
whom were under 35, and the Uterine Fibroid Study, which included 35-49 year-old women 
randomly selected from among members of an urban health plan.  Sensitivity (the proportion 
of women reporting fibroid diagnosis among those with fibroids detected at ultrasound) was 
low (< 0.50) in both study populations.  In contrast, specificity (the proportion of women 
reporting no previous diagnosis among those with no fibroids at ultrasound) was moderate to 
high (0.86 to 0.98).   
 Among the possible determinants of validity that I investigated, race/ethnicity, age, 
and parity were associated with sensitivity and specificity of self-report.  In both studies, self-
report among black women was more sensitive but less specific compared to white women.  
Black women develop fibroids at a younger age and tend to have larger and more numerous 
tumors (20, 28, 30).  Better reporting among black women with fibroids may be a result of 
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more severe symptoms or of increased awareness among medical professionals of black 
women as a “high-risk” group, leading to an increased likelihood of diagnosis.  Age was 
positively associated with sensitivity and negatively associated with specificity.  In white 
women, sensitivity was slightly lower among 45-49 year-olds compared to younger whites, 
for reasons that are not entirely clear.  However, taken in light of the observation that the 
proportion of women with larger tumors increased with age among blacks but not whites, this 
finding suggests that there may be a real difference in the natural progression of these tumors 
among different racial/ethnic groups.  In a study which tracked fibroid growth in tumors from 
72 premenopausal women, older white women had a lower fibroid growth rate than younger 
whites, while this age difference was not seen in black women (31).  It is unknown whether 
or not the inverse relationship between specificity and age truly reflects respondent error, but 
the finding that the proportion of apparent false-positives increased with duration between 
first diagnosis and ultrasound suggests that specificity may be affected by time since 
diagnosis as well as (or instead of) age at interview.  Tumor regression has been observed to 
occur in a small percentage of premenopausal women with fibroids (22, 31, 154).  
Alternatively, pregnancies in the interval between previous diagnosis and study ultrasound 
may have eliminated fibroids (40, 41), which could also explain why parity was associated 
with lower specificity in this analysis.  Parity was also positively associated with self-report 
sensitivity in this analysis, which may reflect an increased opportunity for diagnosis because 
of pregnancy-related ultrasound examinations.  
  For Aim 2, data from the Agricultural Health Study, a large cohort of pesticide 
applicators and their spouses, were used to investigate self-reported fibroid diagnosis and its 
relationship with different pesticide use patterns as well as its association with use of 
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hormonally active pesticides that were identified a priori based on a literature review.  I 
hypothesized that there would be an increase in the odds of fibroids by pesticide type 
(residential; more common, lower toxicity agricultural; restricted use, higher toxicity 
agricultural) and number of pesticides used.  Although women who reported residential 
pesticide use did not have increased odds of fibroids, there was a small positive trend across 
categories of agricultural pesticide use (compared to women who did not use any pesticides).   
 I was also interested in pesticides that showed evidence of endocrine-disrupting 
activity among prior in vitro or in vivo experiments.  I hypothesized that use of pesticides 
which showed evidence of estrogenic/progestagenic activity, effects on follicle-stimulating or 
luteinizing hormones, direct effects on the ovary or uterus, or estrus cycle disruption would 
be positively associated with uterine fibroids.  A review of the toxicology literature resulted 
in the selection of 10 hormonally active pesticides.  I found slightly elevated odds of fibroids 
among women who used hormonally active pesticides compared to those who did not use 
any pesticides.  However, the odds associated with the use of hormonally active pesticides 
were comparable when the referent group consisted of women who used agricultural 
pesticides other than those deemed hormonally active.  I therefore investigated specific 
pesticides and chemical class groupings in an attempt to determine whether any of those not 
originally identified as hormonally active may be associated with fibroids.  I found elevated 
odds among organophosphate pesticide users and specifically, among women who used 
coumaphos, malathion, or parathion.   
 None of these pesticides were identified a priori as hormonally active, in part because 
there were too few experimental studies of their endocrine disrupting effects to make a 
determination.  Those that did examine endocrine disruption were limited mainly to effects 
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on estrogen.  Coumaphos, malathion, and parathion are organophosphate insecticides that act 
through inhibition of the enzyme acetylcholinesterase (168).  Because of their mechanism of 
action, the majority of research on organophosphates has focused on their possible 
neurotoxic effects.  I did not find any published reports of studies examining endocrine 
disrupting effects of coumaphos.  Malathion showed no evidence of estrogenicity in vitro 
(103, 169-171) nor in treated rats or cattle (172, 173), but did exhibit ovotoxic effects in rats 
(174).  Similarly, parathion was not estrogenic in two in vitro assays (103, 170) but was 
found to have effects on ovarian morphology and estrus cycle disruption in rats (175-177).  
Only two published reports were found related to aldicarb, a carbamate pesticide that was 
negatively associated with odds of fibroids in this analysis.  In one study of human breast and 
endometrial cancer cells, aldicarb inhibited estradiol and progesterone activity (178), which 
could explain our negative association of this pesticide with fibroids.  However, aldicarb did 
not show estrogenic or anti-estrogenic activity in another study using estrogen-receptor 
responsive cell lines (108).  Carbon tetrachloride, that was identified as hormonally active 
based on my review, had the strongest association with fibroid diagnosis among all 
individual pesticides.  The evidence for possible hormonal activity comes mainly from 
studies in rats that demonstrated increased serum estradiol and progesterone levels, decreased 
estrone metabolism, and increased levels of these hormones in the uterus following exposure 
(164-166, 179, 180).  However, many of these studies were conducted at doses that cause 
liver toxicity, raising the question of whether these findings can be extrapolated to humans 
with more chronic, low-level exposures.  
 I employed an outcome misclassification correction approach (12) to assess the 
degree to which effect estimates may have been biased by the use of self-report to identify 
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women with and without fibroids.  The “base” model for outcome correction assumed 
moderate sensitivity for women who reported having had a hysterectomy, and age-varying 
sensitivity for those who did not.  Specificity was assumed to be high for both groups.  
Although the base model correction resulted in odds ratios that were further away from the 
null than the uncorrected odds ratios, they were not drastically different.  This is because half 
of the women who self-reported a fibroid diagnosis also reported having had a hysterectomy; 
the net result of setting a higher sensitivity value for these women is to lessen the degree of 
misclassification relative to models in which this distinction was not made.  Underscoring 
this point is the fact that the correction model in which both sensitivity and specificity varied 
with age, regardless of hysterectomy history, yielded odds ratios that were 2 to 3 times higher 
than the uncorrected odds ratios (when odds ratios were above the null).  Specificity seemed 
to be the most influential in determining the magnitude of the change in corrected compared 
to uncorrected odds ratios.  Changing sensitivity estimates had less impact on resulting odds 
ratios when specificity was high (>0.95).      
6.2 STRENGTHS AND LIMITATIONS 
6.2.1 Aim 1  
 Only two studies have assessed the accuracy of self-reported fibroid diagnosis, but 
only focused on validating positive self-reports (37, 158).  Results from the analysis of Right 
from the Start and the Uterine Fibroid Study represent the most detailed assessment of self-
report validity to date.  These studies provided relatively large, ethnically diverse study 
populations in which to examine possible determinants of reporting accuracy.  Furthermore, 
the measurement of “true” fibroid status was based on results from ultrasound examinations 
performed by trained and certified sonographers.  Ultrasound has high sensitivity (99%) and 
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specificity (91%) when compared to histological results, which are considered the gold 
standard (155).       
 There are special characteristics of RFTS and UFS populations that may limit their 
applicability to the AHS or other populations.  RFTS includes volunteers who are pregnant or 
trying to conceive.  These women may be more likely to have regular medical care or be 
more attentive of their reproductive health, which could improve their reporting accuracy 
over the general population.  Similarly, participants in the UFS might be more likely to get 
regular medical care because they were members of a health plan.   
 Because fibroids can affect fertility, RFTS participants may have a lower prevalence 
of fibroids by virtue of the fact that they are pregnant.  Resulting validity estimates may 
therefore not be representative of those in a study population with higher disease prevalence.  
It is possible that ultrasound examinations during pregnancy may not be as accurate because 
they might miss smaller fibroids, or mistake focal contractions for tumors.  However, 
because one of the aims of RFTS2/3 was specifically focused on fibroids in pregnancy, 
sonographers were well-trained in interpreting ultrasound images and performed repeated 
measurements on each tumor to reduce measurement error.  The increased hormone levels 
during pregnancy could cause fibroids to grow (156), in which case the pregnancy ultrasound 
results might detect fibroids that were too small to be detected prior to pregnancy.  This is 
unlikely because the RFTS ultrasounds were performed early (6 to 13 weeks’ gestation) in 
the first trimester, and there was no difference in fibroid prevalence by gestational age at 
ultrasound (28).   
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6.2.2 Aim 2 
 To my knowledge, this is the first epidemiologic investigation of the relationship 
between pesticide use and uterine fibroid prevalence.  Pesticides are a source of exposure to 
potentially endocrine-disrupting chemicals, which could alter the hormonal milieu in a way 
that affects uterine fibroid development.  The Agricultural Health Study provided an 
opportunity to examine specific pesticides and use patterns among a large cohort of women 
who, on average, have higher exposures than the general population.  The fact that uterine 
fibroids affect such a large percentage of reproductive-age women requires both a large 
sample size and high exposure prevalence in order to detect statistically significant 
associations if they exist.   
 Because outcome status was ascertained by self-report, a substantial proportion of 
women with fibroids were likely misclassified as non-cases.  In order to address this bias, I 
used a correction method in the logistic regression models to adjust for imperfect outcome 
measurement.  Unlike simpler methods used previously in the Nurses’ Health Study (44, 
158), this approach allowed for varying sensitivity and specificity estimates (i.e., differential 
misclassification with respect to covariate patterns) that were evident in the analysis from 
Aim 1.  Unlike Bayesian approaches, however, it assumes that sensitivity and specificity are 
known with certainty.   
 There are some considerations with regard to the applicability of the data used to 
inform assumptions about self-report sensitivity and specificity.  There are likely differences 
between women who live and work on farms and women who enroll in a study of pregnancy 
(as in RFTS) or who are members of a health plan in an urban area (as in the UFS); to what 
extent these differences might influence the accuracy of women’s self-reports cannot be 
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completely measured.  Additionally, the AHS analysis population included older, as well as 
postmenopausal, women for whom information on validity of self-report was not available 
from Aim 1.  Results of the sensitivity analyses conducted in the AHS provided some 
information about the extent to which assumptions about reporting accuracy in these women 
might influence the results, but did not clearly indicate one set of assumptions over another.  
The availability of hysterectomy data in the AHS helped in this respect, since it is a 
reasonable assumption that women who have had gynecological surgery are better reporters 
of fibroid status.  In fact, the prevalence of self-reported fibroids was almost 40% among 
women who had hysterectomies, compared to 9% among women who did not have a 
hysterectomy. 
 Additional limitations of this analysis should be noted.  Although the AHS collected 
information on many different pesticides, the exposure information was lacking in terms of 
magnitude, duration, frequency, and timing.  The exposure measures were based on women’s 
report of ever/never pesticide use, and may not reflect exposures that preceded fibroid 
diagnosis.  The lack of a clear temporal relationship between exposure and outcome raises 
the possibility that any associations found in the analysis could be non-causal.   
 Recall of exposure history may be unreliable.  It is unlikely that recall of pesticide use 
is different among women with and without fibroids because outcome data were gathered 
after information on pesticide use was collected.  However, recall of lifetime exposure 
history may be progressively worse as women age, and age up to menopause is related to 
fibroid prevalence.  Excluding older women in the AHS may have reduced errors, but the 
possibility of recall bias does exist.  A recent reliability analysis of self-reported household 
pesticide use among participants of a case-control study in Italy showed good agreement—
   
 103
approximately 75% for indoor pesticide use and over 90% for outdoor pesticide use—for 
both duration and frequency of lifetime pesticide use among a non-occupationally exposed 
group (181).  Although there are no empirical data available, one would suspect that farm 
women are better reporters than the general population.  Validation studies conducted among 
pesticide applicators in the AHS have demonstrated that they provide accurate information 
on pesticide use, farming activities, and lifestyle factors (167, 182, 183).     
 Information on other sources or modifying factors of pesticide exposure was not 
included in the proposed analysis, and could lead to exposure misclassification.  Wives of 
farmers can be exposed to pesticides through spray drift or carry-home contamination from 
their husbands, among other sources (184).  Women who engage in field work on the farm 
will also be indirectly exposed to pesticides even if they do not personally apply them.  In 
addition, women who apply pesticides may have different behaviors that affect the amount of 
pesticide to which they are exposed.  Information on the use of personal protective 
equipment, for example, was available for the female pesticide applicators but not for the 
farmers’ wives.  Although the AHS includes data on the husband’s pesticide use and limited 
data on household hygiene factors that might impact residential contamination, the 
investigation of indirect exposures was not part of the proposed dissertation research.  
Women could therefore have been misclassified as unexposed when they may have been 
exposed through other routes, leading, in general, to an attenuation of any associations 
detected.       
 Finally, there were some differences between participants and nonparticipants in the 
Phase II follow-up which could lead to selection bias.  Women who did not participate were 
slightly younger, less educated, from North Carolina, and more likely to have reported never 
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personally mixing or applying pesticides in the Enrollment Questionnaire.  Follow-up 
participation rates were also lower among women who enrolled as applicators compared to 
applicators’ wives.  If pesticides are associated with fibroid diagnosis, the exclusion of 
pesticide applicators (who may have higher exposures) or of women who never mixed or 
applied pesticides could have resulted in attenuated estimates.  Without knowing the 
prevalence of fibroids in follow-up nonrespondents, however, it is difficult to say with 
certainty how these exclusions may have affected our results.       
6.3 IMPLICATIONS AND CONCLUSIONS 
 Uterine fibroids develop in the majority of reproductive-age women and “by the time 
of menopause in America, the presence of uterine fibroids seems to be the norm, not the 
exception” (185).  Although these are benign tumors, they account for significant symptoms 
that affect women’s quality of life; these include abnormal uterine bleeding, pain, frequent 
urination, infertility, and pregnancy complications (186).  Despite the increasing availability 
of other treatment methods, fibroids remain the leading indication for hysterectomy in the 
United States.  Over 200,000 hysterectomies for uterine fibroids are performed annually in 
this country, and between 3 to 5 billion dollars are spent in their diagnosis and treatment (11, 
187).    
 Epidemiologic investigation of risk factors related to uterine fibroids is subject to 
challenges mainly related to disease detection and outcome misclassification.  The ideal 
prospective design—one that enrolls a defined population of women determined to be 
fibroid-free at enrollment and then follows them over time—would be less prone to disease 
misclassification and better able to tie exposure histories to fibroid onset and development 
through regular screening of its study population.  The gap between ideal designs and 
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practical approaches is a real one, however.  A prospective cohort would have to be quite 
large to be adequately powered to examine factors such as exposures to agricultural 
pesticides, which are rare in the general population.  The utility of ultrasound screening, 
although relatively non-invasive, could be costly (depending on the geographic dispersion of 
the cohort) and prone to loss to follow-up.  Furthermore, established cohorts such as the 
Nurses’ Health Study, the Black Women’s Health Study, and the Agricultural Health Study 
have a wealth of information on potential risk factors and exposures.  The reality of working 
within the limitations of existing, sometimes imperfect, studies underscores the importance 
of understanding how these limitations might affect the results.  When researchers mention 
measurement error there is a tendency to assume first that it is nondifferential, and second 
that it will bias towards the null.  The results presented here suggest that, at least for uterine 
fibroids, measurement error is related to factors that may be of interest in and of themselves  
or may be related to factors of interest, which would lead to biased estimates.  The 
information on sensitivity and specificity provides a good starting point to at least assess the 
impact of measurement error on the magnitude and direction of bias.  The findings also lend 
support to some of approaches that have been used in the past to minimize misclassification, 
for example, by limiting analyses to younger women (37, 157).      
 In conclusion, results of this dissertation research suggest that the use of agricultural 
pesticides may be related to uterine fibroids in this population of farm women.  Significantly 
elevated odds were seen in women who used the five most common, generally less toxic 
pesticides (as classified by the US EPA) (188).  Odds were further elevated among women 
who used less common, typically restricted-use, pesticides.  I illustrated the use of a 
relatively easy-to-use algorithm to assess the influence of bias arising from use of self-report 
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to classify fibroid status.  Whether or not this approach results in an actual “correct” effect 
estimate largely depends on if, and how, pesticides increase fibroid risk.  There is little prior 
information to indicate how hormones, whether endogenous or exogenous, act to either 
initiate these tumors or cause them to progress.  Given that the majority of reproductive-age 
women have fibroids, the more relevant question in terms of public health burden might be: 
What causes some women with fibroids to require treatment?  The uncorrected odds ratio—
using self-reported diagnosis to define outcome—may be “correct” if one assumes that 
pesticide exposure causes existing fibroids to grow to the point of becoming symptomatic, 
and that all symptomatic fibroids are diagnosed and all diagnosed fibroids are symptomatic.  
The difficulty arises from the fact that although symptoms such as heavy bleeding tend to 
increase with fibroid size, even small fibroids can cause heavy bleeding (189).  Furthermore, 
a clinical diagnosis does not necessarily mean that a woman had large and/or symptomatic 
fibroids.  In some women, fibroids are detected incidentally rather than because of symptoms 
(21, 69) and conversely, some women with symptoms do not necessarily get diagnosed (189, 
190).  The purpose of the outcome correction method was simply to obtain a better measure 
of fibroid prevalence (diagnosed or undiagnosed, large or small, symptomatic or 
asymptomatic).  Due to the cross-sectional nature of the data, as well as limitations in our 
knowledge about fibroid etiology in general, it was impossible to speculate as to the relation 
between pesticides and fibroid onset or growth. 
   Pesticides are ubiquitous and many persist in the environment; several have been 
demonstrated to be endocrine disruptors (191).  Women living on farms have increased 
opportunities for pesticide exposure through field work, personally mixing or applying 
pesticides, proximity to farming operations, and carry-home contamination by their husbands 
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(149).  Unlike other established risk factors for fibroids that cannot be changed (e.g., age or 
race), pesticide use is a modifiable exposure.  In vivo or in vitro testing for endocrine-
disrupting effects of the pesticides associated with fibroid diagnosis in this analysis would be 
a first step to confirm these findings, explore possible mechanisms of action, and provide a 
basis for designing future epidemiologic research.       
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APPENDIX A 
Literature Review on Endocrine Disrupting Activity of Pesticides in the Agricultural 
Health Study 
 
 In order to determine the specific pesticides of interest as hormonally active, I 
expanded on work previously performed by Sherry Farr (192), for which she conducted an 
extensive literature review.  Between May and June of 2003, Farr searched the National 
Library of Medicine’s PubMed database using each pesticide name entered singly along with 
the following keywords: hormone, hormone antagonist, ovary, ovarian disease, estrus cycle, 
uterus, uterine disease, genitalia, genital disease, reproduction, and endocrine disease.  
Results of this literature search were used in a weight of evidence review for endocrine 
disrupting effects of each pesticide.  Articles considered were those reporting on in vitro 
assays or in vivo outcomes in animals, and results were grouped according to specific 
hormones (estrogen, androgen, thyroid, progesterone, FSH/LH) and outcomes (ovarian 
effects, estrus cycle effects).  Within each of these groups, Farr assigned a category based on 
the weight of evidence, to create an “endocrine disruption profile” for each pesticide: 
• Lack of data: only one or no published papers for a specific hormone/outcome 
• No effect: majority of papers show no evidence of an effect on specific hormone or 
outcome 
• Conflicting evidence: evidence for and against specific types of endocrine disruption 
• Possible or probable: majority of studies indicate an effect on the specific 
hormone/outcome.  The distinction between “possible” and “probable” was based on 
the weight and strength of evidence.  
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 My approach to expanding on this work was to utilize the same search strategy while 
limiting the results to articles added to PubMed from 2003 to July 2009 (the date of my 
search).  In assessing the weight of evidence, however, my goal was to answer the following: 
1. For those pesticides previously classified as “possible” or “probable” disruptors of 
specific hormones or as “no effect,” is there updated evidence which conflicts with 
this categorization?  (For example, have there been additional reports on a “no effect” 
pesticide that would push it into the “conflicting evidence” category?) 
2. For those pesticides previously classified as “conflicting evidence” or “lack of data,” 
are there additional publications which would strengthen the weight of evidence 
either for or against endocrine disruption? 
3. Finally, do changes in the weight of evidence regarding specific hormones or 
outcomes result in an overall endocrine profile that might be relevant in uterine 
fibroid development?  These would be pesticides that increase estrogen or 
progesterone levels directly, or indirectly by affecting follicle-stimulating and 
luteinizing hormones or causing ovarian/estrus cycle effects. 
 The results of the literature search performed in 2003 and appended in 2009 are listed 
in Table A.1.  Of the 49 unique pesticides asked about in the Agricultural Health Study, 10 
did not have any published studies.  As a group, organochlorines are the most well-
researched, with a total of 156 citations to date.  Pyrethroids seem to have received much 
more attention in recent years, with a total of 26 publications found between 2003 and 2009 
(compared to only eight prior to 2003).  
 Results of the weight of evidence review and endocrine disruption profile appear in 
Table A.2.  Based on the updated literature review, some changes were made to the overall 
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pesticide classifications with regard to specific hormones or outcomes.  This table lists, for 
each endpoint, the number of publications from in vitro or in vivo studies.  The “+” sign after 
each number indicates those studies that show evidence of any effect; those marked with “-” 
are studies that did not show any effect on the endpoint.   
  For purposes of this dissertation research, I examined in more detail the published 
results for any pesticide that had probable, possible, or conflicting data for estrogen, 
progesterone, or FSH/LH disruption or ovarian/uterine and estrus cycle effects.  After 
reviewing all of the published results, I selected 10 pesticides to include as an exposure 
variable in my main analysis.  These pesticides are listed in Table A.3, and sorted in order of 
the strength of the overall endocrine profile with regard to relevance for uterine leiomyomata.  
In this table, a “+” sign precedes results that suggest the pesticide is a hormone agonist or 
mimic, a “-” sign, those that suggest the pesticide is a hormone antagonist, and “ne” for no 
effect. 
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Table A.1 Results of literature search on endocrine disruption, ovarian, or estrus cycle 
effects of pesticides in the Agricultural Health Study  
   
Number of relevant studies 
published 
Pesticide Name 
Year of 
first use Year of last use 
Up to June 
2003a 
June 2003-
August 2009 
Organochlorines     
 Aldrin 1950 1974; 1987b 5 1 
 Chlordane 1948 1983; 1988b 7 2 
 DDT 1948 1972 34 17 
 Dieldrin 1951 1974; 1987b 22 3 
 Heptachlor 1952 1988c 9 3 
 Lindane 1947 d 35 5 
 Toxaphene 1948 1976; 1990b 12 1 
Organophosphates     
 Chlorpyrifos 1965  5 9 
 Coumaphos 1958  0 0 
 Diazinon 1948  4 3 
 Dichlorvos/DDVP 1948  2 3 
 Fonofos 1967 1998 0 2 
 Malathion 1955  9 3 
 Parathion 1954  7 5 
 Phorate 1959  0 2 
 Terbufos 1974  0 0 
 Trichlorfon 1954  2 3 
Carbamates      
 Aldicarb 1970  1 1 
 Carbaryl 1947  8 5 
 Carbofuran 1969 e 4 3 
 Benomyl 1969 2002 9 3 
Thiocarbamates      
 Butylate 1967  1 0 
 EPTC 1958  0 0 
 Mancozeb 1962  5 3 
 Maneb  1952  3 2 
 Ziram 1948  1 0 
Phenoxy herbicides     
 2,4-D 1948  3 3 
table continues 
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Table A.1 Results of literature search on endocrine disruption, ovarian, or estrus cycle 
effects of pesticides in the Agricultural Health Study (cont.) 
   
Number of relevant studies 
published 
Pesticide Name 
Year of 
first use Year of last use 
Up to June 
2003 a 
June 2003-
August 2009 
 2,4,5-TP 1956 1984 0 0 
 2,4,5-T 1948 1985 1 1 
Triazines     
 Atrazine 1959  29 9 
 Cyanazine 1971 1999 2 0 
 Metribuzin 1972  2 0 
Anilides     
 Alachlor 1969  9 1 
 Metolachlor 1976  0 2 
Dinitroanilines     
 Pendimethalin 1974  1 0 
 Trifluralin 1963  3 2 
Phthalimides     
 Captan 1951  1 1 
 Chlorothalonil 1966  3 0 
Others     
 Aluminum phosphide 1958  0 0 
 Carbon tetrachloride 1948 1985 14 1 
 Chlorimuron ethyl 1985  0 0 
 Dicamba 1956  0 0 
 Ethylene dibromide  1948 1983 1 0 
 Glyphosate 1974  4 1 
 Imazethapyr 1989  0 0 
 Metalaxyl 1979  0 0 
 Methyl bromide 1947  4 0 
 Paraquat 1964  0 0 
 Permethrin / pyrethroids  1977  8 26 
 Petroleum oil/distillate 1947  2 0 
 a Table adapted from Farr (192), including results of previous literature search conducted between 
May and June 2003. 
 b First date is EPA partial ban; second date is comprehensive ban. 
 c Only currently approved commercial use is for fire-ant control around power lines. 
 d EPA cancelled in 2007; last year of use in 2009. 
 e EPA banned all but limited crop uses in 2006 with 4-year phase-out.
  
113
Table A.2 Classification of endocrine disrupting potential of pesticides in the Agricultural Health Study based on toxicological 
literaturea 
Pesticide 
Name and 
Classification 
Estrogen Androgen Thyroid Progesterone FSH/LH Ovarian/ 
Uterine 
Estrus cycle 
Organochlorines 
Aldrin 
    
Conflicting  
in vitro:  2 - 
in vivo:   1 +      1 - 
Possible 
in vitro:   0 
in vivo:   2 + 
No data No data Lack of data 
in vitro:   0 
in vivo:   1 + 
Lack of data 
1 - 
Conflicting 
1 + 1- 
Chlordane 
    
Possible 
in vitro:   2 +      2 - 
in vivo:   2 +  
Lack of data 
in vitro:   0 
in vivo:   1 + 
Lack of data 
in vitro: 0 
in vivo:  1 +  
No data No data Lack of data 
1 - 
Conflicting 
(from lack of 
data) 
1 + 1- 
DDT 
    
Probable 
in vitro:   13 +  1 - 
in vivo:   5 + 
Probable 
in vitro:   7 +  1 - 
in vivo:   7 + 2 - 
Possible 
in vitro:   3 +   
in vivo:   0  
Probable 
in vitro:   9 +   
in vivo:   2 +  
Conflicting 
in vitro:   2 +  
in vivo:   2 +  2 - 
Probable 
4 + 1 - 
Probable 
5 + 1 - 
Dieldrin 
    
Conflicting 
in vitro:   5 +  5 - 
in vivo:   1 +  2 - 
Possible 
in vitro:   3 +  1 - 
in vivo:   2 +   
No data No effect 
in vitro:   0 
in vivo:   2 -   
Lack of data 
in vitro:   0 
in vivo:   1 + 
Conflicting 
1 + 1 - 
No effect 
2 - 
Heptachlor 
    
Conflicting (from 
possible) 
in vitro:   1 +  3 - 
in vivo:   2 +  1 - 
Conflicting (from 
lack of data) 
in vitro:   0 
in vivo:   1 +  1 - 
Conflicting  
in vitro:   0 
in vivo:   1 +  1 - 
Possible 
in vitro:   0  
in vivo:   3 + 
Lack of data 
in vitro:   0 
in vivo:   1 + 
Conflicting 
1 + 2 - 
Conflicting 
(from possible) 
2 + 1 - 
Lindane 
    
Conflicting 
in vitro:   3 +  5 - 
in vivo:   10 +  3 - 
Probable 
in vitro:   1 +  1 - 
in vivo:   11 + 2 - 
Conflicting  
in vitro:   0 
in vivo:   3 +  3 - 
Probable 
in vitro:   3 +  
in vivo:   3 + 
Probable 
in vitro:   0  
in vivo:   5 + 1 - 
Conflicting 
(from 
probable) 
3 + 2 - 
Probable 
6 +  
Toxaphene 
    
Possible 
in vitro:   9 +  3 - 
in vivo:   0 
Lack of data 
in vitro:   0 
in vivo:  1 +  
Possible 
in vitro:   2 +  
in vivo:   0 
No data No data No data No data 
table continues 
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Table A.2 Classification of endocrine disrupting potential of pesticides in the Agricultural Health Study based on toxicological 
literaturea (cont.) 
Pesticide 
Name and 
Classification 
Estrogen Androgen Thyroid Progesterone FSH/LH Ovarian/ 
Uterine 
Estrus cycle 
Organophosphates 
Chlorpyrifos 
    
Conflicting (from 
no effect) 
in vitro:  3 +  4 - 
in vivo:   1+  3 - 
Conflicting (from 
lack of data) 
in vitro: 1 +   
in vivo:  1 + 1 - 
Possible (from 
lack of data) 
in vitro: 1+   
in vivo:  3 + 1 - 
No data Lack of data 
in vitro:   0 
in vivo:   1 - 
Conflicting 
(from no effect) 
1 + 2 - 
Lack of data 
1 - 
Diazinon 
    
Conflicting (from 
lack of data) 
in vitro: 2 +  2 - 
in vivo:  0 
Lack of data 
in vitro: 0  
in vivo:  1 + 
No data No data No data No effect 
2 - 
No data 
Dichlorvos 
    
Lack of data 
in vitro: 1 - 
in vivo: 0 
Conflicting 
in vitro: 1 +  1-
in vivo:  2 - 
No data No data Lack of data 
in vitro:   0 
in vivo:   1 - 
Lack of data 
1 + 
Lack of data 
1 + 
Fonofos 
    
Lack of data 
in vitro: 1 + 
in vivo: 0 
Lack of data 
in vitro: 1 + 
in vivo: 0 
No data No data No data No data No data 
Malathion 
    
No effect 
in vitro: 4 - 
in vivo: 2 - 
Conflicting 
in vitro: 0  
in vivo:  2 + 2 - 
Conflicting  
in vitro:   0 
in vivo:   1 +  1 - 
Lack of data 
in vitro:   0 
in vivo:   1 +   
Conflicting 
in vitro: 0  
in vivo: 2 +  1 - 
Conflicting 
(from no effect) 
1 + 1 - 
Lack of data 
Parathion 
    
No effect 
in vitro: 3 - 
in vivo: 0 
Probable (from 
possible) 
in vitro: 2 +   
in vivo:  4 +  
Lack of data 
in vitro:   1 - 
in vivo:  0  
No data No data Possible 
3 +  
Possible 
2 + 
Phorate Lack of data 
in vitro: 1 + 
in vivo: 0 
Lack of data 
in vitro: 1 + 
in vivo: 0 
No data No data No data No data No data 
Trichlorfon No data Lack of data 
in vitro: 1 - 
in vivo: 0 
No data Possible (from lack 
of data) 
in vitro:   2 + 
in vivo:   0   
No data Possible 
2 + 
No data 
table continues 
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Table A.2 Classification of endocrine disrupting potential of pesticides in the Agricultural Health Study based on toxicological 
literaturea (cont.) 
Pesticide 
Name and 
Classification 
Estrogen Androgen Thyroid Progesterone FSH/LH Ovarian/ 
Uterine 
Estrus cycle 
Carbamates 
Aldicarb Conflicting (from 
lack of data) 
in vitro: 1 + 1 - 
in vivo: 0 
No data No data Lack of data 
in vitro:   1 + 
in vivo:   0   
No data No data No data 
Carbaryl Conflicting (from 
lack of data) 
in vitro: 2 + 1 - 
in vivo: 0 
No effect 
in vitro: 1 - 
in vivo: 1 - 
Possible (from 
lack of data) 
in vitro:   1 + 
in vivo:   1 +  
Lack of data 
in vitro:   1 + 
in vivo:   0   
Lack of data 
in vitro:   0 
in vivo:   1 + 
Possible 
3 +  
Lack of data 
1 + 
Carbofuran No effect 
in vitro: 5 - 
in vivo: 0 
Conflicting (from 
lack of data) 
in vitro: 1 +   
in vivo:  1 - 
Conflicting  
in vitro:   0 
in vivo:   1 +  1 - 
No data Lack of data 
in vitro:   0 
in vivo:   1 - 
Possible 
2 + 
Possible 
2 + 
Benomyl Conflicting 
in vitro: 1 + 2 - 
in vivo: 2 + 1 - 
Conflicting (from 
no effect) 
in vitro: 0 
in vivo: 1 + 3 - 
Lack of data 
in vitro: 0 
in vivo:  1 -  
No effect 
in vitro:   0 
in vivo:   2 -   
Conflicting 
in vitro: 0  
in vivo: 1 +  3 - 
Conflicting 
2 + 2 - 
No data 
Thiocarbamates 
Butylate No data No data No data No data No data Lack of data 
1 + 
No data 
Mancozeb Lack of data 
in vitro: 1 - 
in vivo: 0 
No data Conflicting (from 
probable) 
in vitro: 3 + 1 - 
in vivo: 0  
No data No data Possible 
3 + 
Probable 
4 + 
Maneb No data No data Conflicting (from 
possible) 
in vitro: 1 - 
in vivo: 3 +  
No data No data Lack of data 
1 + 
No data 
table continues 
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Table A.2 Classification of endocrine disrupting potential of pesticides in the Agricultural Health Study based on toxicological 
literaturea (cont.) 
Pesticide 
Name and 
Classification 
Estrogen Androgen Thyroid Progesterone FSH/LH Ovarian/ 
Uterine 
Estrus cycle 
Ziram Lack of data 
in vitro: 1 - 
in vivo: 0 
No data No data No data No data No data No data 
Phenoxy Herbicides 
2,4-D No effect 
in vitro: 3 - 
in vivo: 1 - 
Conflicting (from 
lack of data) 
in vitro: 1 + 1 - 
in vivo:  0 
Lack of data 
in vitro: 0 
in vivo:  1 +  
Lack of data 
in vitro:   0 
in vivo:   1 +   
Lack of data 
in vitro:   0 
in vivo:   1 - 
No data No data 
2,4,5-T Lack of data 
in vitro: 1 + 
in vivo: 0 
Lack of data 
in vitro: 0 
in vivo: 1 + 
No data No data No data No data No data 
Triazines 
Atrazine Conflicting 
in vitro: 1+ 10 - 
in vivo: 9 + 2 - 
Probable 
in vitro: 4 +   
in vivo:  6 +  
Conflicting 
in vitro: 2 + 
in vivo: 2 + 2 -  
Probable 
in vitro:  0    
in vivo:   4 + 1 - 
Probable 
in vitro:   0  
in vivo:   6 + 
Probable 
6 + 
Probable 
10 + 1 - 
Cyanazine Lack of data 
in vitro: 1 - 
in vivo: 0 
No data No data No data No data No data Lack of data 
1 + 
Metribuzin No data No data Possible 
in vitro: 0 
in vivo: 2 +  
No data No data No data No data 
Anilides 
Alachlor Conflicting (from 
possible) 
in vitro:   3 +  2 - 
in vivo:   0 
No data Possible 
in vitro: 0 
in vivo: 3 +  
No data No data Possible 
2 +  
No data 
Metolachlor Lack of data 
in vitro: 1 - 
in vivo: 0 
No data Lack of data 
in vitro: 0 
in vivo:  1 -  
No data No data No data No data 
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Table A.2 Classification of endocrine disrupting potential of pesticides in the Agricultural Health Study based on toxicological 
literaturea (cont.) 
Pesticide 
Name and 
Classification 
Estrogen Androgen Thyroid Progesterone FSH/LH Ovarian/ 
Uterine 
Estrus cycle 
Dinitroanilines 
Pendimethalin No data No data Lack of data 
in vitro: 0 
in vivo:  1 +  
No data No data No data No data 
Trifluralin No effect (from 
Lack of data) 
in vitro: 2 - 
in vivo: 0 
Lack of data 
in vitro: 1 - 
in vivo: 0 
Conflicting 
in vitro: 0 
in vivo: 2 + 1 -  
No data Lack of data 
in vitro:   0 
in vivo:   1 + 
No data No data 
Phthalimides 
Captan Lack of data 
in vitro: 1 - 
in vivo: 0 
No data No data No data No data Lack of data 
1 + 
No data 
Chlorothalonil No effect 
in vitro: 2 - 
in vivo: 0 
Lack of data 
in vitro: 1 - 
in vivo: 0 
No data No data No data Lack of data 
1 - 
No data 
Others 
Carbon 
tetrachloride 
Possible 
in vitro:  0 
in vivo:   6 + 2 - 
Conflicting 
in vitro: 0 
in vivo:  1 + 3 - 
Probable 
in vitro: 0 
in vivo: 5 +  
Probable 
in vitro:   0 
in vivo:   4 + 
Conflicting (from 
lack of data) 
in vitro:   0 
in vivo:   1 + 1 - 
Possible 
2 + 
Possible 
2 + 
Ethylene 
dibromide 
No data No data No data No data No data No data Lack of data 
1 + 
Glyphosate No data Lack of data 
in vitro: 0 
in vivo: 1 + 
No data Lack of data 
in vitro:   1 + 
in vivo:   0   
No data Conflicting 
1 + 1 - 
No data 
Methyl bromide No data Lack of data 
in vitro: 0 
in vivo:  1 + 
No data No data No data No effect 
2 - 
Lack of data 
1 - 
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Table A.2 Classification of endocrine disrupting potential of pesticides in the Agricultural Health Study based on toxicological 
literaturea (cont.) 
Pesticide 
Name and 
Classification 
Estrogen Androgen Thyroid Progesterone FSH/LH Ovarian/ 
Uterine 
Estrus cycle 
Permethrin, 
cypermethrin, 
fenvalerate 
Conflicting  
in vitro:   8 +  4 - 
in vivo:   3 - 
Possible (from 
conflicting) 
in vitro: 5 + 1 - 
in vivo:  3 + 2 - 
No data Possible (from no 
effect) 
in vitro:   5 + 2 - 
in vivo:   1 + 1 - 
Possible (from lack 
of data) 
in vitro:   0 
in vivo:   2 + 
Conflicting 
(from no effect) 
3 + 1 - 
Lack of data 
1 + 
Petroleum oil No data No data No data No data No data Possible 
2 + 
Lack of data 
1 + 
Abbreviations: FSH, follicle-stimulating hormone; LH, luteinizing hormone 
 a Table adapted from Farr (192), including results of previous literature search conducted between May and June 2003.  Results shown display 
the classification based on the updated evidence, the previous classification based on the evidence up to June 2003 (if different), the type of test 
(in vitro / in vivo), and the number of publications indicating an effect (+) or no effect (-).  There was no published literature for the following 
pesticides that are excluded from this table: coumaphos, terbufos, EPTC, 2,4,5-TP, aluminum phosphide, chlorimuron ethyl, dicamba, 
imazethapyr, metalaxyl, and paraquat. 
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Table A.3 Pesticides selected as candidates for assessing the association with uterine fibroid 
prevalence  
Pesticide name  Reference  Evidencea 
DDT    
(193) + o,p’-DDT activated E-sensitive gene expression  
(103) + p,p'-DDT, o,p'-DDT, o,p'-DDE, p,p'-DDE, and 
technical-grade DDT mixture increased cell 
proliferation in E-SCREEN 
Mainly estrogenic, 
some metabolites 
anti-estrogenic, 
dependent on 
metabolite, dose, 
duration 
(114) + o,p'-DDT and technical-grade DDT uterotropic in 
several early studies (review) 
 (114) + o,p'-DDT competes for binding to ER; p,p'-DDT 
relatively inactive in several studies (review) 
 (114) +/ne o,p'-DDT advanced vaginal opening in rats exposed 
neonatally; DDT increased time-to-pregnancy; some 
studies showed no effect on fertility and fecundity 
(review) 
 (110) + o,p’-DDT and p,p’-DDE showed estrogenic activity in 
YES, a competition binding assay, and the MCF-7 
cell luciferase assay 
 (115) + DDT increased uterine weight in mice 
 (194) + o,p’-DDT initiated embryo implantation and 
maintained pregnancy; administration at mating time 
or during fertilization caused embryo loss 
 (108) + ERα and ERβ agonist in HELN cell line 
 (109) + p,p’-DDT & p,p’-DDE ERα agonists in yeast assay  
 (107) + p,p’-DDE  cell proliferation in CAMA-1 cells in 
presence of estrogen & androgens 
 (195) ne no effect on cell proliferation of HEECs 
 (111) + p,p’-DDT and p,p’-DDE  estradiol secretion by 
granulosa and theca cells 
 (196) - p,p’-DDT  serum estradiol in vivo 
 (197, 198) + p,p’-DDT & p,p’-DDE ER agonists in transgenic male 
mice 
 (112, 113) +/- o,p’-DDT & metabolites showed antiestrogenic 
action in theca & granulosa cells; p,p’-DDT & 
metabolites showed estrogenic action; all except 
o,p’-DDT increased estradiol secretion 
 (199) - o,p’-DDT & p,p’-DDT & their metabolites  estradiol 
secretion in human placental explants 
(109) - p,p’-DDT & p,p’-DDE PR antagonists in yeast assay 
(196) + p,p’-DDT  serum progesterone in vivo 
(200) - DDT serum progesterone in vivo 
Progesterone 
agonist & 
antagonist effects, 
dependent on 
metabolite, dose, 
duration 
(113, 201) +/- p,p’-DDT & o,p’-DDT  progesterone secretion in 
JEG-3 cells; p,p’-DDE & o,p’-DDE  progesterone 
secretion 
 (199, 202) +/- p,p’-DDE, o,p’-DDT & o,p’-DDE  progesterone 
secretion in human placental explants, but 
secretion after long-term exposure 
 (170, 203) - DDE, o,p’-DDT & p,p’-DDT progesterone synthesis 
in granulosa cells 
table continues 
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Table A.3 Pesticides selected as candidates for assessing the association with uterine fibroid 
prevalence (cont.) 
Pesticide name  Reference  Evidence a 
 (204) - various metabolites  progesterone-induced 
reporter gene activity 
 (205) +/- DDT  progesterone production in rat granulose 
cells at low concentrations,  production at high 
concentration 
No apparent effect 
on FSH/LH 
(203) - DDE  FSH-stimulated cAMP synthesis in 
granulosa cells 
 (206) ne o,p’-DDT  serum LH in male rats but no effect in 
females 
 (196) ne p,p’-DDT no effect on FSH/LH males or females 
(115, 207-
209) 
+ persistent vaginal estrus Disrupts estrus 
cycle and ovotoxic  
(210) +/ne o,p’-DDT altered estrus cycling; p,p’-DDT had no 
effect 
 (196) ne no effect on estrus cycling 
 (200, 207, 
211, 212) 
+ various ovarian effects:  ovulation rate, absence of 
corpora lutea, follicular cysts, ovarian hypertrophy 
 (213) ne no change in ovarian weight 
Toxaphene    
(121) + increased cell proliferation in E-SCREEN Estrogenic effects 
(134) + increased proliferation of uterine leiomyoma cells in 
vitro 
 (214) + induced BRCA1-gene expression in MCF-7 
 (215) + increased cell proliferation in MCF7, but no effect on 
ER or PR levels 
 (216) ne did not bind ER, increase cell proliferation, or alter 
E2 catabolism in MCF-7 focus assay 
 (217) - ER antagonistic activity in MCF-7 cells 
 (218) ~+ no competition with 17β-estradiol for human or 
alligator ER binding when used alone; some 
displacement when used in combination with other 
pesticides 
 (219) ~+ did not bind to the mouse uterine ER; weakly 
estrogenic in MCF-7 cells and yeast-based reporter 
gene assays 
 (108) + ERα and ERβ agonist in HELN cell line 
Carbon tetrachloride   
(165) + serum estradiol levels in rats with CCL4-induced 
cirrhosis 
In females, 
indirectly increases 
estrogen levels (166) + inhibition of 17β-estradiol and estrone metabolism by 
rat liver microsomes in vitro and in vivo, increased 
uterine weight, and increased levels of these 
compounds in uterus 
 (220) + inhibition of 17β-estradiol metabolism in liver-
damaged rats  
 (164) n.e. no change in serum estradiol levels in rats 
table continues 
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Table A.3 Pesticides selected as candidates for assessing the association with uterine fibroid 
prevalence (cont.) 
Pesticide name  Reference  Evidence a 
(165, 221) + serum progesterone levels in rats with CCL4-
induced hepatocellular carcinoma  
In females, 
indirectly increases 
progesterone levels (164) + serum progesterone levels in liver-damaged rats 
 (222) -  serum and liver progesterone levels 
May disrupt estrus 
cycle; ovo- and 
utero-toxicity 
(179, 180) + rats went into persistent diestrus phase; ovaries and 
uterus had less weight and less vascularized 
Permethrin or other pyrethroids 
(223) ne no effect of permethrin on estradiol metabolism by 
HLM 
Some pyrethroids 
may be estrogenic 
(224) +  MCF-7 cell proliferation in presence of estradiol 
(permethrin & cypermethrin) 
 (108) + ERα and ERβ agonist (Fenvalerate only, no effect of 
permethrin) 
 (171) ne no effect of various pyrethroids in E-CALUX 
 (225) ne no effect of various pyrethroids in three assays 
measuring ERα-mediated mechanisms  
 (226, 227) ne no effect in uterotrophic assay (permethrin, 
fenvalerate) 
 (228) +/-  estradiol production &  proliferation of rat 
granulosa cells (fenvalerate) 
 (229) -/ne fenvaerate & permethrin inhibited MCF-7 cell 
proliferation in presence of estradiol; cypermethrin 
had no effect; none of them acted on ER 
 (230) ne perinatal fenvalerate exposure had no effect on 
plasma estrogen in rats 
 (231, 232) +/- bifenthrin enantiomers had differential effects; 
lambda-cyhalothrin had estrogenic activity in E-
SCREEN 
 (169, 233) +  proliferation of MCF-7 cells, competed for binding 
to ER, induced pS2 mRNA gene expression (various 
pyrethroids with differential responses) 
 (234) + fenvalerate & sumithrin estrogenic in two E-
responsive human cell lines 
 NIEHS, 
unpublished
+  proliferation of Eker rat uterine leiomyoma cells 
(fenvalerate) 
Anti-progestagen (235) -  serum progesterone in vivo (fenvalerate) 
 (228, 236, 
237) 
-  FSH-stimulated progesterone production in rat 
and human granulosa cells 
 (234, 238) - antiprogestagen activity in T47D (permethrin, 
fenvalerate, d-trans allethrin) 
 (230) ne perinatal fenvalerate exposure had no effect on 
plasma progesterone 
 (239) - fenvalerate  progesterone production in MLTC-1 
 (240) ne no effect on PR binding, no progesterone 
agonist/antagonist activity in T47D (various 
pyrethroids) 
Limited data on 
FSH/LH 
(241) - esfenvalerate inhibited afternoon LH surge in female 
rats 
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Table A.3 Pesticides selected as candidates for assessing the association with uterine fibroid 
prevalence (cont.) 
Pesticide name  Reference  Evidence a 
(235) + fenvalerate ovotoxic 
(242) - tetramethrin  absolute and relative uterine weights 
May effect estrus 
cycle, ovo-and 
utero-toxic (243) + permethrin  uterine weights 
 (230) + perinatal fenvalerate exposure resulted in disruptions 
in estrus cycling & interaction with uterine weight 
Lindane    
(103, 244, 
245) 
ne no cell proliferation in E-SCREEN or other E-
sensitive cell lines 
(108, 245-
247) 
ne no competitive binding to ER 
Conflicting 
evidence of 
estrogenic and anti-
estrogenic activity 
(244) + some estrogen response element transcription 
 (246) - inhibited formation of estradiol-receptor complex in 
rat uterus 
 (248) +  serum estradiol in ewes 
 (109) - ERβ antagonist in yeast assay 
 (249) ~+ weak estrogenic activity in vivo when combined with 
estradiol 
 (250, 251) +  uterine epithelial height and vaginal epithelial 
thickness or  uterine weight in vivo 
 (252, 253) ne no effect on estrogen levels/number of ER in vivo 
 (254, 255) - delay in vaginal opening and  uterine weight 
 (256) - lack of implantation and fetal loss, reversed by E 
administration 
 (257) ne no change in estradiol metabolism from in utero 
exposure,  uterine weight at weaning but no 
difference at maturity 
Progesterone 
antagonist 
(258) -  FSH and TGFβ1-stimulated progesterone 
production 
 (109) - PR antagonist in yeast assay 
 (259, 260) -  luteal progesterone levels in ewes and serum 
progesterone in mice 
LH disturbances (248) -  basal LH concentrations in ewes 
 (255) -  serum and pituitary LH,  pituitary FSH in rats 
 (259, 261) +/ne increased LH pulse frequency in ewe lambs, but 
nothing in adults 
(259)   number of corpora lutea in ewes 
(200)  reduced ovulation rates in rabbits 
(262) ne no effect on ovulation rates in pigs 
(257) ne no histological changes in ovary from in utero 
exposure 
Disruption of 
ovarian/estrus 
cycles 
(251, 255)  prolonged proestrus phase, delayed ovulation in rats 
 (254)  decreased number of days in proestrus  
 (259, 263, 
264) 
 length of estrus phase in ewes, rats 
table continues 
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Table A.3 Pesticides selected as candidates for assessing the association with uterine fibroid 
prevalence (cont.) 
Pesticide name  Reference  Evidence a 
Dieldrin    
(108) +/- ERα agonist and ERβ antagonist in HELN cell line May have weak 
estrogenic activity (265) + change in ERα and β mRNA steady state levels 
 (121, 266) +  cell proliferation in E-SCREEN and other assays 
with MCF-7 cells 
 (219, 267) ne no effect on cell proliferation in some assays 
 (121, 268) ~+ weak competitive binding to the ER 
 (269) ne no estrogen responsive reporter gene activation of 
HeLN cells 
 (218, 219, 
267, 270) 
ne no competitive binding to human or alligator ER, or 
in other estrogen receptor assays 
 (116) ne no effect on uterine weight or timing of vaginal 
opening 
 (271) -  17β-estradiol metabolism 
(272, 273) ne no change in serum progesterone in mice or pigs Limited data on 
progesterone, 
FSH/LH (274) -? short-term  of FSH/LH levels in rats 
Limited data, but 
appears to have no 
effect on ovary or 
estrus cyle 
(116) ne no change in ovulation in rats 
Alachlor    
May be weak 
estrogen 
(108) ne no significant transactivational activity in ERα or ERβ 
 (103) ne non-estrogenic in E-SCREEN 
 (110) ~+ weak estrogenic effects in YES, the competition 
binding assay, and the MCF-7 cell luciferase assay 
 (218) ~+ weak estrogen in competition binding assay  
 (275) + like 17β-estradiol, has the ability to suppress tumor 
necrosis factor alpha (TNF)-induced apoptosis in 
ER-positive MCF-7 cell line 
May be ovotoxic (276, 277) + decreased ovarian weight in rabbits 
Chlordane    
Estrogen agonist & 
antagonist effects 
(278) - stimulated estrone metabolism; inhibited an increase 
in uterine weight 
 (279) - delayed vaginal opening in mice exposed neonatally 
 (280) + increased cell growth in two estrogen-responsive cell 
lines (MCF-7 and GH3); addition of growth factors 
had a somewhat additive effect 
 (103) ne non-estrogenic in E-SCREEN 
 (218) ~+ no competition with 17β-estradiol for human or 
alligator ER binding when used alone; some 
displacement when used in combination with other 
pesticides 
 (108) ~+ moderate ERα and ERβ agonist in HELN reporter 
cell line 
table continues 
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Table A.3 Pesticides selected as candidates for assessing the association with uterine fibroid 
prevalence (cont.) 
Pesticide name  Reference  Evidence a 
Conflicting results 
on estrus cycling 
(281) ne no estrus cycle or ovarian effects 
 (282) + exposure to chlordane constituent caused shift from 
primarily proestrus and estrus to primarily metestrus 
Atrazine 
(108, 283) ne no activity in ERα or ERβ 
(284) - antiestrogenic in yeast screen 
Either no effect or 
possibly anti-
estrogenic (285) ne no effect on proliferation of rat pituitary cell line or E-
dependent tumor growth 
 (103, 245, 
286) 
ne no proliferation or ER-transactivational activity in E-
sensitive cell lines (MCF-7, HeLa, yeast cells) 
 (287) ~- reduced E-stimulated uterine weight gain in vivo; 
poor binding to ER, plasma estradiol in one rat 
strain 
 (288) - weak inhibition of estrogen-stimulated responses in 
the rat uterus 
 (289-291) - delayed vaginal opening, inhibition of uterine weight 
gain 
 (292) ne no binding to ER, no transactivational activity in 
yeast assay 
 (293) ne non-estrogenic in E-CALUX 
 (294) + plasma estradiol in one rat strain but not another 
 (295) + plasma estradiol in pigs 
(286, 291) - decreases in cytosolic progesterone receptor (PR) 
binding levels in vivo 
Possible 
antiprogestagen 
(287, 296) -  plasma progesterone 
LH/FSH effects 
strain-dependent 
(296-300) - suppresses LH and/or FSH surge in certain strains 
of female rats 
(290, 295, 
297, 301-
303) 
 increased length of diestrus in pigs, rats 
(287, 294, 
304) 
 prolonged estrus phase in rats 
(305)  short-term exposure prolonged diestrus; shift to 
prolonged estrus phase with longer term exposure 
Disrupts estrus 
cycle; may also be 
ovotoxic, but effects 
are strain and 
duration dependent 
(306) ne no effect when administered prior to mating 
 (307)  morphological signs of ovotoxicity in subacute, but 
not subchronic, exposure 
 (290, 294, 
295, 297, 
303, 308) 
  ovarian weight,  ovarian follicular cysts in rats 
and pigs 
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Table A.3 Pesticides selected as candidates for assessing the association with uterine fibroid 
prevalence (cont.) 
Pesticide name  Reference  Evidence a 
Mancozeb 
May be ovotoxic, 
estrus cycle 
disruptor 
(309-312)   number of estrus cycles, shortened estrus phase, 
increased diestrus phase in rats; decreased diestrus 
and increased estrus in mice 
 (309-311)  histopathologic changes in ovaries, decreased 
number of healthy follicles 
 (116, 313) ne no effect on estrus cyclicity 
Abbreviations: FSH, follicle-stimulating hormone; LH, luteinizing hormone; E-CALUX, assay with 
human ovarian carcinoma cells transfected with estrogen-responsive luciferase reporter gene 
plasmid; ER, estrogen receptor; E-SCREEN, assay using ability to induce cell proliferation of 
estrogen-sensitive human breast cancer cells as screening tool for estrogenic compounds; GH3, rat 
pituitary cell line; HELN, HeLa (human cervical cancer) cells transfected with estrogen receptor; HLM, 
human liver microsomes; MCF-7, human breast cancer cell line; MLTC, mouse Leydig tumor cells; 
PR, progesterone receptor; T47D, human breast cancer cell line; YES, in vitro Yeast Estrogen 
System assay using human estrogen receptor to screen for estrogenicity. 
 a  For hormonal endpoints, the short description of study results is preceded by a “+” to indicate that 
the general effect is to increase the hormone, a “-” to indicate the general effect is to decrease the 
hormone, or “ne” to indicate no effect on the hormone.  For the ovarian and estrus cycle endpoints, 
only “ne” is used. 
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APPENDIX B  
Estimates for the Association of Pesticide Use and Fibroids Using Different Referent 
Groups 
 
 Some studies of multiple pesticide exposures have categorized exposures to single 
pesticides (or groupings) as ever/never in which the referent group includes both those 
unexposed to any pesticide as well as those exposed to pesticides other than those of interest.  
This classification allows for a larger sample size and increased precision over excluding the 
“other” pesticide exposure group from the analysis.  On the other hand, keeping the other 
exposure group in the referent category may attenuate the risk estimates for any given 
pesticide/group of interest, making it more difficult to detect an association if one exists.   
 Although analysis of the 50 individual pesticides was not part of the initial aims of 
this research, the associations between specific pesticides and odds of uterine fibroid 
diagnosis were examined in response to findings from the main analysis.  I was specifically 
interested to see if there were any pesticides that were not classified as possibly hormonally 
active based on my literature review, but that were associated with uterine fibroids.  To 
assess the degree to which estimates might be attenuated, I examined associations with the 
referent group both including and excluding never users of any pesticides.  Of the 43 
pesticides examined (some were excluded due to small numbers), fibroid diagnosis was 
statistically significantly associated with ever use of 10 pesticides—chlordane, coumpahos, 
diazinon, malathion, parathion, carbaryl, chlorimuron ethyl, glyphosate, petroleum oil, and 
carbon tetrachloride—when the referent group included never users of any pesticide.  Odds 
ratios were modestly elevated (ORs around 1.2 to 1.5) among users of about one-third of the 
individual pesticides examined; the strongest association with fibroids was seen in users of 
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carbon tetrachloride (OR = 1.87; 95% CI: 1.12, 3.12).  This association remained relatively 
strong when the referent group consisted only of other pesticide users (OR = 1.70; 95% CI: 
1.02, 2.85).  Odds ratios for organophosphates as a class and specific organophosphate 
pesticides remained statistically significant (though attenuated).  Aldicarb use was inversely 
associated with fibroids in both analyses. 
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Table B.1 Association between specific pesticide use and self-reported uterine fibroid 
diagnosis among 16,526 women aged 21-59 in the Agricultural Health Study, 1993-2003 
 
Referent includes 
never users of any 
pesticide and users 
of other pesticides  
Referent includes only 
users of other 
pesticides 
 ORa 95% CI  ORa 95% CI 
Organochlorines 1.16 0.99, 1.36  1.05 0.90, 1.24 
Aldrin 1.05 0.63, 1.76  0.95 0.57, 1.60 
Chlordane 1.22 1.00, 1.49  1.11 0.91, 1.36 
DDT 1.27 0.98, 1.63  1.14 0.88, 1.48 
Dieldrinb      
Heptachlor 1.22 0.76, 1.96  1.11 0.69, 1.78 
Lindane 0.99 0.73, 1.33  0.90 0.67, 1.22 
Toxaphene 1.04 0.62, 1.75  0.96 0.57, 1.61 
      
Organophosphates 1.26 1.15, 1.38  1.17 1.05, 1.31 
Chlorpyrifos 1.16 0.96, 1.40  1.07 0.88, 1.30 
Coumaphos 1.52 1.10, 2.11  1.41 1.01, 1.96 
Diazinon 1.21 1.06, 1.37  1.11 0.97, 1.27 
Dichlorvos/DDVP 1.09 0.84, 1.42  1.00 0.77, 1.31 
Fonofos 1.23 0.93, 1.63  1.13 0.85, 1.50 
Malathion 1.27 1.15, 1.40  1.17 1.05, 1.31 
Parathion 1.53 1.08, 2.15  1.42 1.00, 2.00 
Phorate 1.01 0.76, 1.34  0.92 0.69, 1.23 
Terbufos 1.04 0.82, 1.33  0.96 0.75, 1.22 
Trichlorfonb      
      
Carbamates 1.13 1.03, 1.24  1.00 0.90, 1.12 
Aldicarb 0.61 0.35, 1.08  0.57 0.32, 1.00 
Carbofuran 1.25 0.95, 1.64  1.14 0.87, 1.51 
Carbaryl 1.12 1.02, 1.23  0.99 0.88, 1.11 
Benomyl 0.81 0.55, 1.21  0.75 0.50, 1.11 
      
Triazines 1.11 0.94, 1.31  1.01 0.85, 1.20 
Atrazine 1.14 0.95, 1.38  1.05 0.87, 1.26 
Cyanazine 1.15 0.92, 1.45  1.06 0.84, 1.33 
Metribuzin 0.99 0.74, 1.32  0.90 0.67, 1.21 
      
Other insecticides      
Permethrin 1.13 0.95, 1.35  1.04 0.87, 1.25 
      
Other Herbicides      
2,4-D 1.09 0.97, 1.22  0.98 0.87, 1.11 
2,4,5 TPb      
2,4,5 T 1.41 0.91, 2.20  1.29 0.83, 2.01 
Alachlor 1.16 0.95, 1.40  1.06 0.87, 1.29 
Butylate 1.29 0.95, 1.74  1.18 0.87, 1.60 
Chlorimuron Ethyl 1.31 1.00, 1.71  1.21 0.92, 1.58 
 table continues 
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Table B.1 Association between specific pesticide use and self-reported uterine fibroid 
diagnosis among 16,526 women aged 21-59 in the Agricultural Health Study, 1993-2003 
(cont.) 
 
Referent includes 
never users of any 
pesticide and users 
of other pesticides  
Referent includes only 
users of other 
pesticides 
 ORa 95% CI  ORa 95% CI 
Dicamba 1.10 0.90, 1.34  1.00 0.82, 1.23 
EPTC 0.99 0.71, 1.38  0.90 0.64, 1.27 
Glyphosate 1.18 1.08, 1.30  1.07 0.96, 1.21 
Imazethapyr 1.09 0.87, 1.36  1.00 0.79, 1.26 
Metolachlor 1.17 0.95, 1.44  1.08 0.87, 1.34 
Paraquat 1.22 0.88, 1.71  1.13 0.81, 1.59 
Pendimethalin 0.97 0.76, 1.25  0.90 0.70, 1.15 
Petroleum oil 1.24 1.02, 1.51  1.15 0.94, 1.40 
Trifluralin 1.17 0.98, 1.39  1.07 0.90, 1.28 
      
Other Fungicides      
Captan 1.14 0.89, 1.47  1.05 0.82, 1.36 
Chlorothalonil 1.29 0.91, 1.83  1.20 0.85, 1.71 
Maneb 1.08 0.79, 1.48  1.00 0.73, 1.37 
Metalaxyl 0.84 0.62, 1.15  0.77 0.56, 1.06 
Ziramb      
      
Other Fumigants      
Aluminum phosphideb      
Carbon tetrachloride 1.87 1.12, 3.12  1.70 1.02, 2.85 
Ethylene dibromideb      
Methyl bromide 0.94 0.66, 1.34  0.87 0.61, 1.25 
Abbreviations: OR, odds ratio; CI, confidence interval. 
 a Adjusted for age (continuous), age squared, and state (IA/NC).  Comparison group consists of 
women who used other agricultural pesticides.   
 b Odds ratios not reported if fewer than 10 exposed cases.   
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APPENDIX C 
Sensitivity Analysis Results 
 
 Results of sensitivity analyses with varying assumptions regarding sensitivity and 
specificity of self-report are shown below.  Three main scenarios were examined: 1) varying 
age-specific sensitivity and overall specificity; 2) varying assumptions about overall 
sensitivity and specificity among women reporting a hysterectomy; and 3) varying 
assumptions about age-specific sensitivity among women 50-59 years old (for whom validity 
analysis data were not available).   
 The greatest impact of changes in sensitivity and specificity were observed in 
scenario 1, where I did not differentiate between hysterectomy and non-hysterectomy records 
(Table and Figure C.1).  In all instances, corrected odds ratios were further away from the 
null than the uncorrected odds ratios which assumed no misclassification.  In general, 
changing sensitivity estimates when overall specificity was high (0.97) did not dramatically 
influence the odds ratios.  As specificity decreased, the impact of increases or decreases to 
age-specific sensitivity was greater.  The greatest change was seen when sensitivity was 
decreased by 0.05 for each age group and specificity was 0.90.  Models in which sensitivity 
was decreased by 0.10 points did not converge, indicating that perhaps the maximum 
likelihood estimate of the odds ratio approached 0 or infinity because of negative numbers in 
either the numerator or denominator of the maximum likelihood estimation formula (12): 
 
   
  
 
| |
| |
(1 ) (1 )D E D E
D E D E
p spec p spec
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sens p sens p
+ + + −
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 When women with hysterectomy were differentiated in terms of their assumed 
reporting accuracy, the relative difference between corrected and uncorrected odds ratios was 
smaller.  When overall sensitivity and overall specificity were varied in this subgroup (Table 
and Figure C.2), the biggest change from the uncorrected odds ratio was seen in the lowest 
sensitivity and specificity cell.  Similar patterns were observed as above: varying sensitivity 
values had the greatest impact when specificity was lower.  For the pesticide use exposure 
metric, outcome misclassification correction resulted in a somewhat flatter trend in the odds 
ratios for agricultural pesticide users. 
 Finally, I examined corrected odds ratios when different assumptions were made 
about trends in self-report sensitivity among women not reporting a hysterectomy (Table and 
Figure C.3).  Although corrected odds ratios were further from the null, varying assumptions 
did not change the effect estimates.   
Table C.1 Association between use of hormonally active pesticides and fibroid diagnosis, 
varying assumptions for age-specific sensitivity and overall specificity 
 Specificitya 
Sensitivity 0.90 0.95 0.97 
+0.10 2.24 1.59 1.48 
+0.05 2.40 1.64 1.52 
Age-specificb 2.68 1.71 1.56 
-0.05 3.19 1.78 1.61 
-0.10  c c c 
Note: uncorrected OR = 1.28; 95% confidence interval: 1.12, 1.45.  Referent group is women who did 
not use any pesticides. 
 a  Specificity set to this value for everyone, regardless of age. 
 b  Sensitivity by age 18-29: 0.15; 30-34: 0.20; 35-39: 0.35; 40-44: 0.40; 45-59: 0.30. 
 c   No convergence. 
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Table C.2 Association between use of hormonally active pesticides and fibroid diagnosis, 
varying assumptions for women with hysterectomy 
 Specificitya 
Sensitivityb 0.85 0.90 0.95 
0.85 1.92 1.65 1.48 
0.90 1.87 1.62 1.47 
0.95 1.83 1.60 1.45 
Note: uncorrected OR = 1.28; 95% confidence interval: 1.12, 1.45.  Referent group is women who did 
not use any pesticides. 
 a  Specificity is varied for women regardless of hysterectomy status, based on assumption that 
self-report accuracy in women with hysterectomy will never be lower than for those with no 
hysterectomy. 
 b  Sensitivity is varied for women with hysterectomy only.  For women without hysterectomy, 
sensitivity by age 18-29: 0.15; 30-34: 0.20; 35-39: 0.35; 40-44: 0.40; 45-59: 0.30.   
 
 
Table C.3 Association between use of hormonally active pesticides and fibroid diagnosis, 
varying assumptions for sensitivity among women aged 45-59 
Assumptions OR 95% CI 
Uncorrected (no assumptions) 1.28 1.12, 1.45 
Sensitivity stays levela 1.47 1.21, 1.80 
Sensitivity continues increasing with ageb 1.47 1.22, 1.79 
Sensitivity continues decreasing with agec 1.46 1.19, 1.80 
For women with hysterectomy, Se=0.85 and Sp=0.95. For women with no hysterectomy, Sp=0.95 
and 
 a  Sensitivity by age 18-29: 0.15; 30-34: 0.20; 35-39: 0.35; 40-44: 0.40; 45-59: 0.40. 
 b  Sensitivity by age 18-29: 0.15; 30-34: 0.20; 35-39: 0.35; 40-44: 0.40; 45-49: 0.45; 50-54: 0.50; 
55-59: 0.55. 
 c  Sensitivity by age 18-29: 0.15; 30-34: 0.20; 35-39: 0.35; 40-44: 0.40; 45-49: 0.35; 50-54: 0.30; 
55-59: 0.25. 
   
 
133
Figure C.1 Sensitivity analysis of the association between pesticide use patterns and self-reported uterine fibroid diagnosis, varying 
assumptions for age-specific sensitivity and overall specificity 
Residential Common 1-2 agricultural 3+ agricultural Other
1
0.4
4
J
A
B
C
D
E
F
G
H
I
K
L
M
O
d
d
s
 
R
a
t
i
o
 
M: Uncorrected odds ratio estimates 
A:  Age-specific Se; Sp=0.90 D: Se +0.05; Sp=0.90 G: Se +0.10; Sp=0.90 J:  Se -0.05; Sp=0.90 
B:  Age-specific Se; Sp=0.95 E: Se +0.05; Sp=0.95 H: Se +0.10; Sp=0.95 K:  Se -0.05; Sp=0.95 
C: Age-specific Se; Sp=0.97 F: Se +0.05; Sp=0.97 I: Se +0.10; Sp=0.97 L: Se -0.05; Sp=0.97 
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Figure C.2 Sensitivity analysis of the association between pesticide use patterns and self-reported uterine fibroid diagnosis, varying 
assumptions for women with hysterectomy 
Residential Common 1-2 agricultural 3+ agricultural Other
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J: Uncorrected odds ratio estimates.  Models below have the following Se values for non-hysterectomy women: 18-29: 0.15; 30-34: 0.20; 35-39: 
0.35; 40-44: 0.40; 45-59: 0.30.  Sensitivity was varied for hysterectomy women, as was specificity (for hysterectomy and non-hysterectomy) 
A:  Se=0.85; Sp=0.95 D:  Se=0.85; Sp=0.90 G: Se=0.85; Sp=0.85 
B:  Se=0.90; Sp=0.95 E:  Se=0.90; Sp=0.90 H: Se=0.90; Sp=0.85 
C: Se=0.95; Sp=0.95 F: Se=0.95; Sp=0.90 I: Se=0.95; Sp=0.85 
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Figure C.3 Sensitivity analysis of the association between pesticide use patterns and self-reported uterine fibroid diagnosis, varying 
assumptions for sensitivity among women aged 45-59 
Residential Common 1-2 agricultural 3+ agricultural Other
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D:  Uncorrected odds ratio estimates. 
For women with hysterectomy, Se=0.85 and Sp=0.95. For women with no hysterectomy, Sp=0.95 and  
A:  Sensitivity by age 18-29: 0.15; 30-34: 0.20; 35-39: 0.35; 40-44: 0.40; 45-59: 0.40. 
B:  Sensitivity by age 18-29: 0.15; 30-34: 0.20; 35-39: 0.35; 40-44: 0.40; 45-49: 0.45; 50-54: 0.50; 55-59: 0.55. 
C: Sensitivity by age 18-29: 0.15; 30-34: 0.20; 35-39: 0.35; 40-44: 0.40; 45-49: 0.35; 50-54: 0.30; 55-59: 0.25. 
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